Page last updated: 2024-11-04

baclofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Baclofen is a medication used to treat muscle spasms. It is a gamma-aminobutyric acid (GABA) analog and acts as a GABA receptor agonist. Baclofen is typically administered orally, but it can also be given intravenously or intrathecally. The synthesis of baclofen involves several steps, starting with the reaction of 4-chlorobutyryl chloride with 4-aminobutyric acid. The resulting compound is then reacted with sodium hydroxide to produce baclofen. Baclofen is a potent muscle relaxant that works by suppressing the release of excitatory neurotransmitters in the spinal cord. It is effective in treating muscle spasms associated with conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy. Baclofen is also being studied for its potential therapeutic effects in other conditions, including anxiety, depression, and addiction. The study of baclofen is important because it provides insights into the role of GABA in the central nervous system and has the potential to lead to the development of new and more effective treatments for a wide range of neurological and psychiatric disorders.'

Cross-References

ID SourceID
PubMed CID2284
CHEMBL ID701
CHEBI ID2972
SCHEMBL ID19333
MeSH IDM0002117

Synonyms (237)

Synonym
AC-4530
CHEBI:2972 ,
baclofene
baclofenum
baclofeno
BRD-A84174873-001-05-2
gtpl1084
MLS000028480
DIVK1C_000001
KBIO1_000001
4-amino-3-(4-chlorophenyl)butanoic acid
nsc-329137
baclofen ,
nsc329137
EU-0100163
(+/-)-baclofen, >=98% (tlc), solid
SPECTRUM_000066
BPBIO1_000750
ccris 3722
baclofene [inn-french]
chlorophenyl gaba
ba 34647
c 34647ba
baclofenum [inn-latin]
lioresal intrathecal
ba-34647
pcp-gaba
gabalon
butanoic acid, 4-amino-3-(4-chlorophenyl)-
baclophen
baclofeno [inn-spanish]
ba-34,647
lioresal
brn 2104494
benzenepropanoic acid, beta-(aminomethyl)-4-chloro-
kemstro
ciba 34,647-ba
einecs 214-486-9
hydrocinnamic acid, beta-(aminomethyl)-p-chloro-
baclon
PRESTWICK_85
1134-47-0
baclofen (r,s)
cas-1134-47-0
SMP1_000036
chembl701 ,
bdbm24182
BPBIO1_000012
LOPAC0_000163
BSPBIO_001880
BIOMOL-NT_000251
OPREA1_440627
BSPBIO_000010
PRESTWICK2_000085
UPCMLD-DP142:001
AB00051921
beta-(p-chlorophenyl)-gamma-aminobutyric acid
dl-4-amino-3-p-chlorophenylbutanoic acid
DB00181
dl-baclofen
beta-(aminomethyl)-4-chlorobenzenepropanoic acid
beta-(aminomethyl)-p-chlorohydrocinnamic acid
UPCMLD-DP142
4-amino-3-(4-chlorophenyl)butyric acid
gamma-amino-beta-(p-chlorophenyl)butyric acid
(+-)-baclofen
beta-(4-chlorophenyl)gaba
D00241
kemstro (tn)
lioresal (tn)
baclofen (jp17/usp/inn)
SPECTRUM5_000852
NCGC00024579-05
NCGC00023843-03
NCGC00024579-04
smr000058294
KBIO3_001380
KBIOSS_000466
KBIOGR_000650
KBIO2_000466
KBIO2_005602
KBIO2_003034
NINDS_000001
PRESTWICK0_000085
SPECTRUM4_000245
PRESTWICK1_000085
SPBIO_000044
SPECTRUM3_000310
SPECTRUM2_000092
SPBIO_001949
SPECTRUM1500135
PRESTWICK3_000085
IDI1_000001
NCGC00024579-06
NCGC00024579-03
(?)-baclofen
atrofen
gaba, chlorophenyl
apo-baclofen
NCGC00015156-05
HMS2091M03
( inverted question mark)-baclofen
B 5399 ,
B3343
NCGC00015156-12
fleqsuvy
nsc-755906
lyvispah
(rs)-baclofen
L000002
(+/-)-baclofen
HMS500A03
FT-0662469
FT-0662468
HMS1920E21
HMS1568A12
NCGC00015156-11
HMS2095A12
HMS3260B07
STK535284
h789n3fke8 ,
unii-h789n3fke8
nsc 755906
ipx 056
ipx056
gablofen
baclofen [usan:usp:inn:ban:jan]
BBL010735
pharmakon1600-01500135
nsc755906
dtxsid5022641 ,
tox21_110090
dtxcid002641
CCG-38910
NCGC00015156-08
NCGC00015156-06
NCGC00015156-13
NCGC00015156-04
NCGC00015156-07
AKOS005174692
FT-0622547
LP00163
.beta.-(aminomethyl)-4-chlorobenzenepropanoic acid
S4840
CX1358
baclofen [jan]
.beta.-(aminomethyl)-p-chlorohydrocinnamic acid
baclofen [usan]
baclofen [inn]
baclofen [usp-rs]
baclofen [who-dd]
baclofen [ep monograph]
baclofen [usp monograph]
ozobax
baclofen [mi]
baclofen [orange book]
baclofen [mart.]
baclofen [vandf]
HY-B0007
SCHEMBL19333
NCGC00015156-15
tox21_110090_1
MB00475
HS-1001
tox21_500163
NCGC00260848-01
(y)-baclofen
baclofen o
benzenepropanoic acid, .beta.-(aminomethyl)-4-chloro-
(.+/-.)-baclofen
4-amino-3-(4-chlorophenyl)butanoic acid #
.beta.-(4-chlorophenyl)gaba
hydrocinnamic acid, .beta.-(aminomethyl)-p-chloro-
(.+/-.)-baklofen
4-amino-3-(p-chlorophenyl)butyric acid
.beta.-(p-chlorophenyl)-.gamma.-aminobutyric acid
.gamma.-amino-.beta.-(p-chlorophenyl)butyric acid
(+/- )-beta-(aminomethyl)-4-chlorobenzenepropanoic acid
F2173-1127
baclofen, british pharmacopoeia (bp) reference standard
(rs)-4-amino-3-(4-chlorophenyl)butanoic acid
HB0953
(rs)-4-amino-3-(4-chlorophenyl)buta noic acid
(a+/-)-baclofen
AB00051921_16
mfcd00055143
J-002965
baclofen, european pharmacopoeia (ep) reference standard
SR-01000000107-2
sr-01000000107
baclofen, united states pharmacopeia (usp) reference standard
baclofen, pharmaceutical secondary standard; certified reference material
baclofen; (3rs)-4-amino-3-(4-chlorophenyl)butanoic acid
baclofen 0.5 mg/ml in methanol
SR-01000000107-8
SR-01000000107-4
SR-01000000107-6
SBI-0050151.P004
HMS3712A12
SY023865
(rs)-amino-3-(4-chlorophenyl)butyric acid
Q413717
SY052300
EX-A1378
BCP11844
SDCCGSBI-0050151.P005
stx209; stx-209; stx 209; d-baclofen; arbaclofen
BCP32777
NCGC00015156-26
(+)-baclofen; (l)-baclofen
NCGC00015156-28
baclofen lioresal 4-amino-3-(4-chlorophenyl)butyric acid
SB67382
n-boc-(2s,3s)-2-hydroxy-3-amino-5-methylhexanoicacid
4-amino-3-(4-chlorophenyl)butanoicacid
BB166152
EN300-118715
M01382
(r,s)-baclofen
(+/-)-ss-(aminomethyl)-4-chlorobenzenepropanoic acid
baclofen (usp monograph)
baclofen (usp-rs)
baclofen (intrathecal)
baclofenum (inn-latin)
lioresal (baclofen)
baclofen (ep monograph)
baclofen injection
beta-p-chlorophenyl-gaba
beta-(4-chlorophenyl)-gamma-aminobutyric acid
baclofeno (inn-spanish)
4-amino-3-(4-chlorophenyl)-butanoic acid
ciba ba 34647
baclofen (usan:usp:inn:ban:jan)
baclofen (mart.)
(3rs)-4-amino-3-(4-chlorophenyl)butanoic acid
baclofene (inn-french)
baclofen, 1mg/ml in acetonitrile/water : 1/1

Research Excerpts

Overview

Baclofen (Lioresal) is a derivative of gamma-aminobutyric acid. It is used in both adults and children mainly for symptomatic treatment of muscle spasticity. Baclofen intoxication is a rare cause of brain death mimic.

ExcerptReferenceRelevance
"Baclofen is a γ-aminobutyric acid-B receptor agonist used for control of spastic muscle activity and as a treatment for alcohol abuse. "( Carcinogenicity Evaluation of Baclofen in TgrasH2 Mice.
Aubert, N; Chevalier, G; Palate, B; Singh, P; Thirion-Delalande, C, 2022
)
2.45
"Baclofen is a muscle relaxant of choice for treating spasticity, generally marketed only in tablet form, highlighting the need for liquid formulations to facilitate dose adjustment, administration, and swallowing."( Development, Quality by Design-Based Optimization, and Stability Assessment of Oral Liquid Formulations Containing Baclofen for Hospital Use.
Ayres, MV; de Almeida, SHO; de Saldanha Simon, E; Gobetti, C; Primieri, GB; Steppe, M; Volpato, NM; Wingert, NR, 2022
)
1.65
"Baclofen intoxication is a rare cause of brain death mimic characterised by transient deep coma and absence of brainstem reflexes and might be mistaken with brain death."( Neurological evolution of severe baclofen intoxication: from brain death mimic to recovered brain function.
Berger, S; Fisch, U; Kuster, T; Sutter, R, 2023
)
1.91
"Baclofen is a promising drug for treating patients with alcohol-related disorders. "( Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up.
Jaury, P; Le Jeunne, C; Perrodeau, E; Porcher, R; Rigal, L; Sidorkiewicz, S; Tréluyer, JM, 2020
)
2.42
"Baclofen is a racemic mixture that is commonly used for the treatment for spasticity. "( Simultaneous Quantitation of S(+)- and R(-)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC-APCI-MS/MS: An Application for Clinical Studies.
Chhonker, YS; He, Q; McLaughlin, MJ; Murry, DJ, 2020
)
2.26
"Baclofen overdose is a potentially deadly condition that can cause encephalopathy and can result from multiple etiologies."( Encephalopathy of Unknown Origin in a Baclofen Patient: Case Report and Review of the Literature.
Abraham, M; Behmer Hansen, R; Gold, J; Lad, M; Mammis, A; Zhao, K, 2020
)
1.55
"Baclofen (Lioresal) is a derivative of gamma-aminobutyric acid and is used in both adults and children mainly for symptomatic treatment of muscle spasticity. "( Coma and Respiratory Failure in a 2-Year-Old Child After Accidental Overdose of Baclofen.
Dasgupta, K; Nielson, S, 2020
)
2.23
"Baclofen is a centrally acting skeletal muscle relaxant approved by the US Food and Drug Administration (FDA) for the treatment of muscle spasticity, but the immediate release mode of administration and rapid absorption has been associated with adverse effects. "( Design, characterization and in vivo evaluation of modified release baclofen floating coated beads.
Abdelkader, H; Ibrahim, M; Naguib, YW; Sarhan, HA, 2020
)
2.24
"Baclofen is a gamma-aminobutyric acid (GABA)b receptor agonist used to treat spasticity in various medical conditions."( The effect of baclofen on objective and subjective sleep measures in a model of transient insomnia.
Jones, KR; Orr, WC; Raad, S; Wilkerson, M, 2020
)
1.64
"Baclofen is a structural analogue of gamma-amino-butyric acid (GABA), which reduces spastic hypertonia of striated muscle due to a mechanism of GABA"( Effects of intrathecal baclofen therapy in subjects with disorders of consciousness: a reappraisal.
Brigo, F; Golaszewski, S; Nardone, R; Pucks-Faes, E; Saltuari, L; Sebastianelli, L; Trinka, E; Versace, V, 2020
)
2.31
"Baclofen is a GABA"( A single, clinically relevant dose of the GABA
Capitão, LP; Grigoras, I; Johnstone, A; Petitet, P; Stagg, CJ, 2021
)
2.06
"Baclofen is a psychotropic drug and its recreational use among adolescents and young adults represent a serious problem and should be considered by healthcare professionals."( Baclofen overdose following recreational use in adolescents and young adults: A case report and review of the literature.
Abbara, C; Beloncle, F; Briet, M; Drevin, G; Ghamrawi, S, 2020
)
2.72
"Baclofen is a medication prescribed as a therapy for muscle spasticity that originated from multiple sclerosis or a spinal cord injury, and other cases such as hiccups."( A new feasible approach based on utility of ninhydrin for selective fluorimetric analysis of baclofen. Application to content uniformity evaluation.
Abu-Hassan, AA; Ali, R; Derayea, SM, 2021
)
1.56
"Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD). "( Speaking fluently with baclofen?
Beraha, E; Bodewits, P; van den Brink, W; Wiers, R, 2017
)
2.21
"Baclofen is a promising therapeutic in this area."( Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies.
Owens, L; Pirmohamed, M; Richardson, P; Thompson, A, 2017
)
1.5
"Baclofen is an effective treatment option for patients with rumination syndrome, probably through its effect on LES pressure."( A Randomized Double-Blind, Placebo-Controlled, Cross-Over Study Using Baclofen in the Treatment of Rumination Syndrome.
Broers, C; Pauwels, A; Rommel, N; Tack, J; Van Houtte, B; Vanuytsel, T, 2018
)
2.16
"Baclofen is a drug used mainly to treat muscle spasticity. "( Correlation between the single, high dose of ingested baclofen and clinical symptoms.
Anand, JS; Biliński, P; Jaworska-Łuczak, B; Waldman, W; Wojtyła, A; Zając, M, 2017
)
2.15
"Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment."( Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
Jones, A; Rose, AK, 2018
)
2.64
"Baclofen is a centrally-acting γ-amino butyric acid agonist used mainly in the symptomatic management of spasticity originating from the spinal cord. "( Baclofen-induced neurotoxicity in patients with compromised renal function: Review.
Achanti, A; Arany, I; Beck Gööz, M; Castaneda, J; Dreisbach, AW; Fülöp, T; Salim, SA; Thomas, L, 2018
)
3.37
"Baclofene is a good tool to guarantee patients independence and pain control."( The use ultrasound guided for refilling intrathecal baclofene pump in complicated clinical cases: A practical approach.
Caruso, P; Manganotti, P; Mazzon, G; Sarra, VM; Tacconi, L, 2018
)
1.45
"Baclofen is a derivative of gamma-aminobutyric acid, used mainly for the treatment of muscle spasticity. "( An intoxication mimicking brain death: baclofen.
Arslan, G; Duman, M; Er, A; Karaarslan, U; Koker, A; Köroğlu, T; Özden, Ö, 2020
)
2.27
"Baclofen is a lipophilic γ-aminobutyric acid (GABA) derivative that exhibits strong intrinsic activity and a high affinity for GABAB receptors. "( Molecular mechanisms of the antispasticity effects of baclofen on spinal ventral horn neurons.
Abe, T; Nakatsuka, T; Nishio, N; Taniguchi, W; Yamada, H; Yoshida, M, 2019
)
2.21
"Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder."( A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.
Akhlaghi, F; Deschaine, SL; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Sadighi, A, 2021
)
1.59
"Baclofen is a centrally acting GABA"( Single-dose baclofen-induced neurotoxicity in a patient with end stage renal disease: case report.
Hamdan, Z; Jebrin, K; Khazneh, E; Sawalmeh, O; Shamlawi, A, 2018
)
2.3
"Baclofen is an agonist for a subtype of gamma-amino butyric acid (GABA-B) receptors and traditionally been used for the systemic treatment of spasticity. "( Effect of Topical Baclofen 5% on Post-Hemorrhoidectomy Pain: Randomized Double Blind Placebo-Controlled Clinical Trial.
Ala, S; Alvandipour, M; Mansourifar, M; Monajati, M; Saeedi, M; Shiva, A, 2020
)
2.33
"Baclofen, which functions as a selective agonist for GABA"( Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial.
Akhondzadeh, S; Alichani, R; Mahdavinasab, SM; Mohammadi, MR; Motamed-Gorji, N; Saghazadeh, A; Vaseghi, S, 2019
)
2.68
"Baclofen is a γ-aminobutyric acid (GABA) agonist that is commonly prescribed for the treatment of spasticity in children. "( An unusual cause of flaccid paralysis and coma: baclofen overdose.
Caron, E; Morgan, R; Wheless, JW, 2014
)
2.1
"Baclofen is a gamma-aminobutyric acid agonist used primarily as a muscle relaxant to treat spasticity in children and adults. "( Use of baclofen for withdrawal in a preterm infant.
Devlin, LA; Duncan, SD, 2013
)
2.29
"Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)."( Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
Cundy, KC; Huff, FJ; Vakil, NB, 2013
)
1.4
"Baclofen is a GABA(B) receptor agonist. "( Baclofen in the treatment of persistent hiccup: a case series.
Addolorato, G; Antonelli, M; D'Angelo, C; Ferrulli, A; Landolfi, R; Leggio, L; Mirijello, A; Vassallo, G, 2013
)
3.28
"Baclofen is a useful, but suboptimal treatment option for refractory GERC."( Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough.
Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013
)
2.14
"Baclofen is a GABAB receptor agonist commonly used to relief spasticity related to motor disorders. "( Selective effects of baclofen on use-dependent modulation of GABAB inhibition after tetraplegia.
Barry, MD; Bunday, KL; Chen, R; Perez, MA, 2013
)
2.15
"Baclofen (1) is a potent and selective agonist for bicuculline-insensitive GABA(B) receptors and is used clinically as an antispastic and muscle relaxant agent. "( GABA(B)-agonistic activity of certain baclofen homologues.
Attia, MI; Bräuner-Osborne, H; Herdeis, C, 2013
)
2.1
"Baclofen is a GABA-B receptor agonist used in the treatment of spasticity. "( High variability in the exposure of baclofen in alcohol-dependent patients.
Alvarez, JC; Grassin-Delyle, S; Imbert, B; Jaquet, I; Lançon, C; Marsot, A; Simon, N, 2014
)
2.12
"Baclofen is a structural analogue of γ-aminobutyric acid (GABA) that has been used for the treatment of spasticity since 1977. "( Liquid chromatography-tandem mass spectrometry determination of baclofen in various biological samples and application to a pharmacokinetic study.
Choi, JH; Joo, SH; Kim, TH; Kwon, DR; Lee, AR; Min, BS; Park, GY; Seo, WS; Shin, BS; Shin, JC; Shin, S; Yoo, SD; Yoo, WY, 2013
)
2.07
"Baclofen is a γ-aminobutyric acid B (GABA-B) receptor agonist that is approved for spasticity. "( Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
Bence, C; Bordet, R; Carton, L; Cottencin, O; Deheul, S; Jaillette, E; Rolland, B; Saulnier, F, 2014
)
2.15
"Baclofen showed to be an effective add-on to selective serotonin reuptake inhibitors in treatment of PTSD for better symptom recovery and functional improvement."( Baclofen add-on to citalopram in treatment of posttraumatic stress disorder.
Haghighi, MB; Hebrani, P; Javanbakht, A; Manteghi, AA; Mortezania, M, 2014
)
3.29
"Baclofen is a c-aminobutyric acid (GABA) analog that contains a phenylethylamine moiety."( Olanzapine and baclofen for the treatment of intractable hiccups.
Brzezinski, WA; Ehret Leal, J; Thompson, AN, 2014
)
1.48
"Baclofen is a centrally acting skeletal muscle relaxant with a short elimination half-life, which results in frequent daily dosing and subsequent poor patient compliance. "( Baclofen novel gastroretentive extended release gellan gum superporous hydrogel hybrid system: in vitro and in vivo evaluation.
Aboelwafa, AA; El-Said, IA; ElGazayerly, ON; Khalil, RM, 2016
)
3.32
"Baclofen is a γ-aminobutyric acid (GABA)-β receptor agonist with a muscle relaxant effect. "( Baclofen and γ-hydroxybutyrate (GHB), a dangerous combination.
De Jong, CA; Kamal, RM; Qurishi, R,
)
3.02
"Baclofen is a centrally acting gamma-aminobutyric acid agonist used for the symptomatic relief of skeletal muscle spasm and spasticity in traumatic spinal cord lesions, multiple sclerosis, cerebral palsy, and stroke. "( Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease.
Ijaz, M; Kashif, M; Marquez, JG; Tariq, H, 2015
)
2.13
"Baclofen toxicity is an under-diagnosed condition, especially in patients with renal dysfunction. "( Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease.
Ijaz, M; Kashif, M; Marquez, JG; Tariq, H, 2015
)
2.13
"Baclofen is an oral derivative of gamma-aminobutyric acid (GABA) used to treat muscular spasticity from disorders of the central nervous system. "( Iatrogenic Baclofen Neurotoxicity in ESRD: Recognition and Management.
Roberts, JK; Sparks, MA; Westphal, S,
)
1.96
"Baclofen is a GABA-B receptor agonist currently used in the treatment of spasticity. "( Anticraving Effect of Baclofen in Alcohol-Dependent Patients.
Alvarez, JC; Imbert, B; Simon, N, 2015
)
2.17
"Baclofen is an agonist of peripheral and central B gamma-aminobutyric acid receptors, whose activation causes a myorelaxation and a powerfull depression of the central nervous system. "( Self-induced drug intoxication in baclofen: of the calm hypotonic coma in the status epilepticus.
Aries, P; Di Constanzo, L; Drouillard, I; Montelescaut, É; Pessey, F; Sapin, J; Thill, C; Vaillant, C, 2016
)
2.16
"Baclofen is a commonly used medication to treat spasticity in neurologic disorders. "( Psychosis Following an Increase in Intrathecal Baclofen.
Brkic, N; Driver, SP; Lloyd, R; Maneyapanda, MB; Ripley, DL, 2016
)
2.13
"Baclofen is a muscle relaxant used to treat spasticity and improve mobility in patients with spinal cord injuries, relieving pain and muscle stiffness."( Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity.
Alemón-Medina, R; Cárdenas-Rodríguez, N; Carmona-Aparicio, L; Carrillo-Mora, P; Cázares-Ramírez, E; Coballase-Urrutia, E; Martínez-Vargas, M; Navarro, L; Pérez-Arredondo, A; Sampieri, A,
)
2.3
"Baclofen is a commonly used racemic drug and has a simple chemical structure in terms of the presence of only one stereogenic center. "( Enantioresolution of (RS)-baclofen by liquid chromatography: A review.
Batra, S; Bhushan, R, 2017
)
2.2
"Baclofen is a zwitterion molecule where increased ions in the excipient increase the solubility. "( Baclofen Solution for Low-Volume Therapeutic Delivery.
Meythaler, JM; Peduzzi, JD, 2017
)
3.34
"Baclofen is an agonisit at gamma-aminobutyric acid (GABA) receptors, and is, therefore, a neuroinhibitor, and decreases spasticity."( [Intrathecal baclofen for severe spasticity].
Ueta, T, 2008
)
1.44
"Baclofen is a g-aminobutyric acid receptor agonist commonly used for managing many types of neuropathic pain. "( Baclofen as an adjuvant analgesic for cancer pain.
Matoba, M; Matsuo, N; Suzuki, T; Tamaki, T; Tomiyasu, S; Yomiya, K; Yoshimoto, T,
)
3.02
"Baclofen is a GABA(B) receptor agonist that in preclinical and early pilot clinical trials has shown promise for the treatment of cocaine dependence."( Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals.
Alathari, H; Beresford, T; Biswas, K; Chiang, N; Childress, AR; Collins, J; Elkashef, A; Fudala, PJ; Gorgon, L; Gruber, V; Kahn, R; Li, SH; Liberto, J; McSherry, F; Montoya, I; Shoptaw, S; Stock, C; Wallace, C; Watson, D, 2009
)
1.39
"Baclofen is a racemic GABA(B) receptor agonist that has a number of significant pharmacokinetic limitations, including a narrow window of absorption in the upper small intestine and rapid clearance from the blood. "( Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
Annamalai, T; Bao, Y; Bu, L; Cundy, KC; Dias, T; Gallop, MA; Gao, M; Koller, K; Lal, R; Ludwikow, M; Luo, W; Nguyen, S; Peng, G; Phan, T; Raillard, SP; Scheuerman, RA; Sukbuntherng, J; Tai, EH; Upadhyay, S; Warren, MS; Wu, QQ; Yan, H; Yao, F; Zamora, J, 2009
)
2.52
"Baclofen is a promising tool to explore whether medial preoptic area neurons interact with VTA neurons to control active maternal responses."( Temporary inactivation of ventral tegmental area neurons with either muscimol or baclofen reversibly disrupts maternal behavior in rats through different underlying mechanisms.
Correnti, CM; Dellevigne, AA; Numan, M; Numan, MJ; Stolzenberg, DS, 2009
)
1.3
"Baclofen is a γ-aminobutyric acid-B agonist that is known to reduce the intake of some drugs of abuse. "( Baclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet.
Avena, NM; Berner, LA; Bocarsly, ME; Hoebel, BG, 2009
)
3.24
"Baclofen is a GABA(B) receptor agonist that is effective in inhibiting TLESR and reducing the number of reflux episodes, but is associated with significant central nervous system (CNS) side effects."( Beyond acid suppression: new pharmacologic approaches for treatment of GERD.
Holloway, RH; Kuo, P, 2010
)
1.08
"Baclofen is a gamma amino butyric acid (GABA) derivative that is a specific agonist at GABA-B receptors. "( Baclofen-induced morbiliform rashes: a case series.
Benegal, V; Jayaram, N; Manjunatha, N; Saddichha, S, 2011
)
3.25
"Baclofen is an anti-spastic drug that acts as an agonist of GABA-B receptors. "( [A system of prescriptions without drug approval: example of baclofen].
Bordet, R; Cottencin, O; Danel, T; Deheul, S; Rolland, B,
)
1.82
"Baclofen is an agonist that reduces [(3)H]GABA, whilst the antagonist (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid (Sch 50911) enhances [(3)H]GABA release in electrically-stimulated rat neocortical brain slices preloaded with [(3)H]GABA."( Pharmacological actions of oximino-propofol analogues at GABA(B) autoreceptors.
Badali, M; Khalafy, J; Marino, V; Ong, J; Parker, DA; Prager, RH; Rimaz, M; Sullivan, T, 2011
)
1.09
"Baclofen is a selective gamma-aminobutyric acid (GABA) type B agonist that may have important medicinal uses, such as in analgesics and drug addiction treatment. "( Differential effects of aging on EEG after baclofen administration.
Cui, J; Fu, Y; Ma, Y, 2011
)
2.07
"Baclofen is a synthetic analog of gamma-aminobutryacid, admistrated in intrathecal space by pump."( [Quality of life in cerebral palsy children treated with intrathecal baclofen pump implantation in parents' opinion].
Borowski, A; Miller, F; Pruszczyński, B; Synder, M,
)
1.09
"Baclofen is an effective treatment for patients with rumination or supragastric belching/aerophagia."( Baclofen improves symptoms and reduces postprandial flow events in patients with rumination and supragastric belching.
Blondeau, K; Boeckxstaens, G; Boecxstaens, V; Depeyper, S; Farré, R; Holvoet, L; Rommel, N; Tack, JF, 2012
)
3.26
"Baclofen is a promising medication for the treatment of alcohol dependence, and the prescription of high-dose baclofen (HDB) is increasing within the medical community, especially for patients who are unresponsive to approved treatments. "( A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol.
Bordet, R; Cottencin, O; Danel, T; Deheul, S; Rolland, B,
)
1.81
"Baclofen is a safe and well-tolerated novel drug treatment for alcohol dependence."( Baclofen for the treatment of alcohol dependence.
Howland, RH, 2012
)
2.54
"Baclofen seems to be a promising drug for use with both palliative care and perioperative patients, and using garabentin as an add-on to baclofen may also be a reasonable option to consider"( Management of hiccups in the palliative care population.
Busracamwongs, A; Smith, HS,
)
0.85
"Baclofen (Lioresal) is a drug of choice to treat spasticity and is increasingly being administered intrathecally via an implantable pump in cases refractory to oral therapy. "( Intrathecal baclofen withdrawal mimicking sepsis.
Amin, Y; Kao, LW; Kirk, MA; Turner, MS, 2003
)
2.14
"Baclofen is a stereoselective gamma-aminobutyric acid (GABAB) receptor agonist."( Suppression of alcohol delirium tremens by baclofen administration: a case report.
Abenavoli, L; Addolorato, G; Capristo, E; Caputo, F; DeLorenzi, G; Gasbarrini, G; Janiri, L; Leggio, L; Parente, A; Rapaccini, GL,
)
1.12
"Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the production of TLESRs by acting as a GABA(B) receptor agonist at one or more loci along the vagovagal reflex arc."( Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?
Conklin, JL; Wise, J, 2004
)
1.32
"Baclofen is a GABA(B) agonist that is administered spinally via an implanted drug delivery device to treat spasticity. "( Intrathecal baclofen in pain management.
Abram, SE; Slonimski, M; Zuniga, RE,
)
1.95
"Baclofen is an agonist of delta-aminobutyric acid type B receptors [GABAB], known to inhibit adenylyl cyclase via Gi."( Simultaneous stimulation of GABA and beta adrenergic receptors stabilizes isotypes of activated adenylyl cyclase heterocomplex.
Courtial, C; Pelletier, F; Robichon, A; Tinette, S, 2004
)
1.04
"Baclofen, which is a specific agonist of the metabotropic GABA(B) receptor, is used in clinical practice for the treatment of spasticity of skeletal muscles. "( GABA(B) receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in the rat.
Franek, M; Rokyta, R; Vaculín, S, 2004
)
2.07
"Baclofen is a lipophilic analogue of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in central nervous system. "( Selected clinical aspects of acute intoxication with baclofen.
Burda, P; Chodorowski, Z; Sein Anand, J, 2005
)
2.02
"IT baclofen is a safe and effective treatment to reduce spasticity in MS patients."( Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
Ben Smail, D; Bussel, B; Mailhan, L; Peskine, A; Roche, N; Thiébaut, I, 2006
)
1.23
"Baclofen is a centrally acting gamma-ammino butyric acid agonist that is used like muscular relaxant in disorders with spasticity and intractable hiccups. "( [Baclofen-associated encephalopathy in a hemodialysis patient with hiccups].
Butjosa, M; Lladó, A; Poch, E; Quintana, LF; Santamaría, J; Torras, A, 2006
)
2.69
"Baclofen is an effective drug for treatment of oromandibular dystonia."( [Case of oromandibular dystonia presenting with severe impairment of mouth-opening, and a marked effect by administration of baclofen].
Ikawa, M; Kuriyama, M; Nakagawa, H; Yoneda, M, 2006
)
1.26
"Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. "( Baclofen for binge eating: an open-label trial.
Attia, E; Broft, AI; Corwin, RL; Devlin, MJ; Mayer, L; Spanos, A; Steinglass, J; Walsh, BT, 2007
)
3.23
"Baclofen is a centrally acting gamma-aminobutyric acid agonist used for spasticity of spinal origin and mainly excreted unchanged by the kidneys. "( Haemodialysis clearance of baclofen.
Brvar, M; Bunc, M; Kovac, D; Kozelj, G; Pezdir, T; Vrtovec, M, 2007
)
2.08
"D-Baclofen is an antagonist at spinal baclofen receptors."( GABAergic mechanisms in antinociception.
Sawynok, J, 1984
)
0.83
"D-Baclofen should prove to be a useful tool for investigation of the role of stereoselective baclofen receptors in a variety of pharmacological processes."( D-Baclofen: is it an antagonist at baclofen receptors?
Dickson, C; Sawynok, J, 1984
)
1.55
"Baclofen is a new alternative in the medical treatment of postural non-electrically induced detrusor striated sphincter dyssynergia in spinal cord injury patients."( Baclofen in the treatment of detrusor-sphincter dyssynergia in spinal cord injury patients.
Leyson, JF; Martin, BF; Sporer, A, 1980
)
2.43
"Baclofen is an agonist of spinal GABA receptors."( [Intestinal pseudo-obstruction during use of baclofen].
Ottervanger, JP; Schutter, N; Verhaar, HJ, 1995
)
1.27
"Baclofen is a gamma-aminobutyric acid (GABA) agonist approved for the treatment of spasticity and commonly used in the management of many types of neuropathic pain. "( Baclofen as an adjuvant analgesic.
Fromm, GH, 1994
)
3.17
"Baclofen is a central nervous system agent that is commonly used for the treatment of muscle spasticity in spinal cord injury patients. "( Neurological manifestations of baclofen withdrawal.
Chancellor, MB; Freedman, MK; Hill, K; Rivas, DA, 1993
)
2.01
"Baclofen (Lioresal) is a derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). "( Baclofen-induced dyskinesia.
Blumenthal, FS; Ryan, DM, 1993
)
3.17
"Baclofen is a potent and efficacious inhibitor of TLESRs and reflux in the dog. "( Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs.
Antonsson, M; Bremner-Danielsen, M; Flärdh, M; Hansson-Brändén, L; Kärrberg, L; Lehmann, A, 1999
)
1.75
"Baclofen is a muscle relaxant used in both adults and children with neuromuscular disorders to control spasticity. "( Baclofen overdose in two siblings.
Chapple, D; Connors, R; Johnson, D, 2001
)
3.2
"I.t. baclofen is a fairly simple and cost-effective modality, with significant advantages for management of severe tetanus, especially in tropical environment."( [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu].
Benhamou, D; Engrand, N; Rouamba, A; Vilain, G, 2000
)
1.08
"IT baclofen appears to be an option for patients with intractable CRPS who have failed other modalities, including IT morphine."( Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome.
Abram, SE; Perera, S; Zuniga, RE,
)
1.13
"Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis. "( Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.
Conomy, JP; Feldman, RG; Foley, JM; Kelly-Hayes, M, 1978
)
3.14
"Baclofen is a GABA-like drug which passes through the blood-brain barrier and which reduces the neuroleptic-induced increase of dopamine turn-over."( Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia.
Korsgaard, S, 1976
)
2.42
"Baclofen appears to be a safe and effective agent in the management of spasticity, with the advantage that adequate dosage can usually be achieved without sedation."( Bacloffen (Lioresal) in the long-term management of spasticity.
Jones, RF; Lance, JW, 1976
)
0.98
"Baclofen is a centrally acting muscle relaxant used for treatment of spasticity. "( Clinical and pharmacokinetic aspects of high dose oral baclofen therapy.
Aisen, ML; Cedarbaum, JM; Dietz, MA; Kutt, H; Rossi, P, 1992
)
1.97
"Baclofen is a new antineuralgic drug. "( Baclofen in trigeminal neuralgia--a clinical trial.
Gandhi, IC; Parmar, BS; Shah, KH,
)
3.02
"Baclofen is a centrally acting muscle relaxant marketed as the racemate. "( Comparison of the pharmacokinetics of intravenously administered rac-baclofen and its (-)-(R)- and (+)-(S)-enantiomers in dogs.
Dirks, MJ; Termond, EF; Van der Kleijn, E; Vree, TB; Wuis, EW, 1989
)
1.95
"Baclofen appears to be an agonist for the bicuculline-insensitive gamma-aminobutyrateB receptors associated with C fibre terminals in the dorsal horn of the spinal cord. "( Effects of topical baclofen on C fibre-evoked neuronal activity in the rat dorsal horn.
Brewer, CM; Dickenson, AH; Hayes, NA, 1985
)
2.04
"Baclofen is an analog of the inhibitory neurotransmitter, GABA, which is used clinically to control spasticity. "( Attenuation of epileptiform bursting by baclofen: reduced potency in elevated potassium.
Sutch, CP; Swartzwelder, HS; Wilson, WA, 1986
)
1.98
"Baclofen is a muscle relaxant approved in this country for the treatment of muscle spasms secondary to multiple sclerosis, spinal cord injury, and other spinal diseases. "( Hallucinations after preoperative baclofen discontinuation in spinal cord injury patients.
Harrison, SA; Wood, CA, 1985
)
1.99

Effects

baclofen has a narrow therapeutic range, and a large interindividual pharmacodynamic variability. It has a significant inhibitory effect on the micturition reflex, depressing detrusor contraction strength.

Baclofen (BLF) has been prescribed in the UK since 1972 for the alleviation of spasticity. Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting.

ExcerptReferenceRelevance
"baclofen has a significant inhibitory effect on the micturition reflex, depressing detrusor contraction strength and micturition efficiency, while increasing bladder capacity."( Modulation of detrusor contraction strength and micturition characteristics by intrathecal baclofen in anesthetized rats.
Constantinou, CE; Perkash, I; Watanabe, T, 1997
)
1.24
"baclofen has a narrow therapeutic range, and a large interindividual pharmacodynamic variability."( [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu].
Benhamou, D; Engrand, N; Rouamba, A; Vilain, G, 2000
)
1.34
"Baclofen has been trialled for AUD in cirrhosis and appears to be effective."( Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022
)
1.73
"Baclofen has limited to no effect on volitional swallowing measures, however, does reduce the likelihood of initiation of piecemeal deglutition to large volume challenges."( Effects of the GABA(B) agonist baclofen on volitional swallowing in normal subjects.
Chen, CL; Hung, JS; Lei, WY; Liang, SW; Lin, L; Liu, TT; Omari, T; Wong, MW; Yi, CH, 2023
)
1.92
"Baclofen has been shown to reduce alcohol consumption in some individuals with alcohol use disorder. "( Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results.
Arunogiri, S; Baillie, A; Haber, PS; Hurzeler, T; Logge, W; Morley, K; Towers, E, 2023
)
2.58
"Baclofen (BLF) has been prescribed in the UK since 1972 for the alleviation of spasticity. "( Baclofen: To Screen or Not to Screen in Postmortem Blood?
Murphy, KG; Nahar, LK; Paterson, S, 2021
)
3.51
"Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting. "( Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
Amodio, JP; Bollinger, JW; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Lionetti, TA; Schwandt, ML; Sewell, L; Spero, DE, 2017
)
2.2
"Baclofen has gained interest in treating alcohol use disorder patients. "( Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre.
Boels, D; Brunet, M; Le Roux, G; Léger, M; Lerolle, N, 2017
)
3.34
"Baclofen has potential utility as a pharmacological adjunct and anecdotal reports suggest that it is being used by drug users to self-manage GHB withdrawal symptoms."( Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability.
Dargan, PI; Floyd, CN; Wood, DM, 2018
)
2.64
"Baclofen has been shown to decrease self-administration of GHB in mice and reduce relapse in a case series of GHB-dependent patients."( Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial.
Beurmanjer, H; de Jong, CAJ; Dijkstra, BAG; Kamal, RM; Schellekens, AFA, 2018
)
2.64
"Baclofen has shown promise in the treatment of alcohol dependence. "( Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018
)
2.48
"Baclofen has been shown to reduce alcohol consumption in alcohol-dependent individuals, but there is marked heterogeneity in response. "( Moderation of baclofen response by a GABA
Baillie, A; Dore, G; Fraser, I; Haber, PS; Luquin, N; Morley, KC; Phung, N; Trent, RJ, 2018
)
2.28
"Baclofen has been reported to cause both a metabolic encephalopathy and nonconvulsive status epilepticus. "( Baclofen Neurotoxicity: A Metabolic Encephalopathy Susceptible to Exacerbation by Benzodiazepine Therapy.
Dunne, JW; Lawn, ND; Triplett, JD, 2019
)
3.4
"Baclofen has been shown to effect fMRI alcohol cue reactivity in alcohol dependence, but potential varying effects related to baclofen dose levels have not been examined."( Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
Baillie, AJ; Haber, PS; Logge, WB; Morley, KC; Morris, RW, 2021
)
3.51
"Baclofen has been tested for its capacity to reduce craving for alcohol."( Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013.
, 2013
)
2.55
"Baclofen toxicity has been associated with seizures, coma, apnea, autonomic disturbances, and cardiac conduction abnormalities. "( Acute onset rhythmic hiccup-like respirations secondary to oral baclofen toxicity.
Hoon, A; Johnston, M; Ogborn, J; Srivastava, S, 2014
)
2.08
"Baclofen has been increasingly used in the treatment of alcohol withdrawal syndrome (AWS). "( Increase of baclofen intoxications: risks involved and management.
Arbouw, ME; Hoge, HL; Jansman, FG; Meulenbelt, J, 2014
)
2.22
"Baclofen has been shown to produce enantioselective effects in behavioral assays, including those modeling reflexive and sexual behavior."( Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption.
Blasingame, SN; Boehm, SL; Kasten, CR, 2015
)
1.37
"Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited at present."( Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
Arora, S; Elwadhi, D; Gupta, M; Rastogi, R; Verma, P, 2017
)
1.46
"Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed."( Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Auffret, M; Baguet, A; Bordet, R; Cabe, N; Carton, L; Cottencin, O; Deheul, S; Dervaux, A; Dib, M; Drelon, M; Duhamel, A; Gautier, S; Grit, I; Guillin, O; Jardri, R; Kemkem, A; Labreuche, J; Lapeyre-Mestre, M; Masquelier, C; Rolland, B; Vabret, F, 2017
)
1.43
"Oral baclofen has long been a mainstay in the management of spasticity. "( Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
Calabrese, A; Campo, C; Ertzgaard, P, 2017
)
1.26
"Baclofen alone has minimal abuse liability in heavy social drinkers, and baclofen is relatively well tolerated and safe when given in combination with intoxicating doses of alcohol."( Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Bisaga, A; Evans, SM, 2009
)
2.11
"Baclofen per se has the potential of lowering blood pressure."( Intrathecal baclofen for autonomic instability due to spinal cord injury.
Kofler, M; Poustka, K; Saltuari, L, 2009
)
1.45
"Baclofen has been shown to enhance abstinence, to reduce drinking quantity, to reduce craving, and to reduce anxiety in alcohol-dependent individuals in 2 placebo-controlled trials in Italy."( Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010
)
1.39
"Baclofen has shown promise in treating substance use disorders and also reduced binge frequency in an open-label trial. "( Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study.
Boan, J; Corwin, RL; Peters, KF; Ulbrecht, JS, 2012
)
3.26
"The baclofen pump has been utilized in children with refractory spasticity. "( Placement of baclofen pumps through the foramen magnum and upper cervical spine.
Dziurzynski, K; Iskandar, BJ; Mcleish, D; Ward, M, 2006
)
1.26
"Baclofen has become increasingly popular in the treatment of spasticity disorders. "( An unusual presentation of baclofen overdose.
Chong, CF; Wang, TL, 2005
)
2.07
"Baclofen has been studied for the treatment of alcohol withdrawal, but current research is limited."( Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review.
Schrader, S; Stallings, W, 2007
)
2.5
"Baclofen has potential in the prophylaxis of alcohol withdrawal. "( Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review.
Schrader, S; Stallings, W, 2007
)
3.23
"Baclofen has significantly exhibited analgesic efficacy: all groups, as a whole, were improved by 68.61%."( Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.
Leo, A; Marano, E; Steardo, L, 1984
)
1.37
"Baclofen has been shown to be ineffective against first order excitatory synaptic transmission in the olfactory cortex slice, whereas it is known that GABA-mediated inhibition depresses this transmission in a bicuculline-sensitive manner. "( Effects of baclofen on the olfactory cortex slice preparation.
Cain, CR; Simmonds, MA, 1982
)
2.1
"Baclofen has been reported to be an analgesic in a wide variety of animal pain models. "( Is baclofen an analgesic?
Fromm, GH; Potter, DM; Terrence, CF, 1983
)
2.33
"Baclofen has been used as an antispastic agent for over a decade, yet its mechanism of action is still not fully understood. "( Direct hyperpolarizing action of baclofen on hippocampal pyramidal cells.
Newberry, NR; Nicoll, RA,
)
1.86
"Baclofen has been reported to be epileptogenic in man, but many animal studies have demonstrated an anticonvulsant effect. "( Baclofen. Its effect on seizure frequency.
Fromm, GH; Roussan, MS; Terrence, CF, 1983
)
3.15
"Baclofen has been reported to be anticonvulsant in a variety of seizure models and prevents kindling in immature rats."( Baclofen prevents rapid amygdala kindling in adult rats.
Wurpel, JN, 1994
)
2.45
"Baclofen, however, has little or no effect on cholinergic excitation at motor axon collateral synapses on spinal Renshaw cells and, in the present study, was found not to reduce the duration of the action potential of axon collateral terminations located in the vicinity of Renshaw cells in pentobarbitone-anaesthetised cats."( The lack of effect of baclofen on action potentials of spinal motor axon collateral terminations in vivo.
Curtis, DR; Lacey, G, 1997
)
1.33
"baclofen has a significant inhibitory effect on the micturition reflex, depressing detrusor contraction strength and micturition efficiency, while increasing bladder capacity."( Modulation of detrusor contraction strength and micturition characteristics by intrathecal baclofen in anesthetized rats.
Constantinou, CE; Perkash, I; Watanabe, T, 1997
)
1.24
"Baclofen has been shown to inhibit the cough reflex in able-bodied volunteers."( Baclofen-induced cough suppression in cervical spinal cord injury.
Dicpinigaitis, PV; Grimm, DR; Lesser, M, 2000
)
2.47
"Baclofen has both presynaptic and postsynaptic effects."( gamma-Aminobutyric acid(B) receptor-mediated responses in the nucleus tractus solitarius are altered in acute and chronic hypertension.
Mifflin, SW; Vitela, M, 2001
)
1.03
"Baclofen has been reported in uncontrolled clinical studies to reduce craving for abused drugs and reduce their rewarding effects. "( Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking.
Cousins, MS; de Wit, H; Stamat, HM, 2001
)
2.05
"baclofen has a narrow therapeutic range, and a large interindividual pharmacodynamic variability."( [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu].
Benhamou, D; Engrand, N; Rouamba, A; Vilain, G, 2000
)
1.34
"Baclofen has been used to treat several secondary dystonias: tardive dystonia has occasionally been reported to improve and there are isolated reports of improvement in dystonia occurring in Parkinson's disease and in glutaric aciduria."( Baclofen in the treatment of dystonia.
Greene, P, 1992
)
2.45
"(-)Baclofen has no detectable postsynaptic actions in these cultured neurones."( On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurones.
Harrison, NL, 1990
)
1.08
"Baclofen has been shown to be a selective agonist for a subclass of GABA receptors (GABAB) in many regions of the vertebrate nervous system. "( Some characteristics of baclofen-evoked responses of primary afferents in frog spinal cord.
Mitsoglou, GM; Padjen, AL, 1990
)
2.03
"Baclofen has both inhibitory and disinhibitory effects on neurons."( Baclofen induces spontaneous, rhythmic sharp waves in the rat hippocampal slice.
Jones, LS; Lewis, DV; Mott, DD, 1989
)
2.44
"Baclofen has shown analgesic properties in a number of animal studies but has failed as a conventional analgesic in the human postoperative dental pain model. "( Baclofen as an analgesic in chronic peripheral nerve disease.
Fromm, GH; Tenicela, R; Terrence, CF, 1985
)
3.15

Actions

Baclofen is known to produce anticonvulsant effects in the DBA/2J mouse audiogenic seizure test (AGS) Baclofen failed to inhibit mechanical sensitization of esophageal nodose C-fibers induced by histamine (100 microM)

ExcerptReferenceRelevance
"Baclofen can enhance anti-nociceptive effect of morphine by modulating TRPV-1 channel and PKC activity."( Repeated Administration of Baclofen Modulates TRPV-1 Channel Expression by PKC Pathway in Dorsal Root Ganglia of Spinal Cord in a Morphine Tolerance Model of Rats
Ashabi, G; Hoseini, M; Karimiyan, SM; Mehrabadi, S; Moradbeygi, K, 2020
)
2.3
"Non-baclofen cases had lower rate of endotracheal intubation (n = 1833, 6%, P < 0.001) and mortality rate (n = 299, 0.1%, P = 0.02)."( Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre.
Boels, D; Brunet, M; Le Roux, G; Léger, M; Lerolle, N, 2017
)
2.38
"Baclofen toxicity can produce an acute encephalopathy even at modest doses, with the EEG showing generalized slowing and triphasic waves consistent with a toxic encephalopathy. "( Baclofen Neurotoxicity: A Metabolic Encephalopathy Susceptible to Exacerbation by Benzodiazepine Therapy.
Dunne, JW; Lawn, ND; Triplett, JD, 2019
)
3.4
"Baclofen failed to inhibit mechanical sensitization of esophageal nodose C-fibers induced by histamine (100 microM) or the selective adenosine A(2A) receptor agonist CGS21680 (3 nM)."( Evaluation of the effect of GABA(B) agonists on the vagal nodose C-fibers in the esophagus.
Brozmanová, M; Kollárik, M; Mazúrová, L; Tatár, M, 2013
)
1.11
"Baclofen is known to produce anticonvulsant effects in the DBA/2J mouse audiogenic seizure test (AGS), suggesting it may be a suitable assay for assessing pharmacodynamic effects."( Anticonvulsant effects of structurally diverse GABA(B) positive allosteric modulators in the DBA/2J audiogenic seizure test: Comparison to baclofen and utility as a pharmacodynamic screening model.
Brown, JW; Ma, J; Moeller, A; Nimmrich, V; Rueter, LE; Schmidt, M; Turner, SC; van der Kam, E; Zhang, M, 2016
)
1.36
"Baclofen did not increase positive subjective effects (e.g., Stimulant effects, Drug Liking) but did increase sedation and impair performance."( Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Bisaga, A; Evans, SM, 2009
)
1.39
"Baclofen did not cause any consistent change in the membrane potential or in the EPSP waveform within frog motoneurones."( Dual effect of GABA on descending monosynaptic excitatory postsynaptic potential in frog lumbar motoneurons.
Ovsepian, SV; Vesselkin, NP, 2004
)
1.04
"Baclofen could suppress the response completely, and its action was unaffected by bicuculline."( Baclofen selectively inhibits transmission at synapses made by axons of CA3 pyramidal cells in the hippocampal slice.
Ault, B; Nadler, JV, 1982
)
2.43
"5. Baclofen induced an increase in amplitude of the nonvoltage dependent leak conductance (IL), and the increase was blocked by TEA."( Diverse current and voltage responses to baclofen in an identified molluscan photoreceptor.
Matzel, LD; Muzzio, IA; Rogers, RF, 1995
)
1.07
"Baclofen and dopamine inhibit the oscillations by increasing the potassium conductance and hyperpolarizing the dendrites."( Effect of dopamine and baclofen on N-methyl-D-aspartate-induced burst firing in rat ventral tegmental neurons.
Johnson, SW; North, RA; Seutin, V, 1994
)
1.32
"Baclofen was able to inhibit convulsions only in a relatively high dose (5 mg/kg)."( Effect of GABA-ergic drugs on flunarizine-induced seizures in rabbits.
Roliński, Z; Wlaź, P,
)
0.85
"Baclofen did not cause a similar effect."( OFF pathway is preferentially suppressed by the activation of GABA(A) receptors in carp retina.
Yang, XL; Zhang, DQ, 1997
)
1.02
"Baclofen did not inhibit low threshold Ca2+ currents elicited by voltage steps from -120 to -40 mV."( Inhibition of N- and P/Q-type calcium channels by postsynaptic GABAB receptor activation in rat supraoptic neurones.
Harayama, N; Kabashima, N; Shibuya, I; Tanaka, K; Ueta, Y; Yamashita, H, 1998
)
1.02
"The baclofen-mediated increase in PPF for juvenile slices could be enhanced by first increasing transmitter release through an increased bath Ca2+ concentration."( GABA(b) receptors differentially regulate hippocampal CA1 excitatory synaptic transmission across postnatal development in the rat.
Dumas, TC; Foster, TC, 1998
)
0.78
"Baclofen does not activate a potassium conductance in the presynaptic terminal."( GABAB receptor-mediated modulation of presynaptic currents and excitatory transmission at a fast central synapse.
Isaacson, JS, 1998
)
1.02
"Baclofen at a lower dose (1 mg/kg i.v.) significantly increased the acid secretion even under normothermic conditions when the animals were subjected to chemical deafferenation of capsaicin-sensitive neurons or pretreatment with intracisternal injection of CGRP8-37 (30 ng/rat)."( Body temperature dependency in baclofen-induced gastric acid secretion in rats relation to capsaicin-sensitive afferent neurons.
Araki, H; Kato, S; Kawauchi, S; Takeuchi, K, 2001
)
1.32
"Baclofen did not cause any consistent changes in the concentration, the synthesis and the utilization of noradrenaline."( Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain.
Andén, NE; Wachtel, H, 1977
)
1.29
"3. Baclofen did not cause any consistent change in the membrane potential, nor in the membrane time constant, as estimated from the exponential decay of the tail of the EPSP."( Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetized cat.
Edwards, FR; Harrison, PJ; Jack, JJ; Kullmann, DM, 1989
)
1.16
"L(-)-Baclofen did not increase postsynaptic membrane conductance or block postsynaptic membrane responses to GABA."( (-)-Baclofen activates presynaptic GABAB receptors on GABAergic inhibitory neurons from embryonic rat hippocampus.
Barker, JL; Harrison, NL; Lange, GD, 1988
)
1.29
"Baclofen and oxazepam enhance extinction of conflict behaviour in the Geller-Seifter test while baclofen and diazepam release punished behaviour in Vogel's conflict test. "( GABA-B receptor activation and conflict behaviour.
Bollen, EL; Bruinvels, J; Ketelaars, CE; Rigter, H, 1988
)
1.72
"Baclofen can produce inhibition by increasing potassium conductance, and therefore may fail to appear efficacious in typical anticonvulsant screens due to techniques that cause rapid and massive increases in interstitial potassium."( Attenuation of epileptiform bursting by baclofen: reduced potency in elevated potassium.
Sutch, CP; Swartzwelder, HS; Wilson, WA, 1986
)
1.26
"Baclofen caused an increase in the somatosensory evoked potentials without affecting the EEG in unanaesthetized dogs."( Entropy concept in relation to brain waves and evoked potentials: critique of a physical approach.
Tan, U, 1985
)
0.99

Treatment

Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used. The drug is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug.

ExcerptReferenceRelevance
"Baclofen pumps provide treatment of symptoms of spasticity for disease processes such as cerebral palsy and traumatic brain injury. "( Submuscular Placement of Baclofen Infusion Pumps: Case Series and Technique.
Bogue, JT; Greenfield, JP; Iosim, S; Otterburn, DM; Wald, G, 2020
)
2.3
"In baclofen treatment group, thermal hyperalgesia and formalin test improved in comparison with morphine tolerance group. "( Repeated Administration of Baclofen Modulates TRPV-1 Channel Expression by PKC Pathway in Dorsal Root Ganglia of Spinal Cord in a Morphine Tolerance Model of Rats
Ashabi, G; Hoseini, M; Karimiyan, SM; Mehrabadi, S; Moradbeygi, K, 2020
)
1.48
"Both baclofen-treated groups reported fewer post-scan % HDD when compared to the placebo-treated group, but no subjective craving group differences were found. "( Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
Baillie, AJ; Haber, PS; Logge, WB; Morley, KC; Morris, RW, 2021
)
2.58
"Baclofen overdose is treated with supportive care and antiepileptic medications as indicated."( An unusual cause of flaccid paralysis and coma: baclofen overdose.
Caron, E; Morgan, R; Wheless, JW, 2014
)
1.38
"With baclofen treatment, the cough symptom score began to decrease at week 2, was clearly decreased at week 6 and reached a minimum at week 8."( Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough.
Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013
)
1.15
"Baclofen treatment affected the impact of chronic stress on different phases of morphine-induced CPP."( Effect of baclofen on morphine-induced conditioned place preference, extinction, and stress-induced reinstatement in chronically stressed mice.
Meng, S; Qi, X; Quan, W; Su, Z; Yang, S, 2014
)
1.53
"Baclofen treatment resulted in recovery of the weakened RDD at 1 week post stroke."( Weakened rate-dependent depression of Hoffmann's reflex and increased motoneuron hyperactivity after motor cortical infarction in mice.
Kiyama, H; Lee, S; Toda, T; Yamashita, T, 2014
)
1.12
"Baclofen treatment significantly suppressed their expression, bringing it close to the levels of controls."( Intrathecal baclofen, a GABAB receptor agonist, inhibits the expression of p-CREB and NR2B in the spinal dorsal horn in rats with diabetic neuropathic pain.
Bai, HP; Guo, WY; Liu, P; Wang, Q; Wang, XL; Zhang, YZ; Zhao, XN, 2014
)
1.5
"R-baclofen treatment reversed social approach deficits in BTBR T+ Itpr3tf/J (BTBR), reduced repetitive self-grooming and high marble burying scores in BTBR, and reduced stereotyped jumping in C58/J (C58), at nonsedating doses."( GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism.
Baker, S; Butler-Struben, HM; Crawley, JN; Hayes, JE; Pride, MC; Puhger, KR; Silverman, JL, 2015
)
1.28
"Baclofen treatment decreased craving in all patients."( Anticraving Effect of Baclofen in Alcohol-Dependent Patients.
Alvarez, JC; Imbert, B; Simon, N, 2015
)
1.45
"Baclofen pretreatment prevented the BDNF expression observed in morphine withdrawn male mice in all the brain areas studied except in the CeC."( Baclofen prevents the elevated plus maze behavior and BDNF expression during naloxone precipitated morphine withdrawal in male and female mice.
Balerio, GN; Pedrón, VT; Varani, AP, 2016
)
2.6
"Baclofen treatment significantly improved the spatial working memory impairments caused by 2VO, accompanied with a reversion of 2VO-induced down-regulation of HCN2."( Baclofen ameliorates spatial working memory impairments induced by chronic cerebral hypoperfusion via up-regulation of HCN2 expression in the PFC in rats.
Chen, C; Fu, T; Guo, L; He, Z; Li, C; Lu, Q; Lu, Y; Luo, P; Xu, X, 2016
)
2.6
"In baclofen/muscimol treated eyes the ERG b-wave went from 426+/-101 microV to 148+/-118 microV (n=6)."( GABA agonists fail to protect the retina from ischemia-reperfusion injury.
Agnarsson, BA; Eysteinsson, T; Stefánsson, E; Traustason, S, 2009
)
0.87
"Baclofen treatment facilitated the extinction of COR and reduced conditioned sensitization during extinction when given after, but not before, the activation of the CPP memory trace."( Baclofen enhances extinction of opiate conditioned place preference.
Carey, RJ; Heinrichs, SC; Kaplan, GB; Leite-Morris, KA, 2010
)
2.52
"Baclofen pretreatment blocked the induction of Fos in opiate conditioned subjects."( Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions.
Carey, RJ; Joshi, M; Kaplan, GB; Leite-Morris, KA; Shoeb, MH, 2003
)
2.48
"Baclofen pretreatment (3 mg/kg) not only prolonged the time taken for animals to reach a core body temperature of 40 degrees C (P < 0.001), but also reduced the percentage of rats attaining a core body temperature of 40 degrees C."( Baclofen prevents MDMA-induced rise in core body temperature in rats.
Bexis, S; Irvine, RJ; Ong, J; Phillis, BD; White, JM, 2004
)
2.49
"Baclofen is used for treatment of the spasticity of spinal origin that is a common sequela of spinal cord injury and multiple sclerosis; spasticity occurs in about 50% of patients affected by these disorders. "( A benefit-risk assessment of baclofen in severe spinal spasticity.
Dario, A; Tomei, G, 2004
)
2.06
"Baclofen treatment significantly reduced paired-pulse inhibition in the dentate gyrus."( Altered expression of K+ -Cl- cotransporters affects fast paired-pulse inhibition during GABA receptor activation in the gerbil hippocampus.
Choi, SY; Hwang, IK; Jung, JY; Kang, TC; Kim, DS; Kim, JE; Kwak, SE; Kwon, OS; Won, MH; Yoo, KY, 2006
)
1.06
"baclofen treatment also decreased, where after 5 days of baclofen infusion 1.0 microg (i.t.) baclofen only reduced PMR by 10% (compared to 40-50% preinfusion)."( Development of baclofen tolerance in a rat model of chronic spasticity and rigidity.
Fuchigami, T; Hefferan, MP; Marsala, M, 2006
)
1.41
"Baclofen pretreatment did not modify GTTs in GABAB(-/-) mice, whereas it impaired normal glycemia reinstatement in WT."( GABAB receptors and glucose homeostasis: evaluation in GABAB receptor knockout mice.
Arany, E; Bettler, B; Bonaventura, MM; Catalano, PN; Chamson-Reig, A; Hill, D; Libertun, C; Lux-Lantos, VA; Saravia, F, 2008
)
1.07
"Baclofen treatment abolished the motor responses elicited by AMPA from the shell, core and VP."( Involvement of the ventral tegmental area in locomotion elicited from the nucleus accumbens or ventral pallidum.
Churchill, L; Hooks, MS; Johnson, K; Kalivas, PW; Klitenick, MA, 1996
)
1.02
"Baclofen treatment was unsuccessful."( Congenital periodic alternating nystagmus. Diagnosis and Management.
Goldstein, HP; Gradstein, L; Reinecke, RD; Wizov, SS, 1997
)
1.02
"Baclofen-treated animals then were observed to consume greater amounts of ethanol than did saline controls throughout the remainder of the dark cycle as well as into the light cycle."( The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake.
Amit, Z; Boyle, AE; Smith, BR, 1999
)
1.3
"Baclofen treatment sensitized melanotrope cells to the stimulatory action of 8-bromo-cyclic-AMP on the secretion of alpha-MSH."( The CRF-related peptide sauvagine stimulates and the GABAB receptor agonist baclofen inhibits cyclic-AMP production in melanotrope cells of Xenopus laevis.
de Koning, HP; Jenks, BG; Leenders, HJ; Roubos, EW; van Zoest, ID, 1991
)
1.23
"Baclofen pretreatment increased Bmax in washed cerebellar membranes when bicuculline was present in the incubation mixture."( GABA-B receptor activation and conflict behaviour.
Bollen, EL; Bruinvels, J; Ketelaars, CE; Rigter, H, 1988
)
1
"Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used."( Multiple sclerosis. Current concepts in management.
Giesser, B, 1985
)
0.99
"Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug."( Baclofen for alcohol withdrawal.
Liu, J; Wang, LN, 2019
)
2.3
"Treatment of baclofen withdrawal includes supportive care and reinitiation of baclofen."( Enteral baclofen withdrawal managed with intravenous dexmedetomidine: A case report.
Ahmed, S; Brewer, T; Defayette, A; Perrello, A; Picano, J, 2020
)
1.35
"Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug."( Baclofen for alcohol withdrawal.
Liu, J; Wang, LN, 2017
)
2.24
"Treatment with baclofen further led to a decrease in alcohol cue-modulated functional connectivity between left VTA and left anterior cingulate cortex (ACC) as well as left medial prefrontal cortex (MPFC)."( Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Beck, A; Charlet, K; Geisel, O; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wüstenberg, T, 2018
)
1.14
"The treatment baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. "( Baclofen for alcohol withdrawal.
Liu, J; Wang, LN, 2013
)
2.19
"The treatment baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. "( Baclofen for alcohol withdrawal.
Liu, J; Wang, LN, 2015
)
2.22
"Treatment of baclofen intoxication compares of gastric lavage using a thick pathfinder, accompanied by insertion of adsorbent and apocathartic means, maintaining of impaired vital functions of body."( [Clinical characteristics, diagnosis, and treatment of acute intoxication by baclofen].
Bagrov, AV; Butikov, VP; Gerasimov, GL; Grebeniuk, AN; Kuznetsov, PV; Manuĭlov, VM; Vasiliuk, VB, 2009
)
0.93
"The treatment of baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. "( Baclofen for alcohol withdrawal.
Liu, J; Wang, L, 2011
)
2.15
"Pretreatment with baclofen (1.25 and 2.5 mg/kg i.p.) dose-dependently reduced the nicotine-, morphine-, and cocaine-evoked DA release in the shell of the nucleus accumbens."( Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.
Collu, M; Fadda, P; Fratta, W; Fresu, A; Scherma, M, 2003
)
2.09
"Pretreatment with baclofen had no significant effect alone, nor in combination with cocaine, on any outcome."( Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans.
Allen, TS; Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2004
)
2.09
"Pretreatment with baclofen, which failed to alter alcohol intake when given alone, dose-dependently suppressed morphine- and WIN 55,212-2-induced promotion of alcohol drinking."( Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats.
Carai, MA; Colombo, G; Gessa, GL; Serra, S; Vacca, G, 2004
)
1
"Treatment with baclofen also suppressed the number of daily drinks and decreased the obsessive and compulsive components of alcohol craving."( Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics.
Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Pibiri, F; Serra, S; Vacca, G, 2004
)
0.9
"Pretreatment with baclofen produced dose-dependent reductions in responding for dAMPH under both the FR and PR schedules, and attenuated dAMPH-induced increases in DA levels in the NAc."( Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates.
Ahn, S; Brebner, K; Phillips, AG, 2005
)
0.91
"Treatment with baclofen (4 mg/kg) did not modify spontaneous VCM."( Effects of baclofen on reserpine-induced vacuous chewing movements in mice.
Abílio, VC; Castro, JP; Frussa-Filho, R; Fukushiro, DF; Medrano, WA; Ribeiro, Rde A; Silva, RH, 2006
)
1.06
"Oral treatment with baclofen and sodium valproate was partially successful in one patient, but ineffective in the other."( Propriospinal myoclonus in tetraplegic patients: clinical, electrophysiological and therapeutic aspects.
Alaoui, P; Arné, P; Barat, M; Fouillet, N; Petit, H; Wiart, L, 1995
)
0.61
"Pretreatment with baclofen (0.1-1 nmol/side) into the ventral tegmental area dose dependently suppressed the morphine (8 mg/kg, s.c)-induced place preference."( Activation of ventral tegmental GABAB receptors inhibits morphine-induced place preference in rats.
Ishibashi, Y; Nakagawa, Y; Shimada, M; Suzuki, T; Takashima, T; Tsuji, M; Yoshii, T, 1996
)
0.62
"Treatment with baclofen resulted in a dose dependent decrease in the intensity of tremor."( Baclofen attenuates harmaline induced tremors in rats.
Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2001
)
2.09
"Pretreatment with baclofen decreased both the rate of acquisition of cocaine self-administration and the percentage of rats meeting the acquisition criterion to a greater extent in females than in males."( Sex differences in the effects of baclofen on the acquisition of intravenous cocaine self-administration in rats.
Campbell, UC; Carroll, ME; Morgan, AD, 2002
)
0.92
"Pretreatment with baclofen antagonized the rise in cerebellar cyclic GMP content induced by isoniazid and picrotoxin, but did not affect the increase in cyclic GMP following administration of pentetrazole."( Baclofen and cerebellar cyclic GMP levels in mice.
Dinnendahl, V; Gumulka, SW; Schönhöfer, PS, 1979
)
2.03
"Treatment with baclofen, a GABAB receptor agonist, gave a pertussis toxin-sensitive decrease in the cyclic-AMP level and an inhibition of alpha-MSH release."( The CRF-related peptide sauvagine stimulates and the GABAB receptor agonist baclofen inhibits cyclic-AMP production in melanotrope cells of Xenopus laevis.
de Koning, HP; Jenks, BG; Leenders, HJ; Roubos, EW; van Zoest, ID, 1991
)
0.85
"Pretreatment with baclofen prevented the capacity of a mu opioid agonist to elevate dopamine metabolite levels in the nucleus accumbens and prefrontal cortex in postmortem tissue."( Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists.
Duffy, P; Eberhardt, H; Kalivas, PW, 1990
)
0.6
"Pretreatment with baclofen prolonged the duration of fentanyl-induced analgesia from 18 to 30 min in patients undergoing neurosurgical anaesthesia (fentanyl plus nitrous oxide in oxygen). "( Baclofen prolongs the analgesic effect of fentanyl in man.
de Silva, E; Mantegazza, P; Massei, R; Monza, G; Panerai, AE; Sacerdote, P, 1985
)
2.05

Toxicity

This is the fifth reported case of intrathecal baclofen administered during pregnancy. It adds to the knowledge that thus far it is relatively safe in pregnancy and may in fact be safer for the infant than oral baclfen.

ExcerptReferenceRelevance
" THIP, even at toxic doses, did not alter the anti-PTZ activity of either pentobarbital or phenobarbital."( Effects of gamma-aminobutyric acid (GABA) receptor agonists on the neurotoxicity and anticonvulsant activity of barbiturates in mice.
Chweh, AY; Swinyard, EA; Ulloque, RA, 1986
)
0.27
"To report the toxic effects of baclofen in patients with severely impaired renal function."( Baclofen toxicity in patients with severely impaired renal function.
Bullard, MJ; Chen, KS; Chien, YY; Lee, SY, 1997
)
2.03
"Among our nine patients, the six undergoing chronic hemodialysis and one not undergoing dialysis received early (< 48 h) hemodialysis after toxic symptoms developed."( Baclofen toxicity in patients with severely impaired renal function.
Bullard, MJ; Chen, KS; Chien, YY; Lee, SY, 1997
)
1.74
"As most patients with severely impaired renal function developed toxic symptoms soon after initiating a low-dose baclofen regimen, the accumulated dosage was small and severe complications were less common."( Baclofen toxicity in patients with severely impaired renal function.
Bullard, MJ; Chen, KS; Chien, YY; Lee, SY, 1997
)
1.95
" In the course of Baclofen's therapy, toxic effects of the drug like weakness, nausea, vomiting and fears appeared during the second day of treatment."( [Toxic effects of baclofen in a patient with chronic renal insufficiency].
Kroczak, M; Rakus, A, 2001
)
0.98
" During 80 recipient-years of pump operation, 153 treatment-associated adverse events occurred: 27 of these were device-related."( Long-term safety and efficacy of continuous intrathecal baclofen.
Bjornson, K; Campbell, WM; Ferrel, A; Grant, GA; Graubert, C; Loeser, JD; McLaughlin, JF, 2002
)
0.56
" Overall, the data obtained here suggest that positive modulation of GABAB receptors may serve as a novel therapeutic strategy for the development of anxiolytics, with a superior side effect profile to both baclofen and benzodiazepines."( Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines.
Bettler, B; Chaperon, F; Cryan, JF; Froestl, W; Gentsch, C; Kaupmann, K; Kelly, PH; Lingenhoehl, K; Mombereau, C; Spooren, WP, 2004
)
0.7
" Their use is frequently associated with dose-limiting adverse effects."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" This is the fifth reported case of intrathecal baclofen administered during pregnancy and adds to the knowledge that thus far it is relatively safe in pregnancy and may in fact be safer for the infant than oral baclofen."( The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis.
Buckley, L; Dalton, CM; Jarrett, L; Keenan, E; Stevenson, VL, 2008
)
0.96
" We prospectively recorded effects and adverse events at regular follow-up visits up to 24 months."( Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.
Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009
)
0.61
"4 months (range 12-24), we recorded 80 adverse events."( Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.
Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009
)
0.61
"CITB was effective at 12 months and safe up to 24 months for carefully selected children with intractable spastic CP."( Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.
Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009
)
0.61
" Several publications described clinical adverse effects of baclofen oral treatment, but the effect of baclofen on seizure potentiation is still controversial."( Long-term oral baclofen treatment in a child with cerebral palsy: electroencephalographic changes and clinical adverse effects.
De Rinaldis, M; Gennaro, L; Losito, L; Trabacca, A, 2010
)
0.96
" Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis."( Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.
Addolorato, G; Leggio, L, 2010
)
1.07
" Baclofen was well tolerated with only 2 individuals stopping baclofen because of adverse events."( Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010
)
1.58
" The outcomes considered were alcohol withdrawal seizures, adverse events and dropouts."( Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.
Amato, L; Davoli, M; Minozzi, S, 2011
)
0.37
"Our experience shows that low cervical catheter insertion for administration of a test dose of intrathecal baclofen and feasible and safe to perform via the method described."( Cervical catheter placement for intrathecal baclofen test dose: is it safe?
Ingale, H; Muquit, S; Ughratdar, I; Vloeberghs, M, 2012
)
0.85
"This paper presents a new analytical method for the simultaneous determination of baclofen and gabapentin in feeds based on two modified quick, easy, cheap, effective, rugged and safe (QuEChERS) sample preparation methods and liquid chromatography tandem mass spectrometry (LC-MS/MS)."( Evaluation of two modified quick, easy, cheap, effective, rugged and safe (QuEChERS) sample preparation methods for the analysis of baclofen and gabapentin in feeds by liquid chromatography tandem mass spectrometry.
Chen, RX; Hou, XL; Lv, Y; Wu, YL; Xu, XQ; Zhu, Y, 2014
)
0.83
"To assess the frequency and types of adverse events (AEs) related to intrathecal baclofen (ITB) therapy in adults, and associated risk factors."( Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
Bensmail, D; Borrini, L; Hugeron, C; Jourdan, C; Rech, C; Thiebaut, JB, 2014
)
0.88
" AEs were related to the surgical procedure in 53% of cases, to the device in 29% (predominantly catheter dysfunctions), and to adverse effects of baclofen in 18%."( Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
Bensmail, D; Borrini, L; Hugeron, C; Jourdan, C; Rech, C; Thiebaut, JB, 2014
)
0.85
" These precautions notably consist of a protocolized process for declaring adverse events, and a hepatologic follow-up associated with the usual multidisciplinary care system set up within CAMTEA."( [Baclofen and liver cirrhosis: literature review and safety precautions implemented within the system CAMTEA].
Bordet, R; Cottencin, O; Deheul, S; Gautier, S; Louvet, A; Rolland, B,
)
1.04
" HDB induces frequent neuropsychiatric adverse events (AEs)."( Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015
)
0.62
" However, HDB has been associated with numerous reports of adverse events (AEs)."( Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
Auffret, M; Franchitto, N; Rolland, B, 2016
)
0.7
" Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse events."( A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016
)
0.65
" Both the drugs showed good tolerability with mild self-limiting adverse events."( A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016
)
0.65
" Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed."( Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Auffret, M; Baguet, A; Bordet, R; Cabe, N; Carton, L; Cottencin, O; Deheul, S; Dervaux, A; Dib, M; Drelon, M; Duhamel, A; Gautier, S; Grit, I; Guillin, O; Jardri, R; Kemkem, A; Labreuche, J; Lapeyre-Mestre, M; Masquelier, C; Rolland, B; Vabret, F, 2017
)
1.62
"Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner."( Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Rolland, B, 2017
)
0.65
" However, we still have few data about the adverse effects of a high-dose baclofen prescription, especially in complex addictive disorders."( Gambling disorder: a side effect of an off-label prescription of baclofen-literature review.
Gerardin, M; Guillou-Landreat, M; Victorri Vigneau, C, 2017
)
0.92
" However, adverse effects, such as muscle weakness, nausea, somnolence and paraesthesia, are common with oral baclofen, affecting between 25% and 75% of patients, and limiting its usefulness."( Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
Calabrese, A; Campo, C; Ertzgaard, P, 2017
)
0.96
" The Specialized Health Needs Interagency Collaboration (SHNIC) program at the Kennedy Krieger Institute has complied education and materials that explain the use of baclofen pumps in children with spasticity and the role of the school nurse in providing staff training, developing emergency care plans, and creating a safe school environment for children with special health needs."( Hidden Medical Devices in the School Setting: What the School Nurse Needs to Know About the Safe Use of Baclofen Pumps.
Obst, B; Roesler, M, 2018
)
0.89
" Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes."( A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
Fu, X; Li, J; Li, M; Ma, Q; Wang, C; Wang, Y; Wu, H; Yang, W, 2018
)
0.48
" Cannabinoids, tizanidine and diazepam had significantly more mild adverse effect reports than placebo."( A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
Fu, X; Li, J; Li, M; Ma, Q; Wang, C; Wang, Y; Wu, H; Yang, W, 2018
)
0.48
" Furthermore, tolerability of HDB was low, but serious adverse events were rare."( Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis.
Beraha, EM; Morley, K; Pierce, M; Sutterland, A; van den Brink, W, 2018
)
0.72
" Clinically, these patients with renal failure may present with a variety of toxic symptoms manifesting at therapeutic/sub-therapeutic doses of baclofen."( Baclofen-induced neurotoxicity in patients with compromised renal function: Review.
Achanti, A; Arany, I; Beck Gööz, M; Castaneda, J; Dreisbach, AW; Fülöp, T; Salim, SA; Thomas, L, 2018
)
2.12
" Modified Ashworth scale (mAS) score, disability assessment scale (DAS) score, modified medical research council (mMRC) score, the Barthel Index (BI) score, and treatment-emergent adverse effects were evaluated during the follow-up period."( Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.
Lan, J; Liu, Y; Miao, J; Yan, X, 2018
)
0.48
"Baclofen toxicity can produce an acute encephalopathy even at modest doses, with the EEG showing generalized slowing and triphasic waves consistent with a toxic encephalopathy."( Baclofen Neurotoxicity: A Metabolic Encephalopathy Susceptible to Exacerbation by Benzodiazepine Therapy.
Dunne, JW; Lawn, ND; Triplett, JD, 2019
)
3.4
"The objective of our study was to determine whether treatment with baclofen is neurologically safe with respect to exposure during recovery from spinal cord injury."( A Longitudinal Study of the Neurologic Safety of Acute Baclofen Use After Spinal Cord Injury.
Cashman, N; Cragg, JJ; Geisler, F; Jutzeler, CR; Kramer, JLK; Tong, B; Warner, FM, 2019
)
1
" We compared the informativity concerning the patient, treatment, seriousness and expectedness of adverse events described on these posts, with similar information coded in case reports from the French pharmacovigilance database (FPVD)."( [Informativity of French web forums for the evaluation of side effects of baclofen].
Bousquet, C; Karapetiantz, P; Lillo-Le Louët, A, 2019
)
0.74
" Adverse events were significantly more often unexpected in forums than in the FPVD (43."( [Informativity of French web forums for the evaluation of side effects of baclofen].
Bousquet, C; Karapetiantz, P; Lillo-Le Louët, A, 2019
)
0.74
"29% had (serious) adverse events (60% of clinical manifestations were prevented by remote double-check control)."( Efficiency and Safety of Aftercare With Intrathecal Baclofen on Location.
Delhaas, EM; Frankema, SPG; Goslinga-van der Gaag, SME; Huygen, FJPM, 2019
)
0.76
"The most common adverse effect of baclofen, used for managing hiccups and spasticity, is neurotoxicity."( Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function.
Cheong, M; Kim, SB; Lee, J; Lee, TY,
)
0.7
"This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs."( Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection.
Copeland, L; McCartney, L; Tyack, L; Waugh, MC, 2021
)
1.1
" Regarding the toxicity of the two compounds, our results showed that ABF1-βCD has less toxic effect than baclofen; it reduces the activity of ALT and AST enzymes."( Synthesis and Biological Analysis of Anti-addiction Effect and Hepatotoxicity of Tow Baclofen Analogues Complexed with β-Cyclodextrin.
Dib, MEA; El Ouar, I; Keniche, A; Zeghina, I, 2022
)
1.16
" The objectives of this study were to compare the efficacy and adverse effects of tolperisone compared to baclofen among patients with spasticity associated with spinal cord injury."( Efficacy and safety of tolperisone versus baclofen among Chinese patients with spasticity associated with spinal cord injury: a non-randomized retrospective study.
Chen, R; Fang, S; Huang, Y; Li, M; Liu, N, 2021
)
1.1
" Adverse events and abstinence at last follow-up were compared by Student's t-test, Mann-Whitney U or chi-square test."( Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022
)
1.01
"Data were extracted using the following population, intervention, comparator, outcomes, and study designs criteria: studies including adult patients with SCI with spasticity; the intervention could be oral or intrathecal administration of baclofen; selection was inclusive for control groups, surgical management, rehabilitation, and alternative pharmaceutical agents; outcomes were efficacy, dosing, and adverse events."( Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.
D'Amico, JM; Dietz, N; Harkema, SJ; Wagers, S, 2023
)
1.41
" Forty-three studies addressed adverse events with muscle weakness and fatigue frequently reported."( Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.
D'Amico, JM; Dietz, N; Harkema, SJ; Wagers, S, 2023
)
1.23
" A host of adverse events were reported that may negatively affect quality of life."( Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.
D'Amico, JM; Dietz, N; Harkema, SJ; Wagers, S, 2023
)
1.23
"Study outcomes will determine what dose of baclofen is safe to prescribe to those receiving methadone, to inform a subsequent proof-of-concept trial of the efficacy baclofen to facilitate opiate detoxification."( FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study.
Barker, D; Cro, S; Lingford-Hughes, AR; Mozgunov, P; Nahar, L; Paterson, LM; Paterson, S; Phillips, R; Smith, C, 2022
)
1.21
" The usual side effects such as drowsiness were frequent (22%) but no serious adverse events (AEs) or overt encephalopathy related to baclofen was reported."( Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023
)
2.56
"To determine whether the therapeutic drug levels and adverse events (AEs) associated with renally cleared medications were higher in patients with cancer whose eGFRcys was more than 30% lower than their eGFRcr."( Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.
Gupta, S; Hanna, PE; Harden, D; Katz-Agranov, N; Leaf, DE; Moreno, D; Ouyang, T; Reynolds, KL; Seethapathy, H; Sise, ME; Strohbehn, IA; Wang, Q, 2023
)
0.91
"5 mEq/L), (3) baclofen toxic effect, and (4) supratherapeutic digoxin level (>2."( Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.
Gupta, S; Hanna, PE; Harden, D; Katz-Agranov, N; Leaf, DE; Moreno, D; Ouyang, T; Reynolds, KL; Seethapathy, H; Sise, ME; Strohbehn, IA; Wang, Q, 2023
)
1.27
"07), baclofen toxic effects (5 of 19 [26%] vs 0 of 11; P = ."( Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.
Gupta, S; Hanna, PE; Harden, D; Katz-Agranov, N; Leaf, DE; Moreno, D; Ouyang, T; Reynolds, KL; Seethapathy, H; Sise, ME; Strohbehn, IA; Wang, Q, 2023
)
1.42
" Baclofen safety was evaluated by adverse reaction occurrence during treatment."( Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.
Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023
)
2.06

Pharmacokinetics

Baclofen is known to produce anticonvulsant effects in the DBA/2J mouse audiogenic seizure test (AGS) The developed assay was successfully applied to a pharmacokinetic study and examined urinary excretion and tissue distribution.

ExcerptReferenceRelevance
" The EEG effects of the S-isomer were small and best described by a linear pharmacodynamic model."( Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures.
Danhof, M; De Boer, AG; Heijligers-Feijen, CD; Mandema, JW; Tukker, E, 1992
)
0.51
" Simulations based on mean data suggest that increased drowsiness in the elderly was probably not due to changes in the drug's pharmacokinetic behaviour."( Baclofen in the elderly stroke patient its side-effects and pharmacokinetics.
Hulme, A; John, VA; MacLennan, WJ; Ritchie, RT; Shotton, PA, 1985
)
1.71
" The pharmacokinetic disposition was determined form plasma concentration-time data and urinary recovery after the administration of rate-limiting intestinal infusions and an oral bolus dose."( The pharmacokinetics of baclofen derived from intestinal infusion.
Honc, F; Kershaw, RA; Kochak, GM; Rakhit, A; Wagner, WE; Waldes, L, 1985
)
0.58
" All of the calculated steady-state pharmacokinetic parameter changes for baclofen, tizanidine, and its major metabolites were within the 30% criterion."( A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
Groves, L; Novack, GD; Shah, J; Shellenberger, MK, 1999
)
0.78
"94 mg/kg of racemate) and this effect fits to a linear pharmacodynamic model."( Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of baclofen in mice.
Balerio, GN; Rubio, MC,
)
0.36
" The pharmacokinetics of baclofen in animal and man after intrathecal administration have been investigated to determine the CSF pharmacokinetic parameters."( [Intrathecal baclofen. Experimental and pharmacokinetic studies].
Lazorthes, Y; Sallerin, B, 2003
)
0.99
" In vivo pharmacokinetic studies in rabbits showed Cmax of 189."( Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies.
Joshi, G; Sawant, KK; Thakar, K, 2013
)
0.68
" The developed assay was successfully applied to a pharmacokinetic study and examined urinary excretion and tissue distribution of baclofen in rats following intravenous and oral administration."( Liquid chromatography-tandem mass spectrometry determination of baclofen in various biological samples and application to a pharmacokinetic study.
Choi, JH; Joo, SH; Kim, TH; Kwon, DR; Lee, AR; Min, BS; Park, GY; Seo, WS; Shin, BS; Shin, JC; Shin, S; Yoo, SD; Yoo, WY, 2013
)
0.83
" Cmax was not statistically different between the groups, while AUC and T1/2el increased, and CL/F decreased, with increasing severity of CKD."( Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations.
Barrière, O; Larouche, R; Perreault, MM; Pichette, V; Shink, E; Tanguay, M; Tremblay, PO; Vlavonou, R, 2014
)
0.68
" Baclofen is known to produce anticonvulsant effects in the DBA/2J mouse audiogenic seizure test (AGS), suggesting it may be a suitable assay for assessing pharmacodynamic effects."( Anticonvulsant effects of structurally diverse GABA(B) positive allosteric modulators in the DBA/2J audiogenic seizure test: Comparison to baclofen and utility as a pharmacodynamic screening model.
Brown, JW; Ma, J; Moeller, A; Nimmrich, V; Rueter, LE; Schmidt, M; Turner, SC; van der Kam, E; Zhang, M, 2016
)
1.55
" Our aim was to use an integrative approach to measure multiple cardiovascular-relevant parameters [CV: mean arterial pressure (MAP), systolic BP, diastolic BP, pulse pressure, heart rate (HR); CNS: EEG; renal: chemistries and biomarkers of injury] in tandem with the pharmacokinetic properties of baclofen to better elucidate the site(s) of baclofen activity."( Quantitative pharmacokinetic-pharmacodynamic modelling of baclofen-mediated cardiovascular effects using BP and heart rate in rats.
Barthlow, H; Beaudoin, ME; Bialecki, RA; Kamendi, H; Lengel, D; Mettetal, JT; Snow, D, 2016
)
0.85
" Noncompartmental pharmacokinetic analyses were performed."( A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics.
Agarwal, SK; Cloyd, JC; Coles, LD; Krach, LE; Kriel, RL; Mishra, U; Schmitz, NS, 2017
)
0.71
" First, the HPMC compositions and the corresponding in vitro dissolutions parameters were correlated, and then the in vitro dissolution parameters were correlated with the in vivo dissolution parameters extracted from the pharmacokinetic profiles of the baclofen ER formulations via population pharmacokinetic modeling."( Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics.
Bulitta, JB; Kim, DH; Kim, TH; Shin, BS; Shin, S, 2019
)
0.91
" Baclofen PK in the neonate after birth followed a monoexponential elimination with a half-life of 10 h, 3-fold longer than that in adults."( Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report.
Balakirouchenane, D; Chevillard, L; Chouchana, L; Declèves, X; Khoudour, N; Parat, S, 2021
)
1.86

Compound-Compound Interactions

Baclofen, either alone or in combination with alcohol, produced only modest increases in heart rate and blood pressure and no adverse effects were reported. However, its apparent synergism with carbamazepine and phenytoin combined with its low incidence of serious side effects make it a valuable adjunct in the treatment of trigeminal neuralgia.

ExcerptReferenceRelevance
"The effects of enoxacin, a new quinolone antibacterial agent, and its combination with 4-biphenylacetate (BPA), an active metabolite of the non-steroidal antiinflammatory agent fenbufen, were examined on population spikes induced by electrical stimulation of the stratum radiatum in the CA1 pyramidal cell layer in rat hippocampal slices."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.28
" However, its apparent synergism with carbamazepine and phenytoin combined with its low incidence of serious side effects make baclofen a valuable adjunct in the treatment of refractory trigeminal neuralgia."( Treatment of trigeminal neuralgia: use of baclofen in combination with carbamazepine.
Baker, KA; Lilly, GE; Taylor, JW,
)
0.6
"5 mg/kg), a GABAB agonist, administered alone or in combination with a single dose of naltrexone (1."( The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat.
Stromberg, MF, 2004
)
0.68
" The primary goal of this study was to determine the safety of baclofen in combination with alcohol consumption in heavy drinkers."( Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Bisaga, A; Evans, SM, 2009
)
0.91
"Baclofen, either alone or in combination with alcohol, produced only modest increases in heart rate and blood pressure and no adverse effects were reported."( Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Bisaga, A; Evans, SM, 2009
)
2.11
"Baclofen alone has minimal abuse liability in heavy social drinkers, and baclofen is relatively well tolerated and safe when given in combination with intoxicating doses of alcohol."( Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Bisaga, A; Evans, SM, 2009
)
2.11
" GHB is frequently combined with other recreational drugs although these interactions are not well characterised."( Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
McGregor, IS; van Nieuwenhuijzen, PS, 2009
)
0.35
" Indium111 diethylenetriamine penta-acetic acid (DTPA) scintigraphy combined with computed tomography revealed that the activity of the radioisotope was highest next to the first sacral vertebra and that there was no leakage."( Isotopic scintigraphy combined with computed tomography: a useful method for investigating inefficiency of intrathecal baclofen.
Couturier, O; Dinomais, M; Ferrapie, AL; Frémondière, F; Lacœuille, F; Menei, P; Richard, I; Saoût, V, 2014
)
0.61
"Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)."( Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022
)
0.72
"In this 1-year follow-up series, baclofen was combined with psychosocial treatment in patients with cirrhosis and was well tolerated."( Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023
)
2.63

Bioavailability

The study was aimed to improve bioavailability of baclofen by developing gastroretentive floating drug delivery system (GFDDS) Baclofen transport was measured across excised bovine olfactory and respiratory mucosae to investigate site-specific uptake of the drug.

ExcerptReferenceRelevance
"50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption rate pseudoconstants of the spasmolytic drug decrease as beta-alanine concentration increases, until a limiting value is obtained (36."( Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.
Merino, M; Plá-Delfina, JM; Polache, A, 1991
)
1.02
" If these results were extrapolated to humans, they would explain the excellent bioavailability profiles reported for baclofen at normal doses in spite of its physicochemical properties, which do not favour passive diffusion."( Evidence of a specialized transport mechanism for the intestinal absorption of baclofen.
Casabó, VG; García-Carbonell, MC; Martín-Villodre, A; Merino, M; Peris-Ribera, JE; Plá-Delfina, JM; Sánchez-Picó, A; Torres-Molina, F,
)
0.57
" However, there are no published data on the influence of food on the bioavailability of the drug."( Food does not affect the bioavailability of baclofen.
McLean, S; Millingen, KS; Peterson, GM, 1985
)
0.53
"5 mM baclofen solutions were perfused in the presence of increasing concentrations of the aminoacid (5-100 mM), the apparent absorption rate constant of the drug decreased as the initial leucine concentration increased."( Influence of leucine on intestinal baclofen absorption as a model compound of neutral alpha-aminoacids.
Casabó, VG; Cejudo-Ferragud, E; Cercós-Fortea, T; Merino, M; Nácher, A; Polache, A, 1995
)
1.08
" The bioavailability of Baclofen (Polpharma) and Lioresal (Novartis) in 18 healthy volunteers was investigated."( The bioequivalence study of baclofen and lioresal tablets using capillary electrophoresis.
Chmielewska, A; Konieczna, L; Kowalski, P; Lamparczyk, H; Oledzka, I; Zarzycki, PK, 2004
)
0.92
"In trials to preserve the pharmacological profile and improve the bioavailability via lipophilicity increment of baclofen 1 and searching for more potent and less toxic muscle relaxants and analgesics, nine substituted cyclic analogues of 1 were designed and synthesized."( 5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
Abdel-Hafez, AA; Abdel-Wahab, BA, 2008
)
0.77
" Sustained release formulations of arbaclofen placarbil demonstrated sustained R-baclofen exposure in dogs with bioavailability up to 68%."( Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
Annamalai, T; Bao, Y; Bu, L; Cundy, KC; Dias, T; Gallop, MA; Gao, M; Koller, K; Lal, R; Ludwikow, M; Luo, W; Nguyen, S; Peng, G; Phan, T; Raillard, SP; Scheuerman, RA; Sukbuntherng, J; Tai, EH; Upadhyay, S; Warren, MS; Wu, QQ; Yan, H; Yao, F; Zamora, J, 2009
)
1.35
" Baclofen transport was measured across excised bovine olfactory and respiratory mucosae to investigate site-specific uptake of baclofen, and the intranasal bioavailability of R- and S-baclofen was determined in rats."( Permeation and systemic absorption of R- and S-baclofen across the nasal mucosa.
Donovan, MD; Murry, DJ; Schmidt, M; Zhang, H, 2011
)
1.54
"The study was aimed to improve bioavailability of baclofen by developing gastroretentive floating drug delivery system (GFDDS)."( Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies.
Joshi, G; Sawant, KK; Thakar, K, 2013
)
0.93
"GFDDS provided prolonged gastric residence and showed significant increase in bioavailability of baclofen."( Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies.
Joshi, G; Sawant, KK; Thakar, K, 2013
)
0.89
" In addition, the oral bioavailability of baclofen relative to commercially available Lioresal® immediate release tablets was also investigated."( Baclofen novel gastroretentive extended release gellan gum superporous hydrogel hybrid system: in vitro and in vivo evaluation.
Aboelwafa, AA; El-Said, IA; ElGazayerly, ON; Khalil, RM, 2016
)
2.14
" Mean absolute bioavailability of oral baclofen was 74%."( A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers.
Agarwal, SK; Cloyd, JC; Coles, LD; Krach, LE; Kriel, RL; Scherkenbach, LA; Tobin, MH, 2015
)
0.91
" The 80% bioavailability suggests that a 20% reduction in IV dose will produce comparable total drug exposures to that of the PO dose."( A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics.
Agarwal, SK; Cloyd, JC; Coles, LD; Krach, LE; Kriel, RL; Mishra, U; Schmitz, NS, 2017
)
0.71
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" They have also been tested in vivo for their oral bioavailability and potential side effects."( Design, characterization and in vivo evaluation of modified release baclofen floating coated beads.
Abdelkader, H; Ibrahim, M; Naguib, YW; Sarhan, HA, 2020
)
0.79
"A model using three parameters plus a lag time and bioavailability was necessary to determine the pharmacokinetics of baclofen."( Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function?
Billat, PA; Boels, D; Brunet, M; Le Roux, G; Léger, M; Lelièvre, B; Lerolle, N, 2020
)
2.21
" This approach was found efficient to provide greater bioavailability and minimize hypotension associated with commercial baclofen tablets."( Preformulation-Assisted Design and Characterization of Modified Release Gastroretentive Floating Extrudates Towards Improved Bioavailability and Minimized Side Effects of Baclofen.
Abdelkader, H; Ibrahim, M; Naguib, YW; Sarhan, HA, 2021
)
1.02

Dosage Studied

A 66-year-old man affected by familial spastic paraplegia since he was 22 developed drug tolerance to intrathecal baclofen after 16 years of treatment. A stable dosage of 850 microg/day, achieved after the first two years, appeared to be progressively inadeguate to relief his spasticity.

ExcerptRelevanceReference
" The trouble occurs or is worsened when neuroleptics are withdrawn and is reduced when dosage is increased; it responds to the theoretical model of denervation supersensitivity."( [Tardive dyskinesia induced by neuroleptics. A review of the literature].
Cottereau, MJ; Deniker, P; Diepart, E, 1979
)
0.26
" Recommendations are made regarding dosage of baclogen in childhood."( A controlled trial of baclofen in children with cerebral palsy.
Jackson, AD; Milla, PJ, 1977
)
0.57
"Log dose-response curves for induction of contralateral rotational behaviour in the rat by unilateral intranigral injections of the GABA agonist muscimol and the GABA analogue baclofen have been compared."( Baclofen and muscimol: behavioural and neurochemical sequelae of unilateral intranigral administration and effects on 3H-GABA receptor binding.
Cross, AJ; Waddington, JL, 1979
)
1.9
" Side effects necessitating reduction of dosage were experienced by 20% of patients."( Bacloffen (Lioresal) in the long-term management of spasticity.
Jones, RF; Lance, JW, 1976
)
0.26
" Restoration of effective dosage again led to satisfactory voiding function in all patients."( Bladder training: its role in evaluating the effect of an antispasticity drug on voiding in patients with neurogenic bladder.
Abramson, AS; Feibel, A; Levine, SA; Roussan, MS, 1975
)
0.25
" Dopamine and the GABAB receptor agonist baclofen both inhibited cyclic-AMP efflux and alpha-MSH release, with similar dynamics of inhibition and similar dose-response relationships."( Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis.
de Koning, HP; Huchedé, B; Jenks, BG; Roubos, EW, 1992
)
0.55
" To date, only the antidepressants and the anticonvulsants have shown any effectiveness, albeit incomplete and inconsistent, and many questions remain unanswered: What are the exact indications for the antidepressants? What component of neuropathic pain do they relieve, and through which mechanisms? Which type of antidepressants should be prescribed? A first-generation tricyclic? Or a new compound with a selective action on serotonin reuptake? What are the effective dosage and duration of the treatment? What is it mechanism of action? What other antalgic effects do carbamazepine and baclofen possess apart from their action on trigeminal neuralgia? The opiates are generally considered to be without effect, but recent clinical and experimental findings seem to point otherwise."( [Pharmacological treatment of neuropathic pain].
Ollat, H, 1992
)
0.44
" The GABAB receptor antagonist 2-hydroxy-saclofen caused a 10 fold rightward shift of the baclofen dose-response curve, whereas the GABAA receptor antagonist bicuculline (10-50 microM) was ineffective."( Presynaptic GABAB receptor activation attenuates synaptic transmission to rat sympathetic preganglionic neurons in vitro.
Dun, NJ; Wu, SY, 1992
)
0.5
" On the basis of these considerations and clinical reports describing the use of these drugs, we make dosage recommendations to enable the practitioner to individualize therapeutic regimens."( Drugs used in the management of trigeminal neuralgia.
Patsalos, PN; Zakrzewska, JM, 1992
)
0.28
" Baclofen blood levels were observed to rise gradually over time in some patients on a stable dosing regimen, probably a result of impaired renal clearance."( Clinical and pharmacokinetic aspects of high dose oral baclofen therapy.
Aisen, ML; Cedarbaum, JM; Dietz, MA; Kutt, H; Rossi, P, 1992
)
1.44
" The 5 events during continuous infusion intoxication only happened in high dosed patients."( Intrathecal baclofen overdose: report of 7 events in 5 patients and review of the literature.
Brouwers, JR; Delhaas, EM, 1991
)
0.66
" Dose-response studies of the effect of baclofen on prolactin (PRL) secretion were performed in stressed male rats."( Further evidence for the inhibitory action of baclofen on a prolactin-releasing factor.
Libertun, C; Lux-Lantos, V; Rey, E; Somoza, G, 1991
)
0.81
" Effective dosage was 60 +/- 31 micrograms in the entire group."( Intraspinal baclofen in the treatment of severe spasticity and spasms.
Closa, C; Garcia-Fernandez, L; Guitart, JM; Jodar, R; Muxi, T; Noguer, M; Rubio, E; Sahuquillo, J, 1991
)
0.66
" Baclofen dosage increased from 182 +/- 135 to 528 +/- 266 mcg/day over the 3-22 month follow-up period."( Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury.
Donovan, WH; Loubser, PG; Narayan, RK; Russell, KD; Sandin, KJ, 1991
)
1.47
" The dose-response relationships showed that the effect of enoxacin was 100 times potentiated in the presence of BPA (10(-5) M)."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.28
" The dose-response curve of R-(--)-baclofen for its inhibitory effect on the electrically-induced vasopressor response was shifted to the right by the GABAB-receptor antagonist 2-hydroxysaclofen, but was not affected by the GABAA-receptor antagonist bicuculline."( GABAB receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat.
Kohlenbach, A; Schlicker, E, 1990
)
0.56
" This article reviews the indications, dosing regimens, and potential side effects of the drugs used for the treatment of trigeminal and glossopharyngeal neuralgia, posttherapeutic neuralgia, temporal arteritis, and migraine based on the clinical pharmacology of these drugs, so that the most appropriate treatment for each patient can be chosen on a sound, rational basis."( Clinical pharmacology of drugs used to treat head and face pain.
Fromm, GH, 1990
)
0.28
" The inhibitory effect of GABA was mimicked by the type B GABA agonist baclofen, displaying a similar dose-response relationship as GABA."( Presynaptic effects of gamma-aminobutyric acid on norepinephrine release and uptake in rat pineal gland.
Cardinali, DP; Chuluyan, HE; Rosenstein, RE, 1990
)
0.51
" Even with a very small dosage of Baclofen patients who were previously treated until intoxication without success there was a favorable reduction in spasticity."( [Continuous intrathecal baclofen therapy using an implantable pump system in severe spasticity].
Behrens, C; Braunsdorf, WE; Kleiter, K; Kuhlendahl, HD; Volkheimer, A, 1990
)
0.87
" Histologically, GABA at the high dosage and baclofen at both dosages significantly decreased the labeling index of the antral mucosa and significantly increased the serum gastrin level."( Inhibition by gamma-amino-n-butyric acid and baclofen of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Baba, M; Ichii, M; Iishi, H; Nakaizumi, A; Taniguchi, H; Tatsuta, M, 1990
)
0.8
" Dose-response curves were shifted to the right in a parallel fashion."( Electrophysiological study of SR 42641, a novel aminopyridazine derivative of GABA: antagonist properties and receptor selectivity of GABAA versus GABAB responses.
Desarmenien, M; Desaulles, E; Feltz, P; Hamann, M, 1987
)
0.27
"4 mM Ca2+, the degree of depression was inversely related to the Ca2+ concentration, with an increased sensitivity and sinistral shift of the dose-response curve at lower Ca2+ concentrations."( Calcium dependence of baclofen- and GABA-induced depression of responses to transmural stimulation in the guinea-pig isolated ileum.
Johnston, GA; Kerr, DI; Ong, J, 1987
)
0.59
", dose-response curves for induction of behaviors by SP (i."( Baclofen, gamma-aminobutyric acidB receptors and substance P in the mouse spinal cord.
Hwang, AS; Wilcox, GL, 1989
)
1.72
" Dose-response studies revealed that the gastric acid secretion induced by submaximal but not high doses of RX 77368 was elevated significantly by p-CPA pretreatment."( Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
Garrick, T; Stephens, RL; Taché, Y; Weiner, H, 1989
)
0.28
" Thus (-)-baclofen (100 microM) shifted the dose-response curve to forskolin to the right 5 fold in an apparently parallel fashion."( GABAB receptor modulation of adenylate cyclase activity in rat brain slices.
Hill, DR, 1985
)
0.67
" The dosage was optimized corresponding to the clinical symptoms."( [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
Paulig, M; Pellkofer, M, 1989
)
0.51
" There was a sinistral shift of the GABA dose-response curve in the presence of 10 pM cortisol, with a significant potentiation of the GABA-induced contractions over the lower dose range of GABA (3-30 microM), whereas 100 nM cortisol caused a non-parallel dextral shift of the GABA dose-response curve, with a depression of the maximum GABA response indicative of non-competitive antagonism."( Cortisol: a potent biphasic modulator at GABAA-receptor complexes in the guinea pig isolated ileum.
Johnston, GA; Kerr, DI; Ong, J, 1987
)
0.27
" 3) The phenomenon was specific since the dose-response curve of the adenosine-inhibitory effect was comparable in preparations from tolerant animals and controls."( Decreased response to GABA-B agonists in longitudinal smooth muscle-myenteric plexus preparations from morphine-tolerant guinea-pigs.
Ciuffi, M; Franchi-Micheli, S; Gentilini, G; Gori, AM; Luzzi, S; Zilletti, L, 1988
)
0.27
" Bicuculline 1 microM shifted the dose-response curve of GABA to the right and the excitatory effect was also enhanced."( Excitatory and inhibitory action of GABA on synaptic transmission in slices of guinea pig superior colliculus.
Arakawa, T; Okada, Y, 1988
)
0.27
" Chlorpromazine caused a slight shift in the dose-response curves as did chlordiazepoxide when used with phencyclidine."( Quantitative electrocortical changes in the rat induced by phencyclidine and other stimulants.
Bond, A; Neal, H, 1985
)
0.27
" Dose-response curves for this effect are reported for chlordiazepoxide, diazepam and meprobamate."( Septal driving of hippocampal theta rhythm: role of gamma-aminobutyrate-benzodiazepine receptor complex in mediating effects of anxiolytics.
Gray, JA; McNaughton, N; Mellanby, J; Nordeen, H; Nutt, D; Quintero, S; Thompson, MR, 1985
)
0.27
" Dose-response and time-course studies revealed that baclofen has little influence on neurotransmitter recognition site affinity, but rather enhances the synthesis or accumulation of second messenger that occurs in response to these agents."( Characterization of the relationship between gamma-aminobutyric acid B agonists and transmitter-coupled cyclic nucleotide-generating systems in rat brain.
Enna, SJ; Karbon, EW, 1985
)
0.52
" The effect of GABA was mimicked by (-)-baclofen, which gave a dose-response curve overlapping that of GABA, while (+)-baclofen was about one hundred times less potent."( Modulatory activity of GABAB receptors on cholinergic tone in guinea-pig distal colon.
Giotti, A; Luzzi, S; Maggi, CA; Spagnesi, S; Zilletti, L, 1985
)
0.54
" In each situation the dosage was gradually increased until benefit or troublesome adverse effects were encountered."( Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.
Fahn, S; Greene, P; Shale, H, 1988
)
0.27
" Central adverse effects, such as forgetfulness, can be reduced only by a reduction in dosage of the anticholinergic."( Systemic therapy of dystonia.
Fahn, S, 1987
)
0.27
"835 and a parallel shift of the probit-log dosage regression line to the right."( Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system.
Klockgether, T; Schwarz, M; Sontag, KH; Turski, L; Wüllner, U, 1988
)
0.51
" in a dose-dependent manner up to 5 mg/kg, the highest dosage used."( Baclofen and velocity storage: a model of the effects of the drug on the vestibulo-ocular reflex in the rhesus monkey.
Cohen, B; Helwig, D; Raphan, T, 1987
)
1.72
" Muscimol (2 mg/kg) and THIP (5 and 10 mg/kg) exerted the antiimmobility effect even after single dosing 1 h before the test."( Effect of GABAergic drugs in the behavioral 'despair' test in rats.
Borsini, F; Evangelista, S; Meli, A, 1986
)
0.27
" Although baclofen is considered to have fewer side effects than alternative drugs, problems can occur when the dosage is changed abruptly."( Hallucinations after preoperative baclofen discontinuation in spinal cord injury patients.
Harrison, SA; Wood, CA, 1985
)
0.95
" Spinalization enhanced the inhibitory effects of both enantiomers without altering their dose-response relations."( Stereoselectivity of spinal neurotransmission: effects of baclofen enantiomer on tail-flick reflex in rats.
Smith, DF, 1984
)
0.51
" 5 Methohexitone and thiopentone produced a biphasic dose-response on the K+-stimulated release of both amino acids; low concentrations enhanced release, high concentrations depressed release."( The effects of anaesthetics on the uptake and release of amino acid neurotransmitters in thalamic slices.
Kendall, TJ; Minchin, MC, 1982
)
0.26
" A reduction in the dosage of baclofen in six of these patients resulted in a recurrence of painful paroxysms in five patients."( Baclofen in trigeminal neuralgia: its effect on the spinal trigeminal nucleus: a pilot study.
Chattha, AS; Fromm, GH; Glass, JD; Terrence, CF, 1980
)
1.99
"A 58-year-old woman with long-standing hemifacial spasm experienced dramatic relief of symptomatology while receiving baclofen (Lioresal) in a daily dosage of 37."( Baclofen in hemifacial spasm.
Sandyk, R, 1984
)
1.92
" Limiting the opportunity to gnaw on inanimate objects shifted the dose-response curve for muscimol-induced self-injurious behavior (SIB) to the left and increased the maximum incidence of SIB."( Self-injurious behavior in rats produced by intranigral microinjection of GABA agonists.
Baumeister, AA; Frye, GD, 1984
)
0.27
" Doses of l-baclofen one fifth its equivalent racemic dosage produced a much greater enhancement of segmental inhibition."( Effect of baclofen enantiomorphs on the spinal trigeminal nucleus and steric similarities of carbamazepine.
Chang, CH; Fromm, GH; Sax, M; Terrence, CF; Yoo, CS, 1983
)
1.05
" In 12 patients with a history of epilepsy, baclofen was given in the conventional dosage range."( Baclofen. Its effect on seizure frequency.
Fromm, GH; Roussan, MS; Terrence, CF, 1983
)
1.97
"0 mg/kg induced a significant leftward displacement of the control dose-response curve constructed for apomorphine (0."( Effect of manipulation of the GABA system on dopamine-related behaviors.
Palermo-Neto, J; Sandoval, MR, 1995
)
0.29
" The optimal use of baclofen as an adjuvant analgesic requires an understanding of its pharmacology, side effect spectrum, and dosing guidelines that have proven useful in clinical practice."( Baclofen as an adjuvant analgesic.
Fromm, GH, 1994
)
2.05
" During horizontal acceleratory/deceleratory stimulation in darkness baclofen caused a biphasic pattern in the dose-response curves."( Effects of GABAB activation and inhibition on vestibulo-ocular and optokinetic responses in the pigmented rat.
Eriksson, B; Larsby, B; Niklasson, M; Tham, R, 1994
)
0.52
" To achieve a good therapeutic response in the latter condition the amount of intrathecal baclofen has to be approximately twice the dosage required in spinal spasticity."( Intrathecal baclofen application in patients with supraspinal spasticity secondary to severe traumatic brain injury.
Bramanti, P; Kofler, A; Kofler, M; Kronenberg, M; Rifici, C; Saltuari, L,
)
0.73
" The following were taken as evaluation criteria: age, sex, performance status, duration and dosage of previous systemic and current spinal morphine therapy, concomitant analgesic and co-analgesic medication, pretreatment of the dorsal column and neurological dysfunction due to damage either of the nerval plexus or of the medulla spinalis."( Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking.
Bingel, U; Kloke, M; Seeber, S, 1994
)
0.29
" There was a significant relationship between baclofen dosage and muscle tone in the upper (P = ."( Continuous intrathecal baclofen infusion for spasticity of cerebral origin.
Albright, AL; Barron, WB; Fasick, MP; Janosky, J; Polinko, P, 1993
)
0.85
" We describe a 39-year-old quadriplegic women who, over a 16-week period, developed clinical signs of baclofen toxicity confirmed by progressively rising serum baclofen levels while on a conventional stable dosing regimen."( Baclofen toxicity in a patient with subclinical renal insufficiency.
Aisen, ML; Dietz, M; Kutt, H; McDowell, F, 1994
)
1.95
" Twenty-three patients with severe chronic spasticity underwent bolus test dosing with 50, 75, or 100 micrograms of intrathecal baclofen administered by lumbar puncture."( Intrathecal baclofen for treatment of intractable spinal spasticity.
Abel, NA; Smith, RA, 1994
)
0.87
" Trials were reviewed by dosage regimen, therapeutic response, adverse effects, and complications."( Intrathecal baclofen for severe spasticity secondary to spinal cord injury.
Lewis, KS; Mueller, WM, 1993
)
0.66
" Individual dosage ranges and follow-up care also need to be defined more completely."( Intrathecal baclofen for severe spasticity secondary to spinal cord injury.
Lewis, KS; Mueller, WM, 1993
)
0.66
" Our data show that there was a significant increase in baclofen dosage needed to control spasticity during the first 12 months post implantation."( Intrathecal baclofen: does tolerance occur?
Akman, MN; Donovan, WH; Loubser, PG; O'Neill, ME; Rossi, CD, 1993
)
0.91
" Severely increased spasticity was noted with associated hyperthermia to 107 degrees F after the dosage was gradually decreased."( Hyperthermia associated with baclofen withdrawal and increased spasticity.
Hurvitz, EA; Mandac, BR; Nelson, VS, 1993
)
0.58
" The CIBI dosage had been titrated to reduce over lower extremity spasticity and improve lower extremity function, rather than to improve UE tone."( Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity.
Albright, AL; Barry, MJ; Fasick, MP; Janosky, J, 1995
)
0.57
" Initial dose-response curves revealed that dopamine was approximately equipotent at producing motor activity after microinjection into the core and shell, AMPA was more effective in the core, whereas DAMGO was more potent in the shell."( Involvement of the ventral tegmental area in locomotion elicited from the nucleus accumbens or ventral pallidum.
Churchill, L; Hooks, MS; Johnson, K; Kalivas, PW; Klitenick, MA, 1996
)
0.29
" A reduction in dosage was necessitated by muscular hypotonia in three ambulatory patients, areflexic bladder and urinary retention in three others, and nausea, dizziness, and drowsiness in one."( Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity.
Adamski, E; Fischer, E; Ordia, JI; Spatz, EL, 1996
)
0.58
"]) did not change tail-flick latency in control animals but produced a dose-dependent enhancement of the antinociception induced by clonidine and morphine, and shifted their dose-response curves to the left."( Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors.
Baeyens, JM; Barrios, M; Ocaña, M, 1996
)
0.29
" Repeated (14 days, twice daily), but not single, administration of imipramine (10 mg/kg) shifted the dose-response curves for serotonin and 8-OH-DPAT to the left."( Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding.
Bijak, M; Czyrak, A; Maćkowiak, M; Tokarski, K; Wedzony, K, 1996
)
0.29
"The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1996
)
0.66
"As most patients with severely impaired renal function developed toxic symptoms soon after initiating a low-dose baclofen regimen, the accumulated dosage was small and severe complications were less common."( Baclofen toxicity in patients with severely impaired renal function.
Bullard, MJ; Chen, KS; Chien, YY; Lee, SY, 1997
)
1.95
" They also required higher doses and more rapid dosage increases."( Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus.
Dressnandt, J; Marquardt, G; Mauch, E; Meinck, HM; Müller-Schwefe, G; Rieke, K; Schumm, F; Stayer, C; Tronnier, V, 1997
)
0.68
" ITB infusion allows for baclofen dosage titration to balance between extensor tone for support and suppression of hyperactive reflexes which may impede normal locomotion."( Effect on ambulation of continuous intrathecal baclofen infusion.
Albright, AL; Barry, MJ; Gerszten, PC, 1997
)
0.86
" The mean baclofen dosage was 306 microg/day (range 25-1350 microg/day)."( Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy.
Albright, AL; Gerszten, PC; Johnstone, GF, 1998
)
1.08
" At the functional level, the dose-dependent ability of baclofen (1-100 microM) to inhibit an evoked excitatory postsynaptic potential (f-EPSP) in the CA1 subfield was evaluated at 24 h postischemia, in comparison with the dose-response observed in sham-operated subjects."( Decreased hippocampal expression, but not functionality, of GABA(B) receptors after transient cerebral ischemia in rats.
Eubanks, JH; Francis, J; Ho, W; Wallace, MC; Zhang, L; Zhang, Y, 1999
)
0.55
" The hyperpolarization was dose-dependent, and the GABA(B) receptor antagonist CGP 35,348 produced a rightward shift in the agonist dose-response curve."( A powerful GABA(B) receptor-mediated inhibition of GABAergic neurons in the arcuate nucleus.
Bosch, MA; Kelly, MJ; Rønnekleiv, K; Wagner, EJ, 1998
)
0.3
" Concentrations of tizanidine and baclofen were nearly identical during the single and concomitant dosing periods."( A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
Groves, L; Novack, GD; Shah, J; Shellenberger, MK, 1999
)
0.83
" In fact it showed: (1) very sensitive dose-response not affected by TTX in the bath; (2) an equilibrium potential compatible with Cl-channel conductance; (3) a massive reduction with the competitive GABA(A) antagonist bicuculline; (4) a small reduction, if any, with the potent competitive GABA(B) antagonist CGP55845A; (5) persistence of the responses under 4-AP (4-aminopyridine), the potassium channel blocker, and inhibition of the 4-AP-induced calcium bursts of spikes."( Purkinje cell inhibitory responses to 3-APPA (3-aminopropylphosphinic acid) in RAT cerebellar slices.
Batini, C; Vigot, R, 1999
)
0.3
" At 3, 6, and 12 months, our mean baclofen dosage remained below the dosages administered at the T11-T12 level."( Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity.
Grabb, PA; Guin-Renfroe, S; Meythaler, JM, 1999
)
0.83
" The hyperpolarization was dose dependent, and the GABA(B) receptor antagonist CGP 35,348 produced a rightward shift in the agonist dose-response curve."( A powerful GABA(B) receptor-mediated inhibition of GABAergic neurons in arcuate nucleus.
Bosch, MA; Kelly, MJ; Rønnekleiv, OK; Wagner, EJ, 1999
)
0.3
" In slices prepared from UL animals, MVN cells in the rostral region of the ipsi-lesional nucleus showed a marked downregulation of their response to both muscimol and baclofen, seen as a rightward shift and a decrease in slope of the dose-response relationships for the two agonists."( Rapid compensatory changes in GABA receptor efficacy in rat vestibular neurones after unilateral labyrinthectomy.
Cameron, SA; Dutia, MB; Him, A; Yamanaka, T, 2000
)
0.5
" After pump insertion, baclofen dosage was gradually increased to 450 micrograms/day."( [Intrathecal perfusion pump with baclofen in generalized dystonia].
Bravo, M; Chacón, J; García-Moreno, JM; Grande, MA; Trujillo, A,
)
0.72
"In the first series of experiments, three dose-response curves were generated that examined the effect of three doses of baclofen (1."( Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules.
Brebner, K; Phelan, R; Roberts, DC, 2000
)
0.92
" It is concluded that repeated dosing of baclofen leads to mild tolerance development in terms of the effects on transient lower esophageal sphincter relaxation, but that the tolerance is much less pronounced than that previously reported in other animal models."( Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog.
Hansson-Brändén, L; Kärrberg, L; Lehmann, A, 2000
)
0.84
"6 mg/kg) did not attenuate the discriminative-stimulus effects of the training dose of cocaine or methamphetamine and did not produce any shift in the cocaine and methamphetamine dose-response curves."( Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats.
Goldberg, SR; Kutkat, SW; Miller, CR; Munzar, P, 2000
)
0.7
" Its use has been suggested at high dosage by intrathecal (i."( [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu].
Benhamou, D; Engrand, N; Rouamba, A; Vilain, G, 2000
)
0.62
" Due to the detrusor vesica urinariay's hypofunction (confirmed by repeated urodynamic studies) the patient was prescribed Baclofen with a dosage of 2 x 10 mg per 24 hours."( [Toxic effects of baclofen in a patient with chronic renal insufficiency].
Kroczak, M; Rakus, A, 2001
)
0.85
"0001) increase in intrathecal baclofen dosage requirements during the 1-year follow-up period to maintain the reductions in spasm frequency, reflexes and tone."( Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia.
Burns, AS; Meythaler, JM, 2001
)
0.98
"0 microg) were administered to obtain the dose-response curve and the 50% effective dose (ED(50))."( The interaction between intrathecal neostigmine and GABA receptor agonists in rats with nerve ligation Injury.
Choi, IC; Han, SM; Hwang, JH; Hwang, KS; Kim, JU; Park, PH, 2001
)
0.31
"In the first series of experiments, dose-response curves were generated to examine the effect of CGP56433A (0."( The GABA(B) antagonist CGP56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat.
Brebner, K; Froestl, W; Roberts, DC, 2002
)
0.56
" The inhibition of A reflex potential at this dosage was greater than that of blood pressure and heart rate induced by the same dosage of S(-)-baclofen."( [The effects of intrathecally administered baclofen on somato-sympathetic reflex potentials].
Iida, R; Kobayashi, T; Nakamura, T; Ogawa, S; Saeki, S; Tamura, M, 2002
)
0.78
" Baclofen significantly reduced break points at all doses of methamphetamine, producing a dose-orderly shift of the methamphetamine dose-response function to the right."( Baclofen decreases methamphetamine self-administration in rats.
Poeggel, K; Ranaldi, R, 2002
)
2.67
" Dosing according to clearly defined age groups with the help of therapeutic drug monitoring seems preferable."( Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease.
Benninga, MA; Butter, JJ; Omari, T; van Aalderen, WM; van Boxtel, CJ; Wiersma, HE, 2003
)
0.58
" The dosage of ITB increased from a mean of 157 microg/day 3 months after pump insertion to 300 microg/day at 2 years postimplantation, and remained relatively stable thereafter."( Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.
Albright, AL; Gilmartin, R; Ivanhoe, CB; Krach, LE; McLaughlin, JF; Swift, D, 2003
)
0.63
" In this report, we show that ATP elicits Ca(2+) responses producing a monophasic dose-response curve with an EC(50) value of 24."( GABAB receptor-mediated presynaptic potentiation of ATP ionotropic receptors in rat midbrain synaptosomes.
Gómez-Villafuertes, R; Gualix, J; Miras-Portugal, MT; Pintor, J, 2003
)
0.32
" In a first dose-response study, baclofen (0."( The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system.
Cella, SG; Muller, EE; Pitsikas, N; Rigamonti, AE, 2003
)
0.6
" Dosage errors can be a source of significant morbidity and the risk is greatest when the clinician is changing solution concentration."( Managing spasticity in spinal cord injury: safe administration of bridge boluses during intrathecal baclofen pump refills.
Elovic, E; Kirshblum, SC, 2003
)
0.54
"Nicotine maintained stable self-administration under a progressive ratio schedule with a linear dose-response function ( r=0."( The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat.
Froestl, W; Markou, A; Paterson, NE, 2004
)
0.62
"The purpose of this pilot study was to determine the feasibility of using mechanical measures of stretch reflexes to monitor spasticity after intrathecal baclofen dosage changes."( Mechanical measurements of the effects of intrathecal baclofen dosage adjustments in cerebral palsy: a pilot study.
Gaebler-Spira, D; Schmit, BD, 2004
)
0.77
" Mechanical measurements of stretch reflexes were made before and after pump implant in four of the six participants and after dosage changes in all participants, for a period of up to 2 yrs."( Mechanical measurements of the effects of intrathecal baclofen dosage adjustments in cerebral palsy: a pilot study.
Gaebler-Spira, D; Schmit, BD, 2004
)
0.57
"Mechanical measures of stretch reflexes change after intrathecal baclofen dosage adjustments, reflecting the clinical course of intrathecal baclofen therapy."( Mechanical measurements of the effects of intrathecal baclofen dosage adjustments in cerebral palsy: a pilot study.
Gaebler-Spira, D; Schmit, BD, 2004
)
0.81
") or placebo conditions (N = 35; identical in appearance and dosage rate) using a 2-group, experimental, 16-week double-blind design featuring thrice-weekly cognitive-behavioral drug counseling groups."( Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use.
Charuvastra, VC; Hsieh, YC; Kintaudi, PC; Ling, W; Rotheram-Fuller, EJ; Shoptaw, S; Yang, X, 2003
)
0.59
" The average dosage at follow-up was 57 mg/day of baclofen (range 15-120 mg/day)."( Orally delivered baclofen to control spastic hypertonia in acquired brain injury.
Brunner, RC; Clayton, W; Davis, LK; Guin-Renfroe, S; Meythaler, JM,
)
0.72
"There was no correlation between the dosage of baclofen and the clinical outcome."( [Acute intoxication with baclofen].
Chodorowski, Z; Sein Anand, J; Wiśniewski, M, 2004
)
0.88
"Neurologists safely use up to 300 mg/day (10 times the dosage currently used for alcohol dependence) of high-dose oral baclofen, to control spasticity, in order to avoid invasive therapy."( Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician.
Ameisen, O,
)
0.56
" Somnolence disappeared with a dosage reduction to 120 mg/day, now used for the eighth consecutive month."( Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician.
Ameisen, O,
)
0.35
" Dose-response curves were generated to examine the effect of three doses of baclofen (1."( Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates.
Ahn, S; Brebner, K; Phillips, AG, 2005
)
0.81
" The average dosage for the total group was 463 micrograms per day (microg/day), and 32% used a simple infusion mode."( Intrathecal baclofen therapy over 10 years.
Rawlins, PK, 2004
)
0.7
" Significant line differences were observed in the dose-response curves for both GHB and baclofen, with GHB-S rats displaying a greater sensitivity to the motor incoordinating effects of both drugs than GHB-R rats."( Different sensitivity to the motor incoordinating effects of gamma-hydroxybutyric acid (GHB) and baclofen in GHB-sensitive and GHB-resistant rats.
Carai, MA; Colombo, G; Gessa, GL; Lobina, C, 2005
)
0.77
" Initial studies examined the dose-response effects of injection of baclofen (0."( Injections of baclofen into the ventral medial prefrontal cortex block the initiation, but not the expression, of cocaine sensitization in rats.
Beyer, CE; Steketee, JD, 2005
)
0.92
" There was no statistically significant difference between patients with ITB deprivation who did and did not experience pruritus in their daily infused dosage or in concentration and mode of infusion."( Pruritus after intrathecal baclofen withdrawal: A retrospective study.
Ben Smail, D; Bussel, B; Denys, P; Hugeron, C, 2005
)
0.63
" The system allows programming of any drug dosage in a continuous infusion fashion in the subarachnoid space."( Dosage of intrathecal baclofen maintenance therapy in the spastic syndromes.
Burzaco, JA; del Barrio, ER; Fares, Y; Khazim, RM,
)
0.45
"The goal of this study was to develop a goat model allowing reliable pharmacokinetic (PK) studies of intrathecal baclofen (ITB) sustained release dosage forms using an implanted silicone catheter."( Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model.
Benoit, JP; Desfontis, JC; Faisant, N; Gautier, F; Holopherne, D; Lagarce, F; Marescaux, L; Menei, P; Rousselet, MC, 2005
)
0.82
" The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen."( Baclofen withdrawal: a cause of prolonged fever in the intensive care unit.
Cunningham, JA; Jelic, S, 2005
)
1.96
" The dosage of baclofen in patients with acute respiratory failure (ARF) was significantly higher than in patients without ARF."( Selected clinical aspects of acute intoxication with baclofen.
Burda, P; Chodorowski, Z; Sein Anand, J, 2005
)
0.93
" A smoked cocaine dose-response curve (0, 12, 25, 50 mg) was determined twice: on days 3-4 and days 6-7 of each baclofen maintenance condition."( Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers.
Foltin, RW; Haney, M; Hart, CL, 2006
)
0.93
" Baclofen shifted the flumazenil dose-response curve to the right and down, possibly involving perceptual masking of the discriminative stimulus effects of flumazenil by agonist activity at GABAB receptors."( Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
Carter, LP; Coop, A; France, CP; Koek, W; Wu, H, 2006
)
1.48
"We found a significant dose-response relationship between the soleus H/M ratio and CITB dose."( Dose-response relationship between the H-reflex and continuous intrathecal baclofen administration for management of spasticity.
Hayes, A; Olivier, J; Stokic, DS; Vesovic-Potic, V; Yablon, SA, 2006
)
0.56
" Key recommendations were made in areas including team coordination, patient selection and goals, patient education, patient screening, implant technique, long-term management, individualized dosing options, ongoing evaluation of patient response, appraisal of the integrity of the catheter and infusion system, and appropriate practice resources."( Intrathecal baclofen therapy: ten steps toward best practice.
Rawlins, PK; Ridley, B, 2006
)
0.71
" The diagnosis was confirmed by the plasma dosage providing an 8-fold increase above normal baclofen therapeutic range."( [EEG contribution to the diagnosis of baclofen overdose].
Alvarez, JC; Boutte, C; Durand, M; Vercueil, L; Vincent, F,
)
0.62
" Although in humans it is usually administered at 2 mg/ml, the dosage to be used in the treatment of other diseases is unknown."( Baclofen and potential therapeutic use: studies of neuronal survival.
Dario, A; Fesce, R; Peres, A; Pessina, F; Pisani, R; Protasoni, M; Reguzzoni, M; Sangiorgi, S; Soragna, A; Tomei, G, 2006
)
1.78
" Secondary objectives included determining correlations between dosage and age, injury type, location of spasticity, comorbid seizures, or concomitant antispasticity medications."( Oral baclofen and clonidine for treatment of spasticity in children.
Haase, M; Habersang, R; Lubsch, L; Luedtke, S, 2006
)
0.85
"A patient who had neither tolerated nor benefited from other alcohol treatment modalities was put on trial with baclofen on a dosage up to 140 mg/day."( Suppression of symptoms of alcohol dependence and craving using high-dose baclofen.
Bucknam, W,
)
0.57
" With this method, adequate liquor concentrations for hyperactivity/hipertonicity reduction are possible without the normal side effects that occur with the high oral dosage (about 100 times higher)."( [Intrathecal baclofen in treatment of spasticity casuistry of the Centro Hospitalar de Coimbra].
Martins, F; Martins, L; Veiros, I,
)
0.5
" At 100 mg/kg, CGP35348 shifted the dose-response curves of baclofen and SKF97541 to the right but not those of GHB and GBL; at 320 mg/kg, CGP35348 shifted the curves of all four compounds to the right."( Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
Coop, A; Koek, W; Mercer, SL, 2007
)
0.58
" This method reduces side effects due to a reduction in dosage compared to oral administration."( Paralytic ileus: a complication after intrathecal baclofen therapy.
Boyer, J; Chirivella, J; Escamilla, B; Ferri, J; Morant, A; Noé, E; Trénor, C, 2006
)
0.59
" The treatment was conservative and the dosage of intrathecal baclofen was reduced to lowest drug flow."( Paralytic ileus: a complication after intrathecal baclofen therapy.
Boyer, J; Chirivella, J; Escamilla, B; Ferri, J; Morant, A; Noé, E; Trénor, C, 2006
)
0.83
" The dosage was increased to 10 mg daily two weeks later."( Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Brahm, NC; Brown, RC; McElwain, DL, 2007
)
0.34
" Twice-daily dosing of PPI for inadequate gastric acid suppression and the administration of H2-receptor antagonist before bedtime for nocturnal acid reflux, is effective in most cases."( [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Iwakiri, K; Kawami, N; Kotoyori, M; Sakamoto, C; Sano, H; Tanaka, Y, 2007
)
0.34
" There was no correlation between ITB dosage and CSF baclofen concentration."( Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy.
Albright, AL; Carlos, S; Minnigh, MB; Thompson, K, 2007
)
0.91
" The electronic programmable type has the advantage of flexibility of dosing and frequent change of doses for fine-tuning the patient's optimal dose."( Intrathecal baclofen therapy: indications, pharmacology, surgical implant, and efficacy.
Ethans, K, 2007
)
0.72
"25-10 mg/kg) dose-response curve in a drug discrimination procedure, while baclofen (1."( Effects of GABA(B) receptor antagonist, agonists and allosteric positive modulator on the cocaine-induced self-administration and drug discrimination.
Filip, M; Frankowska, M; Przegaliński, E, 2007
)
0.57
" The patient became comatose and, as a result of the baclofen dosage being left unchanged despite a deterioration leading to renal failure due to hypotension, the concentration of baclofen was determined to be in the toxic range (0."( Haemodialysis clearance of baclofen.
Brvar, M; Bunc, M; Kovac, D; Kozelj, G; Pezdir, T; Vrtovec, M, 2007
)
0.89
" Infusion of 150 microg/day produced overt seizures in one dog and produced adverse side effects in another; a reduction in the dosage given to these animals to 135 microg/day was tolerated with no adverse effects."( Long-term intraventricular baclofen infusion in beagles.
Albright, AL, 2007
)
0.64
" A second dosage of 5 mg Baclofen resulted in the same complications."( Heart conduction problems in a tetraplegic patient caused by a single therapeutic dosage of Baclofen.
Slim, EJ; Smit, CA, 2008
)
0.87
" We report such an experience where a patient in a long-term care facility received multi-day, excessive dosing of glipizide rather than her anti-spasticity medication, baclofen."( Look-alike medications: a formula for possible morbidity and mortality in the long-term care facility.
Grossberg, R; Reed, MD; Walliser, G, 2007
)
0.53
" Separate groups of rats received bilateral intra-VTA injections of the GABA-A antagonist picrotoxin (34 ng/side, n = 7; 68 ng/side, n = 8), GABA-A agonist muscimol (14 ng/side, n = 8), GABA-B agonist baclofen (56 ng/side, n = 7; 100 ng/side, n = 6), picrotoxin (68 ng/side) co-injected with the GABA-B antagonist 2-hydroxysaclofen (100 ng/side, n = 7; 2 microg/side, n = 8) or artificial cerebrospinal fluid (aCSF, n = 6) to assess the effects of the various compounds on the cocaine self-administration dose-response curve."( Contribution of ventral tegmental GABA receptors to cocaine self-administration in rats.
Backes, EN; Hemby, SE, 2008
)
0.53
"The objective of the present study was to understand the clinical reasons for changes from simple continuous to complex (flex) dosing for tone reduction in individuals receiving intrathecal baclofen."( Complex dosing schedules for continuous intrathecal baclofen infusion.
Krach, LE; Kriel, RL; Nugent, AC, 2007
)
0.78
" Dose-response functions determined with both training compounds revealed a clear dissociation between the discriminative stimulus effects of these drugs."( Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats.
Baker, LE; Poling, A; Pynnonen, DM; Searcy, GD, 2008
)
0.35
" Ketamine, PCP, and MK-801 enhanced catalepsy along inverted U-shaped dose-response curves likely because higher doses affected motor coordination, which limited their catalepsy-enhancing effects."( Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonists.
France, CP; Koek, W, 2008
)
0.59
" Dosing adjustments need to be considered in these patients."( Sexual dysfunction associated with intrathecal baclofen use: a report of two cases.
Chiodo, AE; Saval, A, 2008
)
0.6
" Lower doses of baclofen also did not reduce discriminative stimulus effects of the training dose of nicotine and did not significantly shift the dose-response curve for nicotine discrimination."( Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats.
Goldberg, SR; Le Foll, B; Wertheim, CE, 2008
)
1.08
"Drugs were tested in a repeated dosing paradigm (four daily injections)."( Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies.
Bennett, GJ; Naso, L; Xiao, W,
)
0.13
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)."( Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009
)
0.65
" There are few published guidelines for dosing efficacy and no studies looking at the effect of concentration of ITB on spasticity management."( Effect of intrathecal baclofen concentration on spasticity control: case series.
Chiodo, AE; Saval, A, 2008
)
0.66
" Future studies are warranted to determine the optimal dosing and titration schedules for ziconotide-baclofen usage."( Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.
Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009
)
0.87
" Arbaclofen placarbil was efficiently absorbed and rapidly converted to R-baclofen after oral dosing in rats, dogs, and monkeys."( Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
Annamalai, T; Bao, Y; Bu, L; Cundy, KC; Dias, T; Gallop, MA; Gao, M; Koller, K; Lal, R; Ludwikow, M; Luo, W; Nguyen, S; Peng, G; Phan, T; Raillard, SP; Scheuerman, RA; Sukbuntherng, J; Tai, EH; Upadhyay, S; Warren, MS; Wu, QQ; Yan, H; Yao, F; Zamora, J, 2009
)
1.7
" CGP35348 shifted the dose-response curve of each agonist to the right, but the magnitude of the shift differed among the agonists."( Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348).
Coop, A; France, CP; Koek, W; Mercer, SL, 2009
)
0.35
" AZD3355 potently stimulated recombinant human GABA(B) receptors and inhibited TLESR in dogs, with a biphasic dose-response curve."( (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
Antonsson, M; Blackshaw, LA; Brändén, L; Bräuner-Osborne, H; Christiansen, B; Dent, J; Elebring, T; Holmberg, AA; Jacobson, BM; Jensen, J; Lehmann, A; Mattsson, JP; Nilsson, K; Oja, SS; Page, AJ; Saransaari, P; von Unge, S, 2009
)
0.35
" Pharmacists should remain knowledgeable about therapy management in patients receiving treatment for spasticity, including adverse event monitoring, infusion device complications, and dosage adjustments."( Considerations in the treatment of spasticity with intrathecal baclofen.
Mullarkey, T, 2009
)
0.59
" Pharmacists should be well-versed in spasticity treatment, particular intrathecal therapies since close monitoring, dosage adjustment, concentration accuracy, and product sterility are necessary for optimal patient outcomes."( Considerations in the treatment of spasticity with intrathecal baclofen.
Mullarkey, T, 2009
)
0.59
" We describe a 10-year-old female patient with cerebral palsy, epilepsy, and mental retardation who developed clinical adverse effects (confusion, agitated state, insomnia, diffuse hypotonia, and hyporeflexia) and electroencephalographic (EEG) changes (quasiperiodic, generalized burst of sharp waves that take up >50% of standard EEG) during long-term oral baclofen treatment, after gradually increasing the dosage but still within the therapeutic dose."( Long-term oral baclofen treatment in a child with cerebral palsy: electroencephalographic changes and clinical adverse effects.
De Rinaldis, M; Gennaro, L; Losito, L; Trabacca, A, 2010
)
0.88
"Parameters evaluated included daily dosage of medication required, flex vs simple continuous delivery modes, dosing changes, need for other local spasticity treatment, and catheter complications."( Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
Chiodo, AE; Saval, A, 2010
)
0.74
" At 6 months, there was a statistically significant difference in dosing between individuals with multiple sclerosis and those without."( Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
Chiodo, AE; Saval, A, 2010
)
0.74
"Cortical and spinal spasticity appear to parallel each other with no significant differences in daily dosing, dosing changes, and mode of delivery of intrathecal baclofen."( Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
Chiodo, AE; Saval, A, 2010
)
0.94
"A 66-year-old man affected by familial spastic paraplegia since he was 22 developed drug tolerance to intrathecal baclofen after 16 years of treatment A stable dosage of 850 microg/day, achieved after the first two years, appeared to be progressively inadeguate to relief his spasticity."( A case of very long-term appearing drug tolerance to intrathecal baclofen.
Broggi, G; Dones, I, 2010
)
0.81
" A five minute quantitative perfusion fMRI resting baseline (RB) scan was acquired at two time points; prior to the dosing regimen (Time 1) and on the last day of 21 days of drug administration (Time 2)."( Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study.
Childress, AR; Detre, JA; Ehrman, R; Franklin, TR; Hakun, J; Harper, D; Kampman, K; Kildea, S; Li, Y; O'Brien, CP; Sciortino, N; Wang, Z, 2011
)
0.6
"This is provisional evidence of a dose-response effect for baclofen in the treatment of alcohol dependence."( Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial.
Addolorato, G; Bedogni, G; Caputo, F; Cardone, S; Ferrulli, A; Gasbarrini, G; Landolfi, R; Leggio, L,
)
0.68
" Dosage adjustments improved all patients with normal studies."( Combined C-arm fluoroscopy and C-arm cone beam computed tomography for the evaluation of patients with possible intrathecal baclofen delivery system malfunctions.
Kinnett, D; Maugans, T; Racadio, J; Schapiro, A, 2011
)
0.58
" The aim of our study was to evaluate how dosage level improves the symptoms of spasticity."( [Adequate dose of intrathecal baclofen therapy for spasticity].
Hirabayashi, H; Motoyama, Y; Nakase, H; Nishimura, F; Wajima, D, 2011
)
0.66
"Baclofen exhibits insufficient CNS-availability when dosed systemically."( Baclofen ester and carbamate prodrug candidates: a simultaneous chromatographic assay, resolution optimized with DryLab.
Abouzid, K; Hanafi, R; Mosad, S; Niess, R; Spahn-Langguth, H, 2011
)
3.25
" Questions still remain about optimal dosing and duration."( Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.
Gagliardi, JP; Muzyk, AJ; Rivelli, SK, 2012
)
0.7
" When dosage of rocuronium reached 20 mg, train-of-four count reached 1 and his trachea was intubated without coughing or moving."( [Anesthetic management for a patient with amyotrophic lateral sclerosis; the neuromuscular monitoring was useful to determine appropriate dosages of rocuronium].
Iwabuchi, Y; Kumagai, M; Miyata, M; Nagata, H; Suzuki, K; Wakimoto, M, 2012
)
0.38
" With this in mind, research was undertaken to evaluate two of the most often applied pattern recognition methods, hierarchical cluster analysis (HCA) and principal component analysis (PCA), as supporting techniques in the identification of potential physicochemical interactions that may occur during the preformulation of solid dosage forms."( Application of chemometrically processed thermogravimetric data for identification of baclofen-excipient interactions.
Piotrowska, J; Rojek, B; Wesolowski, M,
)
0.35
" Thus, baclofen should benefit from further studies of its biobehavioral mechanisms, dose-response effect, and indications in various alcoholic patient profiles."( Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates.
Aubin, HJ; Benyamina, A; Blecha, L; Gorsane, MA; Hache, G; Kebir, O; Reynaud, M, 2012
)
1.46
" The severity of spasticity as a consequence of brain injury can change during years and it is necessery to follow it with dosage and dynamics of baclofen therapy."( [Results of intrathecal baclofen therapy on spasticity in patients with brain injury].
Both, B; Dénes, Z; Klauber, A; Lóránd, E, 2012
)
0.89
" Among these, PPIs are considered first-line treatment for the control of nighttime gastric acid secretion; however, the timing and dosing of PPI administration should be individualized for each patient."( Gastroesophageal reflux disease and sleep.
Arakawa, T; Fass, R; Fujiwara, Y, 2013
)
0.39
" Few preclinical investigations, however, have utilized chronic dosing of baclofen, which is important given that tolerance can occur to many of its effects."( Differential development of tolerance to the functional and behavioral effects of repeated baclofen treatment in rats.
Beveridge, TJ; Porrino, LJ; Smith, HR, 2013
)
0.84
"To investigate the long-term dosage evolution and complication rate of intrathecal baclofen use in multiple sclerosis and spinal cord injury patients, based on a large population with a long follow-up."( Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013
)
0.99
" Daily baclofen dosage after 3 and 6 months, and yearly thereafter."( Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013
)
1.22
" The mean dosage of baclofen stabilizes two years after implantation at 323 µg/day in the multiple sclerosis population."( Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013
)
1.09
" The intrathecal baclofen dosage stabilizes in the long term, indicating that long-term tolerance, defined as progressive diminution of the susceptibility to the effects of a drug, is not present."( Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013
)
1.11
" Although this therapy is useful in treating spasticity, risks unique to intrathecal drug delivery systems include medication dosing errors, pump malfunction, infection, and catheter breakage or dislocation."( False positive radiographical evidence of pump catheter migration into the spinal cord.
Alsharif, KI; Chang, EY; Dardashti, S; Hata, JT; Kim, RB; Perret, DM,
)
0.13
" Average dosing increased from 57-187 µg/day at baseline to 218."( Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review.
Hsieh, J; Janzen, S; Mays, R; McIntyre, A; Mehta, S; Teasell, R; Townson, A; Wolfe, D, 2014
)
0.67
"The pharmacokinetics of baclofen is well delineated in subjects with normal kidney function (KF); however, pharmacokinetics data in patients with chronic kidney disease (CKD) are not and dosage recommendations remain empirical."( Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations.
Barrière, O; Larouche, R; Perreault, MM; Pichette, V; Shink, E; Tanguay, M; Tremblay, PO; Vlavonou, R, 2014
)
0.98
" Our population PK findings suggest that baclofen dosage can be based on body weight (2 mg/kg per day) and the current baclofen dose escalation strategy is appropriate in the treatment of children with CP older than 2 years of age."( Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.
Brunstrom-Hernandez, JE; Butler, M; Christensen, A; Dai, H; Dosa, NP; Gaebler-Spira, D; Gaedigk, A; He, Y; Hoon, AH; Jusko, WJ; Kennedy, D; Krach, LE; Kuroda, MM; Lackey, S; Leeder, JS; Lewandowski, A; Lopez, C; Lowenhaupt, S; McLaughlin, JF; Roge, D; Schwabe, A; Stashinko, E; Stevenson, RD; Thio, LL; Tilton, A; Vargus-Adams, J, 2014
)
0.94
"The objective of the present study was to fabricate and evaluate a multiparticulate oral gastroretentive dosage form of baclofen characterized by a central large cavity (hollow core) promoting unmitigated floatation with practical applications to alleviate the signs and symptoms of spasticity and muscular rigidity."( Formulation and evaluation of gastroretentive microballoons containing baclofen for a floating oral controlled drug delivery system.
Dube, TS; Ranade, AN; Ranpise, NS, 2014
)
0.84
" We found that intrahippocampal application of 2-OH saclofen could significantly enhance the population spike (PS) amplitude with a dose-response relationship, and 20 μM 2-OH saclofen evidently facilitated the formation of behavioral LTP in the perforant pathway to the dentate gyrus (PP-DG) and led to an obvious improvement in maze learning performance."( Effects of intrahippocampal GABAB receptor antagonist treatment on the behavioral long-term potentiation and Y-maze learning performance.
Cai, ZL; Li, CH; Liu, QY; Liu, WX; Wang, CY; Xiao, P; Xu, ST, 2014
)
0.4
"Baclofen is a centrally acting skeletal muscle relaxant with a short elimination half-life, which results in frequent daily dosing and subsequent poor patient compliance."( Baclofen novel gastroretentive extended release gellan gum superporous hydrogel hybrid system: in vitro and in vivo evaluation.
Aboelwafa, AA; El-Said, IA; ElGazayerly, ON; Khalil, RM, 2016
)
3.32
"0001) and a correlation between ITB dosage and IIEF scores (ρ = -0."( Sexual dysfunction induced by intrathecal baclofen administration: is this the price to pay for severe spasticity management?
Bramanti, P; Calabrò, RS; D'Aleo, G; De Cola, MC; Leo, A; Sessa, E, 2014
)
0.67
" Although ITB has been used for more than 20 years clinically, much is still unknown about the most optimal dosing regimens and intrathecal catheter tip placement."( Intrathecal baclofen bolus dosing and catheter tip placement in pediatric tone management.
Fournier, CM; Skalsky, AJ, 2015
)
0.8
"To perform an analysis of oral baclofen dosage in patients with traumatic spinal cord injuries over time and to ascertain the clinical determinants of long-term baclofen dosage trends."( Baclofen dosage after traumatic spinal cord injury: a multi-decade retrospective analysis.
Anderson, WS; Cheng, JJ; Sunshine, A; Veerakumar, A; Ye, X; Zorowitz, RD, 2015
)
2.15
"From time of injury, an aggregate of all dosage assignments for each patient demonstrated a significant yearly increase in baclofen dosage (1."( Baclofen dosage after traumatic spinal cord injury: a multi-decade retrospective analysis.
Anderson, WS; Cheng, JJ; Sunshine, A; Veerakumar, A; Ye, X; Zorowitz, RD, 2015
)
2.07
"We observed a marginal increase in baclofen dosage over nearly 25 years in a single provider's patient database and observed different timings of first dose between two causes of traumatic SCI."( Baclofen dosage after traumatic spinal cord injury: a multi-decade retrospective analysis.
Anderson, WS; Cheng, JJ; Sunshine, A; Veerakumar, A; Ye, X; Zorowitz, RD, 2015
)
2.14
" Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose."( Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Aksoy, SN; Dai, AI; Demiryürek, AT, 2016
)
0.91
" Meropenem serum concentrations were obtained and indicated that T>MIC was at least 75% of the dosing interval."( Success With Extended-Infusion Meropenem After Recurrence of Baclofen Pump-Related Achromobacter Xylosoxidans Meningitis in an Adolescent.
Christenson, JC; Jackson, NG; Knoderer, CA; Manaloor, JJ; Nichols, KR, 2015
)
0.66
" The mean dosage of baclofen at the onset of the first adverse effect was 83 ± 57 mg/day."( Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study.
Alexandre-Dubroeucq, C; Jaury, P; Le Jeunne, C; Legay Hoang, L; Pinot, J; Rigal, L, 2015
)
1.04
" The lack of proper recommendations regarding the dosage has important implications for safety in clinical management."( High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern.
Baby, S; Chand, P; Gowda, GS; Holla, B; Murthy, P; Prabhu, L; Viswanath, B, 2015
)
0.78
"Randomized or not randomized controlled trials and cohort studies comparing the effect of any dosage of oral baclofen with that of no treatment, placebo, or another antispastic medication in children and adolescents with spastic cerebral palsy were selected."( Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy.
Gonzalez, W; Nahuelhual, P; Navarrete-Opazo, AA, 2016
)
0.96
" Studies show a great variability in motor classification, dosage of baclofen, and outcome measures."( Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy.
Gonzalez, W; Nahuelhual, P; Navarrete-Opazo, AA, 2016
)
0.98
"To examine dosing patterns in patients receiving baclofen via intrathecal baclofen pumps to assess for common patterns by diagnosis, ambulation ability, and affected limbs distribution."( Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.
Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016
)
1.07
"Significant differences in dosing were found between diagnoses and trended to differ by ambulatory status at the end of the study, and similar trends could be observed in achieving initial stable dose."( Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.
Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016
)
0.81
" Data studied included baseline demographic and injury variables, implantation data, spasticity and function, ITB dosage over time and complications."( Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore.
Chua, KS; King, NK; Law, JH; Ng, WH; Rajeswaran, DK; Rao, JP; Soh, S; Wang, ZM, 2016
)
0.67
" Detailed information on baclofen dosing was found in 17 out of 20 (85%) articles, whereas alcohol doses were given only in 10 (50%) publications."( Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
Auffret, M; Franchitto, N; Rolland, B, 2016
)
1.01
"The aims of this study were to investigate the effects and the drug dosage of intrathecal Baclofen in a selected population of MS patients, affected by severe spasticity at long term follow-up."( Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Gerini, A; Mazzoleni, S; Stampacchia, G, 2016
)
0.9
" Spasticity and pain were periodically assessed and the Baclofen dosage was adjusted."( Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Gerini, A; Mazzoleni, S; Stampacchia, G, 2016
)
0.93
"The initial Baclofen dosage was 136."( Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Gerini, A; Mazzoleni, S; Stampacchia, G, 2016
)
1.06
" To obtain these results a dosage adjustment was needed only in the first year after the implantation."( Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Gerini, A; Mazzoleni, S; Stampacchia, G, 2016
)
0.68
" Step dosing can be used for outpatients who cannot return daily."( Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.
Adair, RL; Boster, AL; Gooch, JL; Nelson, ME; Saulino, M; Toomer, A; Urquidez, J, 2016
)
0.72
"ITB dosing is multistep and individualized."( Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.
Adair, RL; Boster, AL; Gooch, JL; Nelson, ME; Saulino, M; Toomer, A; Urquidez, J, 2016
)
0.72
" The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume)."( Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.
Anderson, DJ; Boster, AL; Doble, J; Farid, R; Gul, F; Konrad, P; Saulino, M, 2016
)
0.72
" THC:CBD mean dosage was 6 sprays/day."( Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Trojano, M; Vermersch, P, 2016
)
0.43
"Previous randomised placebo-controlled trials with low-to-medium doses of baclofen (30-60mg) showed inconsistent results, but case studies suggested a dose-response effect and positive outcomes in patients on high doses of baclofen (up to 270mg)."( Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial.
Bakker, A; Beraha, EM; Bodewits, P; de Jong, D; Defourny, H; Geest, DV; Goudriaan, AE; Salemink, E; Schiphof, T; Smits, N; van den Brink, W; van Tricht, M; Wiers, RW; Zwart, JW, 2016
)
0.95
" Although literature exists regarding the efficacy of ITB, there has been minimal investigation related to dosing in the adult-acquired brain injury population, particularly at long-term duration."( Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017
)
0.74
"To investigate long-term dosing of ITB in adult patients with spasticity of cerebral origin due traumatic brain injury (TBI), stroke, and hypoxic-ischemic encephalopathy (HIE)."( Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017
)
0.74
"Medical records and device manufacturer records of included patients were reviewed to obtain demographic data, dosing information, dates of pump and catheter placements, and revisions."( Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017
)
0.74
" A complex dosing pattern was used more frequently in those with stroke (36."( Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017
)
0.74
" A complex dosing pattern was used more frequently in patients with stroke."( Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017
)
0.74
" At a mean dosage of 40 mg/day (extremes: 30-210), the median daily alcohol consumption reduced from 80 to 0 g/day (P<0."( One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience.
Barrault, C; Béhar, V; Cadranel, JF; Costentin, C; Garioud, A; Hagège, H; Lison, H; Medmoun, M; Pulwermacher, G; Roudot-Thoraval, F, 2017
)
0.83
" Further randomized studies alongside investigation of dosing strategies are required."( A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic.
Gilmore, I; Owens, L; Pirmohamed, M; Richardson, P; Rose, A; Thompson, A, 2017
)
0.7
" Dosage regimens varied between and within doctors, particularly for the use of gabapentin and diazepam."( Oral medication prescription practices of tertiary-based specialists for dystonia in children with cerebral palsy.
Harvey, A; Reddihough, D; Scheinberg, A; Williams, K, 2018
)
0.48
" For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function."( Alcohol addiction - the safety of available approved treatment options.
Addolorato, G; Antonelli, M; Ferrulli, A; Gasbarrini, A; Mirijello, A; Mosoni, C; Rando, MM; Sestito, L; Tarli, C; Vassallo, GA, 2018
)
0.48
"The study found statistically significant correlations between dosage of ingested baclofen and presence of acute respiratory failure, as well as duration of mechanical ventilation."( Correlation between the single, high dose of ingested baclofen and clinical symptoms.
Anand, JS; Biliński, P; Jaworska-Łuczak, B; Waldman, W; Wojtyła, A; Zając, M, 2017
)
0.93
"To indicate the appropriate baclofen dosage to control severe spasticity of spinal origin and to develop the optimal administration protocol for long-term intrathecal baclofen (ITB) therapy."( The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin.
Hayashi, T; Kawano, O; Maeda, T; Masuda, M; Morishita, Y; Sakai, H; Takao, T; Ueta, T, 2018
)
1.02
" The effect of baclofen treatment, and the moderating effects of baclofen dosing (low-dose (LDB) 30-60 mg versus high-dose (HDB) targeted as >60 mg/day), and the amount of alcohol consumption before inclusion were studied."( Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis.
Beraha, EM; Morley, K; Pierce, M; Sutterland, A; van den Brink, W, 2018
)
1.08
" When sodium channel blockers cannot reach full dosage because of side effects, an add-on treatment with lamotrigine or baclofen should be considered."( Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia.
Cruccu, G; Di Stefano, G; Truini, A, 2018
)
0.69
" Furthermore there is no consistency between dosing and severity of withdrawal."( A Novel Approach to Avoid Baclofen Withdrawal When Faced With Infected Baclofen Pumps.
Collison, C; Hwang, RS; Pilitsis, JG; Prusik, J; Sukul, V, 2019
)
0.81
" A novel polytherapeutic proof-of-principle approach using PXT3003, a low-dose combination of baclofen, naltrexone and sorbitol, slowed disease progression after long-term dosing in adult Pmp22 transgenic rats, a known animal model of CMT1A."( Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S, 2019
)
0.73
" As renal function improved, spasticity returned, necessitating increase in ITB dosing toward the premorbid dose."( Intrathecal baclofen toxicity in a patient with acute kidney injury.
Ayyangar, R; Bowman, A; Gonzales, I; Hornyak, J,
)
0.51
"The aim of the study was to identify oral baclofen dosing variability at steady state based on weight and Gross Motor Function Classification System level using a retrospective cross-sectional study design."( Variability of Steady State Oral Baclofen Prescribing Practices in Pediatric Patients With Cerebral Palsy.
McGhee, E; McLaughlin, MJ; Ratnasingam, D, 2020
)
1.1
" Demographic characteristics, clinical diagnoses, date of placement or withdrawal/replacement of intrathecal baclofen infusion pumps, baclofen dosage and complications of intrathecal baclofen infusion pumps were collected."( Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre.
Barbosa, P; Gomes, A; Midões, AC; Rebelo, V; Reis, PV; Vieira, CR, 2019
)
1.11
" However, the optimal dose and dosing interval to achieve effective cerebral spinal fluid (CSF) concentrations of baclofen are not known."( Simultaneous Quantitation of S(+)- and R(-)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC-APCI-MS/MS: An Application for Clinical Studies.
Chhonker, YS; He, Q; McLaughlin, MJ; Murry, DJ, 2020
)
1.03
" Renal disease can contribute to baclofen overdose and encephalopathy, and there are currently no dosing recommendations for patient's on baclofen with renal impairment."( Encephalopathy of Unknown Origin in a Baclofen Patient: Case Report and Review of the Literature.
Abraham, M; Behmer Hansen, R; Gold, J; Lad, M; Mammis, A; Zhao, K, 2020
)
1.11
" After replacement, prerevision and stable postrevision dosage was examined to determine the impact system replacement had on the daily dosage."( Screening Intrathecal Baclofen Pump Systems for Catheter Patency via Catheter Access Port Aspiration.
Dalal, P; Ewing, E; Le, J; Skalsky, AJ; Yaszay, B, 2020
)
0.87
" Finally, in vitro results demonstrated that GABA (ranging from 10 to 50 μg/μL) markedly inhibited preimplantation embryo development in a dose-response manner."( GABA consumption during early pregnancy impairs endometrial receptivity and embryo development in mice.
Cao, K; Liang, H; Luo, W; Tan, D; Tan, Y; Tian, N; Wang, X; Zhang, Q, 2020
)
0.56
" These devices provide continuous infusion or periodic dosing of intrathecal baclofen (ITB)."( Submuscular Placement of Baclofen Infusion Pumps: Case Series and Technique.
Bogue, JT; Greenfield, JP; Iosim, S; Otterburn, DM; Wald, G, 2020
)
1.09
" Interrogation of the patient's ITB pump revealed normal function, and the patient had no clinical change with intravenous benzodiazepines, but his condition ultimately improved when his Baclofen dosing was decreased, indicating toxicity instead of withdrawal."( Intrathecal Baclofen Overdose With Paradoxical Autonomic Features Mimicking Withdrawal.
Frawley, MT; Parker-Pitts, CK; Weymouth, CW, 2020
)
1.13
" The use of xeomin in a total dosage of up to 800 U has shown its efficacy and safety for the treatment of spasticity of the upper and lower limbs."( [Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity].
Frunza, DN; Iskra, DA; Koshkarev, MA; Kovalenko, AP, 2019
)
0.51
" We evaluated the risk factor for baclofen neurotoxicity and the recommended dosage for patients with severe CKD."( Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function.
Cheong, M; Kim, SB; Lee, J; Lee, TY,
)
0.7
" With the background that individualized, rather than fixed, high dosing with baclofen could be critical for success, a large (n = 320), industry-independent, 62-center French RCT (the Bacloville trial) examined whether individually uptitrated, high-dose baclofen could reduce alcohol consumption in heavy drinkers across a year of treatment."( Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption.
Andrade, C, 2020
)
1.09
" This research employs preformulation studies to design an optimum dosage form for baclofen to enhance therapeutic outcomes."( Preformulation-Assisted Design and Characterization of Modified Release Gastroretentive Floating Extrudates Towards Improved Bioavailability and Minimized Side Effects of Baclofen.
Abdelkader, H; Ibrahim, M; Naguib, YW; Sarhan, HA, 2021
)
1.04
" Ultimately, the proposed approach was applied successfully for baclofen analysis in raw material, dosage form and spiked urine and it was also extended to test content uniformity."( A new convenient methodology based on dihydropyridine derivative for selective fluorimetric analysis of baclofen: Application to spiked urine and content uniformity evaluation.
Abu-Hassan, AA; Ali, R; Derayea, SM, 2021
)
1.07
"Oral medications are often first-line medical management for children with cerebral palsy who have generalised dystonia; however, evidence for their effectiveness is limited and dosing practices are inconsistent."( National surveillance of oral medication prescription for children with dystonic cerebral palsy.
Antolovich, G; Bear, N; Harvey, A; Rice, J; Waugh, MC, 2021
)
0.62
" Dosage regimens were variable, particularly for trihexyphenidyl and diazepam."( National surveillance of oral medication prescription for children with dystonic cerebral palsy.
Antolovich, G; Bear, N; Harvey, A; Rice, J; Waugh, MC, 2021
)
0.62
"Inconsistencies in dosing regimens remain for oral medication prescription by Australian doctors when managing dystonia in cerebral palsy."( National surveillance of oral medication prescription for children with dystonic cerebral palsy.
Antolovich, G; Bear, N; Harvey, A; Rice, J; Waugh, MC, 2021
)
0.62
" However, his spasticity and pain then began to worsen with each dosage increase."( Paradoxical reaction to increased doses of intrathecal baclofen in a patient with Leigh syndrome.
Erlandson, E; Khaliq, F; Santia, C, 2021
)
0.87
"The aim of this study was to describe and analyze dosing patterns for patients with ITB treatment over time and to identify possible subgroups demonstrating diversity in patterns."( Dosing Patterns In Treatment of Disabling Spasticity With Intrathecal Baclofen.
Alehagen, S; Berntsson, S; Ertzgaard, P; Gunnarsson, S; Lemming, D; Samuelsson, K,
)
0.37
" Line graphs of each patient's doses were analyzed and grouped based on similarities in dosing pattern."( Dosing Patterns In Treatment of Disabling Spasticity With Intrathecal Baclofen.
Alehagen, S; Berntsson, S; Ertzgaard, P; Gunnarsson, S; Lemming, D; Samuelsson, K,
)
0.37
"The analyses of the dosing patterns resulted in four different subgroups classified as stable, slow increase, rapid increase, and fluctuating."( Dosing Patterns In Treatment of Disabling Spasticity With Intrathecal Baclofen.
Alehagen, S; Berntsson, S; Ertzgaard, P; Gunnarsson, S; Lemming, D; Samuelsson, K,
)
0.37
" The most commonly used ITB dosing modes were continuous (73%) and flexible (23%)."( Intrathecal baclofen pumps in the management of hypertonia in childhood: a UK and Ireland wide survey.
Amin, S; Ammar, A; Bellis, L; Brink, P; Calisto, A; Crimmins, D; Eunson, P; Forsyth, RJ; Goodden, J; Kaminska, M; Kehoe, J; Kirkpatrick, M; Kumar, R; Leonard, J; Lodh, R; Lording, A; Lumsden, DE; Martin, K; Miller, R; Mordekar, SR; Pettorini, B; Smith, M; Smith, R; Sneade, C; Vloeberghs, M; Whitney, A; Zaki, H, 2021
)
1
" The main analysis quantified the odds ratio (OR) between opioid overdose and each nonopioid medication dispensed in the 90 days immediately before the opioid overdose date after adjustment for prescription opioid dosage and benzodiazepine codispensing."( Coprescription of Opioids With Other Medications and Risk of Opioid Overdose.
Barnett, ML; Bykov, K; Gagne, JJ; Glynn, RJ; Khan, NF, 2021
)
0.62
"The activities related to intrathecal baclofen (ITB) therapy could not be interrupted at the outbreak of COVID-19 pandemic due to possible life-threatening related complications such as withdrawal and over dosage syndromes."( The impact of strategies to manage the COVID-19 pandemic on patients with intrathecal baclofen therapy.
Burattini, B; D'Ercole, M; Fuggetta, F; Izzo, A; Montano, N; Rapisarda, A, 2023
)
1.4
" Reducing baclofen dosing regimen of the mother to the lowest and therefore reducing fetal exposure to baclofen is essential."( Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report.
Balakirouchenane, D; Chevillard, L; Chouchana, L; Declèves, X; Khoudour, N; Parat, S, 2021
)
1.35
"Cumulative intraperitoneal dosing (1-8 mg/kg IP) and cumulative intrathecal dosing (10-160 ng IT) of baclofen led to dose-dependent inhibition of visceromotor responses (VMRs) to urinary bladder distension (UBD) in all tested models."( Systemic and intrathecal baclofen produce bladder antinociception in rats.
DeWitte, C; Hildebrand, K; Ness, TJ; Randich, A; Su, X, 2021
)
1.14
"Further research is needed to assess the incidence of neonatal baclofen withdrawal with regard to maternal dosage and route of administration, and to determine the most appropriate monitoring and management protocols for the neonate."( Neonatal baclofen withdrawal following intrauterine exposure.
Daunter, AK; Mousigian, MA; Neil Knierbein, EE; Rosenblum, SA, 2022
)
1.38
" As the dosage decreased, the frequency of outbursts also decreased."( Behavioral dysregulation exacerbated by intrathecal baclofen in an adolescent with severe traumatic brain injury.
Lam, NY; Montagnino, J; Patel, H; Pham, K; Qin, ES, 2022
)
0.97
" Extensor spasticity was lower in the high-responders compared to the low-responders as was the dosage of baclofen."( Predictors of muscle hypertrophy responsiveness to electrically evoked resistance training after spinal cord injury.
Adler, RA; Cardozo, C; Goldsmith, JA; Gorgey, AS; Khalil, RE; Liu, XH; Pan, J, 2023
)
1.12
"7%) were still receiving baclofen at a mean dosage of 75 mg/day (r30-210)."( Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023
)
2.66
"Twenty-eight recently detoxified patients (13 receiving baclofen (BAC), 15 receiving placebo (PLA)) were investigated within a longitudinal, double-blind, and randomized pharmaco-fMRI design with an individually adjusted daily dosage of 30-270 mg."( Effects of baclofen on insular gain anticipation in alcohol-dependent patients - a randomized, placebo-controlled, pharmaco-fMRI pilot trial.
Beck, A; Charlet, K; Geisel, O; Genauck, A; Gleich, T; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wackerhagen, C; Wüstenberg, T, 2023
)
1.55
" However, adverse effects, administration, and dosing can be barriers to effectiveness."( Is baclofen the least worst option for spasticity management in children?
Brandenburg, JE, 2023
)
1.53
" Future prospective studies are needed to improve and personalize GFR estimation and medication dosing in patients with cancer."( Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.
Gupta, S; Hanna, PE; Harden, D; Katz-Agranov, N; Leaf, DE; Moreno, D; Ouyang, T; Reynolds, KL; Seethapathy, H; Sise, ME; Strohbehn, IA; Wang, Q, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
central nervous system depressantA loosely defined group of drugs that tend to reduce the activity of the central nervous system.
GABA agonistA drug that binds to and activates gamma-aminobutyric acid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
gamma-amino acidA non-proteinogenic amino-acid in which the amino group is located on the carbon atom at the position gamma to the carboxy group.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency8.42150.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
NFKB1 protein, partialHomo sapiens (human)Potency5.62340.02827.055915.8489AID895; AID928
GLI family zinc finger 3Homo sapiens (human)Potency0.34480.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency0.11880.000221.22318,912.5098AID1259243
regulator of G-protein signaling 4Homo sapiens (human)Potency0.10620.531815.435837.6858AID504845
67.9K proteinVaccinia virusPotency3.16230.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency0.00020.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.19950.540617.639296.1227AID2364; AID2528
D(1A) dopamine receptorHomo sapiens (human)Potency0.58040.02245.944922.3872AID488982
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.03160.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency6.30960.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.03161.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Gamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)IC50 (µMol)0.05000.05000.33000.6100AID255270
Gamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)Ki6.00006.00006.00006.0000AID1237981
Gamma-aminobutyric acid type B receptor subunit 2Rattus norvegicus (Norway rat)IC50 (µMol)0.27620.00001.01016.8100AID71388; AID71390; AID71399; AID71401
Gamma-aminobutyric acid type B receptor subunit 2Rattus norvegicus (Norway rat)Ki0.22000.00510.06830.2200AID1798404
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Gamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)IC50 (µMol)0.05000.05000.33000.6100AID255270
Gamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)Ki6.00006.00006.00006.0000AID1237981
Gamma-aminobutyric acid type B receptor subunit 1Rattus norvegicus (Norway rat)IC50 (µMol)0.27620.00001.05326.8100AID71388; AID71390; AID71399; AID71401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)EC50 (µMol)1.70000.53001.87365.3700AID729173
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.01901.73677.0000AID729172
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.01902.149910.0000AID729172
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.01901.73677.0000AID729172
Gamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)EC50 (µMol)1.70000.07941.62765.3700AID729173
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
negative regulation of adenylate cyclase activityGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
neuron-glial cell signalingGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
osteoblast differentiationGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
negative regulation of cell population proliferationGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
positive regulation of glutamate secretionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
negative regulation of gamma-aminobutyric acid secretionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
negative regulation of epinephrine secretionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
negative regulation of dopamine secretionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
response to nicotineGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
response to ethanolGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
negative regulation of synaptic transmissionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
positive regulation of growth hormone secretionGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
neuron-glial cell signalingGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
G protein-coupled GABA receptor activityGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
protein bindingGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
protein heterodimerization activityGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
G protein-coupled GABA receptor activityGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
G protein-coupled GABA receptor activityGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
protein bindingGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
protein heterodimerization activityGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
extracellular matrix protein bindingGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
cytoplasmGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
G protein-coupled GABA receptor complexGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
G protein-coupled receptor heterodimeric complexGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid type B receptor subunit 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
extracellular spaceGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
endoplasmic reticulum membraneGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
synaptic vesicleGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
axolemmaGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
mitochondrial membraneGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
dendritic spineGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
dendritic shaftGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
glutamatergic synapseGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
G protein-coupled GABA receptor complexGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
G protein-coupled receptor heterodimeric complexGamma-aminobutyric acid type B receptor subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (183)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID363866Analgesic activity in albino mouse assessed as retention latency at 3 mg/kg, ip after 30 mins by hot plate test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID363693Neuropharmacological effect in albino mouse assessed as onset of loss of righting reflex at 3 mg/kg, ip2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID363861Neuropharmacological effect in albino mouse assessed as endurance time at 3 mg/kg, ip after 90 mins by rotarod test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID363859Neuropharmacological effect in albino mouse assessed as endurance time at 3 mg/kg, ip after 45 mins by rotarod test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID339810Intrinsic activity at human recombinant GABAB receptor expressed in CHO-K1 cells assessed as inhibition of intracellular calcium release by FLIPR relative to GABA2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID71258Inhibition of [3H]-baclofen binding to Gamma-aminobutyric acid type B receptor of cat cerebellum1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID363696Neuropharmacological effect in albino mouse assessed as spontaneous locomotor activity at 3 mg/kg, ip after 45 mins2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID363698Neuropharmacological effect in albino mouse assessed as spontaneous locomotor activity at 3 mg/kg, ip after 90 mins2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID71562Displacement of [3H]-GABA from Gamma-aminobutyric acid A receptor in rat brain membranes1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of gamma-aminobutyric acid related biological properties in vitro and in vivo.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID764972Competitive inhibition of rat brain GABAB receptor after 30 mins by liquid scintillation counting analysis in presence of [3H]GABA2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID339808Displacement of [3H]GABA from GABABreceptor in rat brain synaptic membranes2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID175515Deterioration of rotarod performance of rats 0.5-1 hour after subcutaneous administration of compound1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID1687096Activation of human GABAB1/GABAB2 expressed in HEK293 cells co-transfected with rat CaV2.2 channel assessed as reduction in CaV2.2-mediated peak-current amplitude in response to depolarizing pulse at 10 uM by whole cell patch clamp assay relative to contr2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Targeting of N-Type Calcium Channels via GABA
AID363873Decrease in cognitive impairment in albino mouse assessed as retention latency at 3 mg/kg, ip after 90 mins by passive avoidance reflex test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID130063Anticonvulsant activity by using subcutaneous pentylenetetrazole (Metrazol) seizure threshold test in mice1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID729173Agonist activity at human GABA-B B1/B2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 3 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681406TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, Baclofen: 1000 uM) in Xenopus laevis oocytes2002Journal of neurochemistry, Oct, Volume: 83, Issue:1
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
AID255270Percent inhibition against GABA-B receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1237981Displacement of [3H]CGP54626 from GABA-B receptor (unknown origin) by radioligand binding assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Activation of the γ-Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators.
AID168418Amount of metabolite produced in brain of rat at a concentration of 12000 g of the compound1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID71396Displacement of [3H]-GABA from Gamma-aminobutyric acid type B receptor in rat brain membranes1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of gamma-aminobutyric acid related biological properties in vitro and in vivo.
AID71399Displacement of [3H]baclofen from Gamma-aminobutyric acid type B receptor of rat brain membranes1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABAB sites.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID168422Amount of metabolite produced in liver of rat at a concentration of 12000 g of the compound1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID71390Inhibition of [3H]baclofen binding to rat gamma-aminobutyric acid type B receptor.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID129017Anticonvulsant activity by using maximal electroshock seizure test in mice1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID71401Inhibition of [3H]CGP-27492 binding to Gamma-aminobutyric acid type B receptor of rat cortex1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID71395Displacement of [3H]baclofen from Gamma-aminobutyric acid type B receptor in rat brain membranes1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and activity of 5-(aminomethylene)-1,3-cyclohexanediones: enolic analogues of gamma-aminobutyric acid.
AID729167Anxiolytic activity in high alcohol preferring-2 mouse assessed as reduction of startle response under light and noise condition at 7.5 mg/kg, ip treated 25 mins prior to test2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor.
AID729168Anxiolytic activity in high alcohol preferring-2 mouse assessed as reduction of startle response under noise alone condition at 7.5 mg/kg, ip treated 25 mins prior to test2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID363860Neuropharmacological effect in albino mouse assessed as endurance time at 3 mg/kg, ip after 60 mins by rotarod test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID71388Displacement of [3H]baclofen from gamma-aminobutyric-acid B receptor1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis and biochemical evaluation of baclofen analogues locked in the baclofen solid-state conformation.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID168419Amount of metabolite produced in brain of rat at a concentration of 700 g of the compound1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID735850Neurotoxicity in CD-1 mouse assessed as impairment in motor coordination at 8 mg/kg, sc measured up to 3 hrs by rotarod test2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID72152Displacement of [3H]GABA from Gamma-aminobutyric acid A (GABA-A) receptor in rat brain membranes1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and activity of 5-(aminomethylene)-1,3-cyclohexanediones: enolic analogues of gamma-aminobutyric acid.
AID233587Ratio of IC50 for GABA-B and GABA-A receptors1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID363694Neuropharmacological effect in albino mouse assessed as duration of loss of righting reflex at 3 mg/kg, ip2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID174353Cyclic AMP accumulation in Rat brain cerebral cortical slices by the compound, activity expressed as % conversion1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of gamma-aminobutyric acid related biological properties in vitro and in vivo.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID363872Decrease in cognitive impairment in albino mouse assessed as retention latency at 3 mg/kg, ip after 60 mins by passive avoidance reflex test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID363864Muscle relaxant activity in albino mouse at 3 mg/kg, ip after 60 mins by traction test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1209592Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID363699Neuropharmacological effect in albino mouse assessed as endurance time at 3 mg/kg, ip after 30 mins by rotarod test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID71997Inhibition of [3H]muscimol binding to GABA-A receptor of rat cortex1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID339809Agonist activity at human recombinant GABABreceptor expressed in CHO-K1 cells assessed as inhibition of intracellular calcium release by FLIPR2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID363865Muscle relaxant activity in albino mouse at 3 mg/kg, ip after 90 mins by traction test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID363871Decrease in cognitive impairment in albino mouse assessed as retention latency at 3 mg/kg, ip after 45 mins by passive avoidance reflex test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID681420TP_TRANSPORTER: inhibition of Homovanillic acid uptake (HVA: 0.2 uM, Baclofen: 1000 uM) in Xenopus laevis oocytes2003Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Apr, Volume: 23, Issue:4
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID363868Analgesic activity in albino mouse assessed as retention latency at 3 mg/kg, ip after 60 mins by hot plate test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID363695Neuropharmacological effect in albino mouse assessed as spontaneous locomotor activity at 3 mg/kg, ip after 30 mins2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID363869Analgesic activity in albino mouse assessed as retention latency at 3 mg/kg, ip after 90 mins by hot plate test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID363862Muscle relaxant activity in albino mouse at 3 mg/kg, ip after 30 mins by traction test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID363870Decrease in cognitive impairment in albino mouse assessed as retention latency at 3 mg/kg, ip after 30 mins by passive avoidance reflex test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID729172Agonist activity at rat GABA-A alpha1beta2gamma2 receptor expressed in human TSA201 cells by whole cell voltage-clamp method2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID175652Deterioration of rotarod performance of rats 1-2 hour after subcutaneous administration of compound1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID773896Displacement of [3H]-3-hydroxycyclopent-1-enecarboxylic acid from GHB binding site in Sprague-Dawley rat cerebral cortex at 1 mM after 1 hr by scintillation counting analysis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
New synthesis and tritium labeling of a selective ligand for studying high-affinity γ-hydroxybutyrate (GHB) binding sites.
AID363867Analgesic activity in albino mouse assessed as retention latency at 3 mg/kg, ip after 45 mins by hot plate test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID363863Muscle relaxant activity in albino mouse at 3 mg/kg, ip after 45 mins by traction test2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID363697Neuropharmacological effect in albino mouse assessed as spontaneous locomotor activity at 3 mg/kg, ip after 60 mins2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID180672The inhibitory concentration of compound against sodium dependent [3H]GABA synaptosomal uptake in rats1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and activity of 5-(aminomethylene)-1,3-cyclohexanediones: enolic analogues of gamma-aminobutyric acid.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID136087Anticonvulsant activity by using rotarod toxicity test in mice1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID168423Amount of metabolite produced in liver of rat at a concentration of 700 g of the compound1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype gamma-aminobutyric acid prodrug to lactam and gamma-aminobutyric acid type metabolites.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1798404[3H]GABA Filtration Binding Assay (Ki) and FLIPR Assay for Agonism (EC50) from Article 10.1021/jm701425k: \\Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.\\2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,678)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901016 (17.89)18.7374
1990's1517 (26.72)18.2507
2000's1491 (26.26)29.6817
2010's1287 (22.67)24.3611
2020's367 (6.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 118.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index118.02 (24.57)
Research Supply Index8.76 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index223.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (118.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials372 (6.18%)5.53%
Reviews516 (8.58%)6.00%
Case Studies850 (14.13%)4.05%
Observational23 (0.38%)0.25%
Other4,256 (70.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (117)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Testing the GABAergic Hypothesis of Nicotine Dependence: a Randomized Clinical Trial of Baclofen [NCT01228994]Phase 26 participants (Actual)Interventional2010-10-31Terminated(stopped due to The study was terminated because of difficulties recruiting subjects.)
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders [NCT01288716]Phase 2150 participants (Actual)Interventional2011-05-31Completed
Modulation of the Brain Excitatory/Inhibitory (E/I) Balance Through Neuronal and Glial Systems in Autism Spectrum Disorder (ASD [NCT03594552]87 participants (Actual)Interventional2018-02-01Completed
Intrathecal (IT) Baclofen Drug Distribution Pilot Study [NCT02903823]Phase 427 participants (Actual)Interventional2016-04-22Completed
"Epidural Spinal Cord Stimulation: Addressing Spasticity and Motor Function" [NCT05422716]20 participants (Anticipated)Interventional2022-07-14Not yet recruiting
Open-label Randomized Controlled Prospective Study of Baclofen in the Treatment of Chemotherapy-related Hiccups [NCT03778281]Phase 4120 participants (Anticipated)Interventional2018-12-12Not yet recruiting
Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen [NCT01352611]0 participants (Actual)Interventional2014-09-30Withdrawn(stopped due to No subjects enrolled.)
GABA-B Receptor Function in Healthy Volunteers: a Pilot, Double Blind Crossover Study of the Effects of 2 Doses of Baclofen and Placebo on Objective and Subjective Measurements of Brain Function [NCT01563224]8 participants (Actual)Interventional2013-07-31Completed
Comparison of the Efficacy and Safety of Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients [NCT04509336]5 participants (Actual)Interventional2020-08-20Terminated(stopped due to COVID 19 Pandemic)
Effect of Baclofen Treatment on Nocturnal Muscle Cramps in Patients With Lumbar Spinal Stenosis: a Randomized Clinical Trial [NCT05392361]40 participants (Actual)Interventional2022-06-09Completed
Doctor, Physical Medicine and Rehabilitation [NCT03860662]Phase 429 participants (Actual)Interventional2018-05-26Completed
Effect of Baclofen on Marijuana Withdrawal and Relapse [NCT00373295]Phase 213 participants (Actual)Interventional2006-05-31Completed
Comparative Study Between the Functional Outcomes of Neuromodulation and Neuroablation Techniques for Treatment of Secondary Dystonia [NCT03347240]120 participants (Actual)Interventional2013-12-01Completed
Baclofen Versus Gabapentin in Preventing Postoperative Pain After Laparoscopic Sleeve [NCT05921604]Phase 3100 participants (Anticipated)Interventional2023-06-30Recruiting
Clinical Study Evaluating the Efficacy of Baclofen in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy [NCT05516953]Phase 2/Phase 3100 participants (Anticipated)Interventional2022-08-22Recruiting
A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome [NCT03113396]Phase 420 participants (Actual)Interventional2012-02-01Completed
Neurophysiological and Acute Pharmacological Studies in FXS Patients [NCT02998151]Early Phase 129 participants (Actual)Interventional2016-01-31Completed
Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence. An Adaptive, Single-blind, Placebo-controlled Ascending Dose Study of Acute Baclofen on Safety Parameters in Opioid Dependence During Methadone-maintenance [NCT05161351]Phase 464 participants (Anticipated)Interventional2022-01-11Recruiting
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study [NCT00871455]20 participants (Actual)Interventional2003-04-30Completed
A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis [NCT01359566]Phase 3228 participants (Actual)Interventional2011-05-31Completed
Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction: Medical and Cognitive Effects [NCT03065998]Early Phase 1140 participants (Anticipated)Interventional2017-03-31Recruiting
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms [NCT00817986]Phase 2161 participants (Actual)Interventional2008-12-31Completed
Predictive Factors for Treatment Success of Intrathecal Baclofen Therapy in Children With Cerebral Palsy - The Netherlands CP Register as a Unique Model for Practice Based, Long Term Data From Children With Cerebral Palsy. [NCT05817409]75 participants (Anticipated)Observational [Patient Registry]2023-06-01Not yet recruiting
Usage of Baclofen for Sleep Improvement After Cardiac Surgery [NCT02529514]Phase 430 participants (Anticipated)Interventional2015-07-31Suspended
A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis [NCT02221570]100 participants (Anticipated)Interventional2014-06-30Recruiting
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI) [NCT00978016]Phase 2460 participants (Actual)Interventional2009-09-30Completed
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis [NCT00914290]Phase 223 participants (Actual)Interventional2009-04-30Completed
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder: 5 Years Follow-up of the BACLOREA Randomized Trial [NCT05877807]314 participants (Anticipated)Observational2023-09-03Recruiting
Baclofen in Chronic Pelvic Pain, a Randomized, Double-Blind, Placebo Controlled Trial [NCT05968937]Phase 244 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Baclofen for the Treatment of Alcohol Dependence - BACLAD [NCT01266655]Phase 2/Phase 356 participants (Actual)Interventional2011-02-28Completed
Transcranial Magnetic Stimulation (TMS) Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers for R-baclofen Effects in Normal Volunteers [NCT01172509]Phase 16 participants (Actual)Interventional2010-10-31Terminated(stopped due to too much variability in the TMS measures)
Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence [NCT05935553]Phase 2/Phase 393 participants (Anticipated)Interventional2024-03-01Not yet recruiting
A Randomized Double Blind Placebo Controlled Cross-over Trial of Baclofen and Diazepam Suppositories for the Management of Pelvic Floor Myalgia [NCT03427216]60 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated With Cerebral Palsy [NCT00607542]Phase 1/Phase 261 participants (Actual)Interventional2008-11-30Completed
Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial [NCT01003249]Phase 412 participants (Actual)Interventional2009-09-30Terminated(stopped due to recruitment was going too slowly)
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors [NCT01265550]Phase 3366 participants (Actual)Interventional2012-08-13Completed
Baclofen as a Perioperative Analgesic Adjuvant [NCT03720717]Phase 486 participants (Anticipated)Interventional2019-10-17Recruiting
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment [NCT01032239]Phase 461 participants (Actual)Interventional2009-11-30Completed
Study to Assess the Safety of 3 mg/mL Gablofen® (Baclofen Injection) Delivered by Intrathecal Administration Using the Synchromed® II Programmable Infusion System [NCT01520545]Phase 3153 participants (Actual)Interventional2012-12-31Completed
A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis [NCT00488839]Phase 3173 participants (Actual)Interventional2007-06-30Completed
Prospective Analgesic Compound Efficacy (PACE) Study [NCT02403687]300 participants (Actual)Observational [Patient Registry]2015-06-30Completed
Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study [NCT02298868]Phase 210 participants (Actual)Interventional2012-10-31Completed
Assessment of the Effect of the GABA-B Receptor Agonist, Baclofen, on Hypoxia-induced Periodic Ventilation, in Healthy Subjects [NCT01095679]Phase 153 participants (Actual)Interventional2010-03-31Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months [NCT05092841]Phase 3176 participants (Anticipated)Interventional2021-09-28Recruiting
A Randomized Placebo-controlled Study of Baclofen ER on Brain and Behavioral Outcomes in Cocaine Dependence [NCT02003664]Phase 20 participants (Actual)Interventional2013-11-30Withdrawn(stopped due to This study never started due to delays in medication development)
Feasibility and Tolerability of a Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study. [NCT00614328]Phase 140 participants (Actual)Interventional2007-07-31Completed
Steady-State Bioequivalence Study of Multiple Doses of Oral Versus Intravenous Baclofen in Healthy Adult Volunteers [NCT02760992]Phase 1/Phase 242 participants (Anticipated)Interventional2017-05-31Not yet recruiting
Single Dose Crossover Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State [NCT00647738]Phase 127 participants (Actual)Interventional2003-10-31Completed
Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome [NCT05418049]Phase 245 participants (Anticipated)Interventional2022-09-08Recruiting
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome [NCT01013480]Phase 245 participants (Actual)Interventional2009-11-30Terminated(stopped due to all active subjects rolled into 209FX303/NCT01013480)
Combined Magnetic Resonance Imaging and High Resolution Manometry Studies [NCT01053585]24 participants (Actual)Interventional2007-02-28Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease [NCT00838396]Phase 258 participants (Actual)Interventional2005-10-31Completed
Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial [NCT00597701]79 participants (Actual)Interventional2003-04-30Completed
Baclocur® Post-Authorisation Safety Study in Real-life Settings in France [NCT04679142]975 participants (Anticipated)Observational2020-12-22Recruiting
A Phase 1, Single-Center, Open-Label Study of the Pharmacokinetics of Baclofen Formulations Administered to Healthy Adults [NCT00802035]Phase 116 participants (Actual)Interventional2008-11-30Completed
Effect of Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP) in Spinal Cord Injury (SCI) Patients. Preliminary Study. [NCT02705950]12 participants (Actual)Interventional2014-12-31Completed
[NCT00752934]Phase 420 participants (Actual)Interventional2010-10-31Terminated(stopped due to Lack of funding)
Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy [NCT01386255]Phase 40 participants (Actual)Interventional2009-04-30Withdrawn(stopped due to No participants were enrolled)
Effects of Baclofen on Binge Eating in Bulimia Nervosa and Binge Eating Disorder [NCT00320047]10 participants (Actual)Interventional2005-04-30Completed
Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers [NCT04251819]Phase 2/Phase 315 participants (Actual)Interventional2021-01-21Active, not recruiting
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis [NCT01743651]Phase 3353 participants (Actual)Interventional2012-11-30Completed
Prevention of Baclofen Withdrawal Syndrome: Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers [NCT01931319]Phase 139 participants (Actual)Interventional2014-01-31Completed
Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study [NCT02596763]Phase 4792 participants (Anticipated)Interventional2015-12-31Recruiting
Phase IIIa Trial of Baclofen for Alcohol Dependence [NCT00877734]Phase 2/Phase 380 participants (Actual)Interventional2005-04-30Completed
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders [NCT01064973]Phase 232 participants (Actual)Interventional2010-02-28Terminated(stopped due to all active subjects were rolled into study 209AS209/NCT01706523)
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome [NCT01325220]Phase 3172 participants (Actual)Interventional2011-06-30Completed
Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study [NCT01955655]Phase 470 participants (Actual)Interventional2005-12-31Completed
Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy [NCT00367068]Phase 318 participants Interventional2002-01-31Completed
[NCT02001584]Phase 10 participants InterventionalCompleted
[NCT00640003]Early Phase 110 participants (Actual)Interventional2007-04-30Completed
A Randomized Controlled Pilot Trial of Baclofen for Children With Rumination Syndrome [NCT05975684]Phase 350 participants (Anticipated)Interventional2023-01-31Recruiting
Alcohol Treatment: Pragmatic Therapeutic Trial Randomized, Double-blind for a Year in Ambulatory Care of Baclofen Versus Placebo. [NCT01604330]Phase 2/Phase 3323 participants (Actual)Interventional2012-05-29Completed
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial [NCT02723383]Phase 3314 participants (Actual)Interventional2016-06-27Completed
Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients and Its Effect on Quality of Life, Clinical and Psychosocial Features: A 12-Week Double-Blind Randomized Controlled Trial [NCT01002105]Phase 475 participants (Actual)Interventional2010-01-31Completed
Evaluation of Efficacy and Safety of Oral Baclofen Taking in Comparison With Botulinum Toxin A Injections in Myofascial Pelvic Pain Syndrome. Prospective Multicenter Cohort Study. [NCT05617118]52 participants (Anticipated)Observational2022-12-01Recruiting
Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients [NCT00164801]60 participants (Actual)Interventional2004-11-30Terminated(stopped due to Funding ended)
Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence [NCT00082485]Phase 2160 participants (Actual)Interventional2004-06-30Completed
GABA Agonists as Pharmacotherapies for Cocaine Abuse [NCT00218166]Phase 278 participants (Actual)Interventional2001-08-31Completed
Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence. [NCT06175507]110 participants (Anticipated)Interventional2023-12-25Not yet recruiting
A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking [NCT01076283]Phase 214 participants (Actual)Interventional2009-12-31Completed
Early Treatment of Paroxysmal Dysautonomia and Hypertonia for Severe Brain Injured Patients by Intrathecal Baclofen Therapy [NCT00221689]Phase 24 participants (Actual)Interventional2003-03-31Terminated(stopped due to very slow recruitment and treatments beyond expiry date)
Does Reducing Spasticity Permit an Increase in Strength? [NCT00255073]Phase 210 participants Interventional2005-01-31Completed
Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers [NCT01749319]Phase 112 participants (Actual)Interventional2013-01-31Completed
Vanderbilt University Spasticity Management Program Evaluation Plan [NCT00179114]Phase 420 participants Interventional2002-08-31Completed
Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study [NCT00493428]Phase 20 participants (Actual)Interventional2007-07-31Withdrawn(stopped due to The study have been stoped because the protocol is going to be modify.)
Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study [NCT00525252]Phase 1/Phase 286 participants Interventional2003-02-28Completed
Multiple-Dose Efficacy and Safety Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury [NCT00557973]Phase 237 participants (Actual)Interventional2007-12-31Completed
Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity [NCT00221611]Phase 280 participants Interventional2000-01-31Completed
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study [NCT00516503]Phase 3208 participants (Actual)Interventional2008-02-29Completed
An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 Deletion [NCT04271332]Phase 260 participants (Anticipated)Interventional2022-09-01Recruiting
Double-blind Comparison of Botox Versus Baclofen for the Treatment of Subjects With Upper Limb Spasticity - Pilot Study [NCT00280280]Phase 18 participants (Actual)Interventional2006-02-28Terminated(stopped due to low patient accrual)
Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study [NCT03034408]Phase 237 participants (Actual)Interventional2016-07-01Completed
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) [NCT04762758]Phase 3350 participants (Anticipated)Interventional2021-03-30Active, not recruiting
Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease [NCT01711125]Phase 3104 participants (Actual)Interventional2013-03-31Completed
A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients [NCT01738282]Phase 3316 participants (Anticipated)Interventional2012-12-31Completed
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders [NCT03682978]Phase 2124 participants (Actual)Interventional2019-09-19Completed
Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen) [NCT00000303]Phase 20 participants Interventional1997-10-31Completed
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence [NCT01980706]Phase 2120 participants (Actual)Interventional2013-12-12Completed
Baclofen Effects on Smoking Urge and Withdrawal [NCT00257894]Phase 241 participants (Actual)Interventional2005-12-31Terminated(stopped due to Enrollment was completed with insufficient sample size for publishable results)
Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone When Administered Individually or Concurrently [NCT05257447]Phase 119 participants (Actual)Interventional2022-04-27Completed
Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV [NCT01008280]Phase 4180 participants (Actual)Interventional2010-10-31Completed
A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers [NCT03058237]Phase 140 participants (Actual)Interventional2017-01-24Completed
Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen. [NCT02462317]Phase 4184 participants (Actual)Interventional2015-04-30Completed
A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD) [NCT00557401]Phase 2156 participants (Actual)Interventional2007-11-30Completed
Effects of Baclofen on Presynaptic Inhibition in Humans [NCT04471714]Phase 20 participants (Actual)Interventional2020-01-10Withdrawn(stopped due to Study recruitment was halted due to restrictions and we have decided to not pursue it further.)
Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: A Randomized Trial [NCT03068897]Phase 4320 participants (Actual)Interventional2017-05-03Completed
[NCT00004431]30 participants (Anticipated)Interventional1998-06-30Completed
The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands [NCT02485145]Early Phase 140 participants (Anticipated)Interventional2015-07-31Not yet recruiting
Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial [NCT01937364]Phase 217 participants (Actual)Interventional2013-11-30Terminated(stopped due to The enrollment in the study was too limited for meaningful data analysis.)
Novel Topical Therapies for the Treatment of Genital Pain [NCT02099006]Phase 2/Phase 39 participants (Actual)Interventional2013-11-30Completed
A Placebo Controlled Trial With Baclofen for the Treatment of GERD Patients With Incomplete PPI Response [NCT03835442]60 participants (Actual)Interventional2010-01-31Completed
Baclofen Effects on Brain and Behavior in Cigarette Smokers [NCT01821560]Phase 244 participants (Actual)Interventional2013-03-31Completed
Excessive Crying in Children With Cerebral Palsy and Communication Deficits -a Fixed-sequence, Crossover Clinical Trial [NCT04523935]Phase 4131 participants (Actual)Interventional2005-12-07Completed
Baclofen Bij de Behandeling Van Acute Alcoholontwenning [NCT03293017]Phase 490 participants (Anticipated)Interventional2016-02-01Recruiting
A Randomized Placebo-controlled Study of Baclofen on Brain and Behavioral Outcomes in Marijuana Dependence [NCT02011516]Phase 247 participants (Actual)Interventional2013-12-31Completed
A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics [NCT01751386]Phase 239 participants (Actual)Interventional2012-12-03Completed
Preventing Alcohol Withdrawal Syndrome With Oral Baclofen: A Randomized, Placebo Controlled Trial [NCT02052440]Phase 3102 participants (Actual)Interventional2014-03-15Terminated(stopped due to Insufficient funding to complete with low enrollment rate)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00257894 (4) [back to overview]Cigarette Choice Task
NCT00257894 (4) [back to overview]Minnesota Nicotine Withdrawal Questionnaire
NCT00257894 (4) [back to overview]Nicotine Self-administration as Quantified by Carbon Monoxide Boost During a Behavioral Self-administration Task.
NCT00257894 (4) [back to overview]Total Score on Questionnaire of Smoking Urges
NCT00373295 (1) [back to overview]Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase
NCT00516503 (7) [back to overview]Adverse Event Profile of Topical Amitriptyline HCl/ Baclofen/Ketamine > Frequency and Severity of Adverse Events Reported by the Patient in the > Symptom Experience Diary and Evaluated Through Clinical Assessment by NCI CTCAE v3.0
NCT00516503 (7) [back to overview]Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral Neuropathy [CIPN20]
NCT00516503 (7) [back to overview]Numbness, Tingling, and Pain as Measured by the Peripheral Neuropathy Questionnaire at Baseline and Weekly for 4 Weeks
NCT00516503 (7) [back to overview]Motor Neuropathy as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4
NCT00516503 (7) [back to overview]Autonomic Symptoms and Functioning as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4
NCT00516503 (7) [back to overview]Mood States and Total Mood Disturbance as Measured by the Profile of Mood States (POMS)
NCT00516503 (7) [back to overview]Pain Severity and Interference as Measured by the Brief Pain Inventory (BPI) at Baseline and Week 4
NCT00597701 (1) [back to overview]Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups
NCT01002105 (6) [back to overview]Percent Abstinent Days
NCT01002105 (6) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT01002105 (6) [back to overview]Obsessive-Compulsive Drinking Scale Scores
NCT01002105 (6) [back to overview]Multidimensional Scale of Perceived Social Support
NCT01002105 (6) [back to overview]General Self-Efficacy Scale
NCT01002105 (6) [back to overview]General Health Questionnaire
NCT01003249 (6) [back to overview]Average Scores on Dysfunctional Voiding as Measured With Quality of Life (QOL) Questionnaire
NCT01003249 (6) [back to overview]Average Scores on International Consultation on Incontinence Modular Questionnaire- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)
NCT01003249 (6) [back to overview]Efficacy of Baclofen vs. Placebo on Number of Voidings Per Day
NCT01003249 (6) [back to overview]Number (and Percentage) of Participants With External Anal Sphincter Muscle Dysfunction Via Patient Symptoms.
NCT01003249 (6) [back to overview]Number of Participants Exhibiting Abnormal EMG Activity During Voiding
NCT01003249 (6) [back to overview]Urine Flow Rate, as Measured With Uroflometry
NCT01008280 (3) [back to overview]Number of Heavy Drinking Days Per Two Week Segment
NCT01008280 (3) [back to overview]Number of Drinks Consumed Per Two Week Segments
NCT01008280 (3) [back to overview]Number of Drinking Days in the Past Two Weeks
NCT01032239 (11) [back to overview]Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Functional Independence Measure (FIM) Score From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6
NCT01032239 (11) [back to overview]Therapy Satisfaction
NCT01032239 (11) [back to overview]Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance
NCT01032239 (11) [back to overview]Healthcare Resource Utilization
NCT01032239 (11) [back to overview]Change in SF-12 (12-item Short Form) From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6
NCT01032239 (11) [back to overview]Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6
NCT01076283 (2) [back to overview]Alcohol Drinking
NCT01076283 (2) [back to overview]Alcohol Urge
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Reflux Esophagus.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Unspecified Functional Bowel Disorder
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Weak Peristalsis I
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Weak Peristalsis II
NCT01265550 (54) [back to overview]Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months
NCT01265550 (54) [back to overview]Number of Successful Participants With Anxiety and/or Depression.
NCT01265550 (54) [back to overview]Number of Successful Participants With Belching Disorders
NCT01265550 (54) [back to overview]Number of Successful Participants With Chronic Idiopathic Nausea
NCT01265550 (54) [back to overview]Number of Successful Participants With Cyclic Vomiting Syndrome
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Bloating
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Diarrhea
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Dysphagia
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Gallbladder Disorder
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Heartburn
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Vomiting
NCT01265550 (54) [back to overview]Number of Successful Participants With Globus
NCT01265550 (54) [back to overview]Number of Successful Participants With Irritable Bowel Syndrome
NCT01265550 (54) [back to overview]Number of Successful Participants With Unspecified Functional Bowel Disorder
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Gastric Outlet Obstruction
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Anxiety and/or Depression
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Achalasia
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Aperistalsis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Belching Disorders
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Candida Esophagitis.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Chronic Idiopathic Nausea
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Cyclic Vomiting Syndrome
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Distal Esophageal Spasm
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Eosinophilic Esophagitis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Esophageal Ulceration.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Bloating
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Diarrhea
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Dysphagia
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Gallbladder Disorder
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Heartburn
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Vomiting
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Globus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Hypertensive Peristalsis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Ineffective Esophageal Motility
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Irritable Bowel Syndrome
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Jackhammer Esophagus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Nutcracker Esophagus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Rapid Contraction
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.
NCT01751386 (1) [back to overview]Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session
NCT01821560 (1) [back to overview]Cigarettes Smoked Per Day
NCT01937364 (3) [back to overview]Severity of Alcohol Withdrawal Symptoms as Measured on the CIWA-Ar Scale and Assessed at 24, 48, and 72 Hours After Enrollment
NCT01937364 (3) [back to overview]Peak and Total Benzodiazepine Dose Required
NCT01937364 (3) [back to overview]Moderate or Severe Alcohol Withdrawal Syndrome
NCT01980706 (6) [back to overview]Mean Percentage of Abstinent Drinking Days
NCT01980706 (6) [back to overview]Mean Percentage of Heavy Drinking Days
NCT01980706 (6) [back to overview]Mean Spielberger State-Trait Anxiety Inventory Score [State]
NCT01980706 (6) [back to overview]Self-reported Sedation on at Least One Occasion by a Participant
NCT01980706 (6) [back to overview]Carbohydrate-deficient Transferrin
NCT01980706 (6) [back to overview]Mean Penn Alcohol Craving Scale Score
NCT02011516 (1) [back to overview]Urine Drug Screen
NCT02052440 (4) [back to overview]Reduced Severity of Alcohol Withdrawal as Measured by Severity of Ethanol Withdrawal Score. .
NCT02052440 (4) [back to overview]Difference in Cumulative Dose of Ethanol Withdrawal Symptom Driven Benzodiazepine Administration, as Assessed by SEWS Score, in Treatment Group Compared With Placebo Group.
NCT02052440 (4) [back to overview]Difference in Maximal Dose of Ethanol Withdrawal Symptom Driven Benzodiazepine Administration, as Assessed by SEWS Score, in Treatment Group When Compared to Placebo Group
NCT02052440 (4) [back to overview]Prevention of Progression to Severe Alcohol Withdrawal as Assessed by Severity of Ethanol Withdrawal Score (SEWS).
NCT02099006 (2) [back to overview]Reduction in Daily Genital Pain.
NCT02099006 (2) [back to overview]Reduction in Tampon Test Pain
NCT02298868 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Somnolence)
NCT02298868 (9) [back to overview]Change in Frequency of Muscle Cramps After Washout Period
NCT02298868 (9) [back to overview]Change in Severity of Muscle Cramps After Washout Period
NCT02298868 (9) [back to overview]Efficacy of Baclofen to Change Frequency of Muscle Cramps in Patients With Cirrhosis at the End of 4 Weeks of Therapy
NCT02298868 (9) [back to overview]Efficacy of Baclofen to Change Severity of Muscle Cramps in Patients With Cirrhosis After 4 Weeks of Therapy
NCT02298868 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Dizziness)
NCT02298868 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Encephalopathy)
NCT02298868 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache)
NCT02298868 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Nausea)
NCT02903823 (2) [back to overview]Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin
NCT02903823 (2) [back to overview]Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin
NCT02998151 (5) [back to overview]Change From Pre-dose in the Repeatable Battery for the Assessment of Neuropsychological Status at 4 Hours Post Dose
NCT02998151 (5) [back to overview]Change in EEG Relative Gamma Power
NCT02998151 (5) [back to overview]Test of Attentional Performance for Children (KiTAP) Test of Alertness
NCT02998151 (5) [back to overview]Clinical Global Impressions-Improvement
NCT02998151 (5) [back to overview]Woodcock Johnson Test of Cognitive Abilities - Auditory Attention Task
NCT03068897 (4) [back to overview]Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)
NCT03068897 (4) [back to overview]Levels of Disability
NCT03068897 (4) [back to overview]Number of Participants Who Experience Change in Low Back Pain
NCT03068897 (4) [back to overview]Number of Participants With Need for Medication for Low Back Pain

Cigarette Choice Task

"At 20 times spaced over a 2.5 h period, participants chose between smoking two puffs (of pre-determined size) of a cigarette and receiving US$0.10. The primary behavioral outcome measure was number of cigarette choices, ranging from 0 (no smoking) to 20 (smoking the most allowed).~These data are only available on the subset of participants who participated through Day 10." (NCT00257894)
Timeframe: Tenth day of medication titration

Interventionchoices (Mean)
Baclofen Condition15.4
Placebo Condition18.2

[back to top]

Minnesota Nicotine Withdrawal Questionnaire

"Measure of degree of nicotine withdrawal at the time. Scored as the mean of 8 5-point ratings so the total score ranges from 0 (no withdrawal) to 4 (severe withdrawal).~These data are only available on the subset of participants who participated through Day 10." (NCT00257894)
Timeframe: Day 10

Interventionunits on a scale (Mean)
Baclofen Condition1.06
Placebo Condition1.58

[back to top]

Nicotine Self-administration as Quantified by Carbon Monoxide Boost During a Behavioral Self-administration Task.

"Expired carbon monoxide (CO) assessed before and after a 2.5-h period when they make choices for cigarette puffs versus money. CO Boost is the difference score, possibly ranging from -25 (improved) to +25 (worse).~These data are only available on the subset of participants who participated through Day 10.." (NCT00257894)
Timeframe: Measures are assessed on the tenth day of medication titration, after 5 hours of smoking deprivation.

Interventionunits on a scale (Mean)
Baclofen Condition4.69
Placebo Condition5.27

[back to top]

Total Score on Questionnaire of Smoking Urges

"Questionnaire of Smoking Urges assesses cravings to smoke. the score is the mean of 10 7-point Likert ratings so the range of the total score is from 1 (no urge) to 7 (intense urge).~These data are only available on the subset of participants who participated through Day 10." (NCT00257894)
Timeframe: Measures are assessed on the tenth day of medication titration, after 5 hours of smoking deprivation.

Interventionunits on a scale (Mean)
Baclofen Condition5.5
Placebo Condition5.3

[back to top]

Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase

"This is a measure of marijuana self-administration and relapse since each initial puff costs $7 and is a burden to overcome just to smoke.~Over each 3 day period, the puffs chosen by each participant is averaged for a single value." (NCT00373295)
Timeframe: Days 1-3 (Baseline) and Days 6-8 (Relapse Phase)

Interventiondollars spent on marijuana (Mean)
Baclofen 60, Marijuana7.15
Placebo, Marijuana9.77
Baclofen 90, Marijuana7.25

[back to top]

Adverse Event Profile of Topical Amitriptyline HCl/ Baclofen/Ketamine > Frequency and Severity of Adverse Events Reported by the Patient in the > Symptom Experience Diary and Evaluated Through Clinical Assessment by NCI CTCAE v3.0

Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00516503)
Timeframe: Up to 4 weeks

,
InterventionParticipants (Count of Participants)
Grade 3+ Adverse EventGrade 4+ Adverse Event
Baclofen-amitriptyline Hydrochloride-ketamine81
Placebo51

[back to top]

Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral Neuropathy [CIPN20]

The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The primary analysis was the change in sensory neuropathy subscale of the CIPN-20 from baseline to week 4. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's sensory neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From baseline to 4 weeks

Intervention(units on a scale) * week (Mean)
Baclofen-amitriptyline Hydrochloride-ketamine61.0
Placebo60.9

[back to top]

Numbness, Tingling, and Pain as Measured by the Peripheral Neuropathy Questionnaire at Baseline and Weekly for 4 Weeks

The Peripheral Neuropathy Questionnaire was used to analyze this endpoint. Patient neuropathy symptoms were scored on a 0 - 100 scale (higher score represents less symptomatic). The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks

Interventionunits on a scale * week (Mean)
Baclofen-amitriptyline Hydrochloride-ketamine172.6
Placebo175.7

[back to top]

Motor Neuropathy as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4

The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the motor neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From Baseline to week 4

Intervention(units on a scale)* week (Mean)
Baclofen-amitriptyline Hydrochloride-ketamine69.2
Placebo70.1

[back to top]

Autonomic Symptoms and Functioning as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4

The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the autonomic neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: Up to 4 weeks

Intervention(units on a scale)*week (Mean)
Baclofen-amitriptyline Hydrochloride-ketamine85.0
Placebo86.8

[back to top]

Mood States and Total Mood Disturbance as Measured by the Profile of Mood States (POMS)

Each mood scale (0 - 100, higher is better mood) will be analyzed as an endpoint along with the total mood disturbance score. (NCT00516503)
Timeframe: At 4 weeks

,
Interventionunits on a scale (Mean)
POMS Tension-Anxiety SubscalePOMS VA SubscalePOMS Anger-Hostility ScorePOMS Confusion-BewildermentPOMS Depression-Dejection ScorePOMS Fatigue-Inertia ScoreMean POMS Score
Baclofen-amitriptyline Hydrochloride-ketamine83.231.187.876.986.467.271.5
Placebo83.033.087.777.985.863.671.8

[back to top]

Pain Severity and Interference as Measured by the Brief Pain Inventory (BPI) at Baseline and Week 4

Pain severity, defined by the four items addressing worst, least, and average pain and pain right now as measured by the BPI will be analyzed identical to the primary endpoint. Additionally, total pain interference as measured by the BPI will be transformed onto a 0-100 ( higher is less pain) point scale. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks

,
Interventionunits on a scale * week (Mean)
Worst PainLeast PainAverage PainBPI Total Interference
Baclofen-amitriptyline Hydrochloride-ketamine58.178.066.476.5
Placebo58.777.365.477.3

[back to top]

Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups

In acutely-withdrawing alcoholic patients treated with either baclofen or placebo, symptom-driven benzodiazepine doses were assessed for the 72 hours following the first Clinical Institute Withdrawal Assessment (CIWA) score of 11 or greater. (NCT00597701)
Timeframe: From eligibility for randomization (Clinical Institute Withdrawal Assessment [CIWA] score of at least 11) until 72 hours of observation had been completed.

Interventionmg of benzodiazepine per 8 hours (Mean)
Baclofen14.1
Placebo124.4

[back to top]

Percent Abstinent Days

Percent abstinent days at 52 weeks. % of abstinent days were assessed by (1) patient's self-evaluation; (2) family member interview; (3) calculation of cumulative abstinence duration (CAD), defined as the total number of days of abstinence, Abstinent days was calculated for each Arm as a whole. (NCT01002105)
Timeframe: one year

Interventionpercentage of abstinent days (Number)
Baclofen40
Placebo36

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)

"Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is a self-report form composed of 16 items, each rated on a 5-point scale that indicates the degree of enjoyment or satisfaction with: physical health; social relations; ability to function in daily life; ability to get around physically; mood; family relations; sexual drive and interest; ability to work on hobbies, work, leisure time activities; economic status; household activities; and living/housing situation. A total score of 1 to 15 items was computed while item 16 assessing overall life satisfaction was not included to avoid exaggerated scores. The total score was averaged from items 1 to 15 and ranged from 1 to 5, with higher scores indicating higher satisfaction." (NCT01002105)
Timeframe: baseline, 6 weeks, 12 weeks, 26 weeks, 52 weeks

,
Interventionunits on a scale (Mean)
BaselineWeek 6 (n=21,26)Week 12 (n=17,23)Week 26 (n=16,17)Week 52 (n=13,12)
Baclofen2.83.13.43.43.4
Placebo2.83.23.43.63.6

[back to top]

Obsessive-Compulsive Drinking Scale Scores

Used to evaluate self-reported alcohol craving. 14 items that provided a total (OCDS) as well as two subscale scores - obsessive drinking (OD) and compulsive drinking (CD). Each of the 14 items are scored from 0 to 4 with the inclusion of 4 split items with only the higher of the two scored items to be used in the total or subscale scores. The OCDS total score ranges from 0-40; the subscales both range from 0 to 20. On all scales, higher scores represent a worse outcome. Data for CD at 6 weeks not available to report (NCT01002105)
Timeframe: baseline, 6 weeks, 12 weeks, 26 weeks, 52 weeks

,
Interventionunits on a scale (Mean)
OCDS at BaselineOD at BaselineCD at BaselineOCDS at 6 weeks (n=21,26)OD at 6 weeks (n=21,26)OCDS at 12 weeks (n=17,23)OD at 12 weeks (n=17,23)CD at 12 weeks (n=17,23)OCDS at 26 weeks (n=16,17)OD at 26 weeks (n=16,17)CD at 26 weeks (n=16,17)OCDS at 52 weeks (n=13,12)OD at 52 weeks (n=13,12)CD at 52 weeks (n=13,12)
Baclofen28.711.417.317.46.911.54.57.111.14.66.510.54.36.2
Placebo28.611.117.615.16.112.84.68.37.93.44.37.83.43.6

[back to top]

Multidimensional Scale of Perceived Social Support

The MSPSS is a self-report instrument for assessment of emotional help and the level of satisfaction with the social support obtained from three sources - family, friends and significant others. The scale includes 12 items, each of which refer to the people to whom the respondent would turn if he/she had problems of a personal, health or family nature, as well as financial and employment problems. Responses are scored on a 7-point scale from 1 ('completely disagree') to 7 ('completely agree'). The MSPSS index and three subscales - family, friends and significant others - are computed. MSPSS total score ranged from 12 to 84, with a higher score indicating greater satisfaction with total support. Subscores ranged from 4 to 28, with higher score indicating greater satisfaction. (NCT01002105)
Timeframe: Baseline, 52 weeks

,
Interventionunits on a scale (Mean)
Total at BaselineFamily at BaselineFriends at BaselineOthers at BaselineTotal at 52 weeks (n=13,12)Family at 52 weeks (n=13,12)Friends at 52 weeks (n=13,12)Others at 52 weeks (n=13,12)
Baclofen55.119.415.620.160.920.618.320.8
Placebo55.218.216.820.355.918.318.219.2

[back to top]

General Self-Efficacy Scale

"The GSES measures one's belief in his/her ability to cope with stressful situations. The scale consists of 10 items (e.g. Usually I am able to control a situation or In unexpected situations, I always know how I must behave myself). Responses are rated on a 4- point Likert-scale ranging from absolutely not true (weighted as 1) to absolutely true (weighted as 4), where the higher GSES total scores indicate stronger self-efficacy beliefs.All responses are added to a sum score. The range is from 10 to 40 points with a higher score indicating more self-efficiency." (NCT01002105)
Timeframe: baseline, 6 weeks, 12 weeks, 26 weeks, 52 weeks

,
Interventionunits on a scale (Mean)
BaselineWeek 6 (n=21,26)Week 12 (n=17,23)Week 26 (n=16,17)Week 52 (n=13,12)
Baclofen25.424.127.827.125.8
Placebo23.623.625.627.426.5

[back to top]

General Health Questionnaire

The General Health Questionnaire measures whether the respondent has recently experienced a particular symptom or behavior and ranges from 0-much less than usual to 3-much more than usual. Total scores range from 0 to 36 and vary by study population: total scores of about 11-12 are typical, and a score higher than 20 suggests severe problems and psychological distress. (NCT01002105)
Timeframe: baseline, 6 weeks, 12 weeks, 26 weeks, 52 weeks

,
Interventionunits on a scale (Mean)
BaselineWeek 6 (n=21,26)Week 12 (n=17,23)Week 26 (n=16,17)Week 52 (n=13,12)
Baclofen17.715.113.29.910.1
Placebo18.014.315.89.87.2

[back to top]

Average Scores on Dysfunctional Voiding as Measured With Quality of Life (QOL) Questionnaire

This was measured using the Urogenital Distress Inventory (UDI-6). The UDI-6 is a symptom inventory specific to lower urinary tract dysfunction and genital prolapse. There are 6 items scored. The score range is from 0-100 Lower scores denotes better outcomes. (NCT01003249)
Timeframe: Baseline and 4 weeks

,
Interventionscores on a scale (Mean)
BaselineAfter Treatment
Baclofen15.114.3
Placebo14.312.8

[back to top]

Average Scores on International Consultation on Incontinence Modular Questionnaire- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)

Diagnosis of dysfunctional bladder is based on symptoms demonstrating no relaxation or over stimulation of external urinary sphincter during voiding. Symptoms will be scored by International Consultation on Incontinence Modular Questionnaire- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol). The ICIQ-LUTSqol is a patient-completed questionnaire for evaluating quality of life (QoL) in urinary incontinent patients There are 20 items and the score range is 10-200. Higher scores denotes better outcomes. (NCT01003249)
Timeframe: Baseline and 4 weeks

,
Interventionscores on a scale (Mean)
BaselineAfter Treatment
Baclofen165.3120.7
Placebo174160

[back to top]

Efficacy of Baclofen vs. Placebo on Number of Voidings Per Day

The number of voiding per day before and after treatment. (NCT01003249)
Timeframe: Baseline and 4 weeks

,
Interventionnumber of voids (Mean)
BaselineAfter Treatment
Baclofen10.78.3
Placebo10.39.2

[back to top]

Number (and Percentage) of Participants With External Anal Sphincter Muscle Dysfunction Via Patient Symptoms.

The percent of patient in each group who had defecation problem (NCT01003249)
Timeframe: Baseline and 4 weeks

,
InterventionParticipants (Count of Participants)
Before TreatmentAfter Treatment
Baclofen42
Placebo33

[back to top]

Number of Participants Exhibiting Abnormal EMG Activity During Voiding

EMG with patch electrodes was completed at the end of this four week period. The number of participants with EMG activity during voiding was collected. EMG activity during the voiding is considered abnormal and is a criteria for voiding dysfunction.Lower numbers denotes better outcomes. (NCT01003249)
Timeframe: Baseline and 4 weeks

,
InterventionParticipants (Count of Participants)
BaselineAfter Treatment
Baclofen64
Placebo66

[back to top]

Urine Flow Rate, as Measured With Uroflometry

Uroflometry with patch electrodes will also be completed at the end of this four week period. Higher flow rate denotes better outcome. (NCT01003249)
Timeframe: Baseline and 4 weeks

,
Interventionml/s (Mean)
BaselineAfter Treatment
Baclofen7.910.1
Placebo8.48.9

[back to top]

Number of Heavy Drinking Days Per Two Week Segment

A heavy drinking day was defined as ≥4 drinks/ day if female or ≥5 drinks/day if male (NCT01008280)
Timeframe: 12 weeks

,
InterventionNumber of heavy drinking days/2 weeks (Mean)
BaselineWeeks 0-1Weeks 2-3Weeks 4-5Weeks 6-7Weeks 8-9Weeks 10-11
Baclofen6.483.672.592.402.522.101.37
Placebo7.184.043.073.292.442.182.15

[back to top]

Number of Drinks Consumed Per Two Week Segments

(NCT01008280)
Timeframe: 12 weeks

,
InterventionNumber of Drinks/2 Weeks (Mean)
BaselineWeeks 0-1Weeks 2-3Weeks 4-5Weeks 6-7Weeks 8-9Weeks 10-11
Baclofen60.0941.8933.8828.4631.8226.0118.82
Placebo67.2347.6839.0737.7330.7326.6922.85

[back to top]

Number of Drinking Days in the Past Two Weeks

(NCT01008280)
Timeframe: 12 Weeks

,
InterventionNumber of Drinking Days/2 weeks (Mean)
BaselineWeeks 0-1Weeks 2-3Weeks 4-5Weeks 6-7Weeks 8-9Weeks 10-11
Baclofen8.66.86.25.75.45.14.6
Placebo8.97.16.35.85.44.84.7

[back to top]

Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.66
Best Medical Treatment (BMT)-0.17

[back to top]

Change in Functional Independence Measure (FIM) Score From Baseline to Month 6

FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy2.68
Best Medical Treatment (BMT)-2.58

[back to top]

Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6

"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy0.26
Best Medical Treatment (BMT)0.05

[back to top]

Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6

"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Utility ScoreVAS
Best Medical Treatment (BMT)0.014.40
ITB Therapy0.099.68

[back to top]

Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6

"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Actual painLeast PainWorst Pain
Best Medical Treatment (BMT)0.000.24-0.04
ITB Therapy-1.17-1.61-1.35

[back to top]

Therapy Satisfaction

"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6

InterventionParticipants (Count of Participants)
Patient Satisfaction with Spasticity Reduction72364475Patient Satisfaction with Spasticity Reduction72364476Patient Therapy Reccomandation72364475Patient Therapy Reccomandation72364476
disagreeneutralagree
ITB Therapy2
Best Medical Treatment (BMT)7
ITB Therapy4
ITB Therapy16
Best Medical Treatment (BMT)11
Best Medical Treatment (BMT)5
ITB Therapy3
Best Medical Treatment (BMT)4
Best Medical Treatment (BMT)14

[back to top]

Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance

Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6

InterventionParticipants (Count of Participants)
Baseline72364475Baseline72364476Month 372364475Month 372364476Month 672364475Month 672364476
HLPLLP
ITB Therapy22
Best Medical Treatment (BMT)24
ITB Therapy9
Best Medical Treatment (BMT)21
ITB Therapy6
ITB Therapy19
Best Medical Treatment (BMT)19
ITB Therapy5
Best Medical Treatment (BMT)5

[back to top]

Healthcare Resource Utilization

Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6

,
InterventionParticipants (Count of Participants)
Baseline : general practitionerBaseline : neurologistBaseline : nurse (hospital setting)Baseline : nurse (home care)Baseline : orthopedic surgeonBaseline : otherITB test:general practitionerITB test: neurologistITB test :otherSecond Assessment: general practitionerSecond Assessment: neurologistSecond Assessment: nurse (home care)Second Assessment: otherweek 6: general practitionerweek 6: nurse (hospital setting)week 6: othermonth 3: general practitionermonth 3: neurologistmonth 3: othermonth 6: general practitionermonth 6: neurologistmonth 6: other
Best Medical Treatment (BMT)8801013NANANA5114NANANA8397211
ITB Therapy14410310113NANANANA422716838

[back to top]

Change in SF-12 (12-item Short Form) From Baseline to Month 6

The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
PCSMCS
Best Medical Treatment (BMT)-1.13-0.82
ITB Therapy3.131.05

[back to top]

Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.99
Best Medical Treatment (BMT)-0.43

[back to top]

Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6

Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6

Interventionseconds (Mean)
ITB Therapy4.86
Best Medical Treatment (BMT)-2.48

[back to top]

Alcohol Drinking

"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionstandard drinking units (Mean)
Baclofen0.17
Cyproheptadine1.43

[back to top]

Alcohol Urge

"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionunits on a scale (Mean)
Baclofen22.5
Cyproheptadine19.4

[back to top]

Number of Enrolled Participants With Reflux Esophagus.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

[back to top]

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled56

[back to top]

Number of Enrolled Participants With Weak Peristalsis I

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled10

[back to top]

Number of Enrolled Participants With Weak Peristalsis II

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled9

[back to top] [back to top]

Number of Successful Participants With Anxiety and/or Depression.

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Belching Disorders

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group12
Placebo Medical Treatment Group2

[back to top]

Number of Successful Participants With Chronic Idiopathic Nausea

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group3
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Cyclic Vomiting Syndrome

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group7
Placebo Medical Treatment Group1

[back to top]

Number of Successful Participants With Functional Bloating

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Diarrhea

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Dysphagia

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Gallbladder Disorder

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Heartburn

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group7
Surgical Treatment Group14
Placebo Medical Treatment Group3

[back to top]

Number of Successful Participants With Functional Vomiting

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group1

[back to top]

Number of Successful Participants With Globus

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Irritable Bowel Syndrome

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group10
Placebo Medical Treatment Group3

[back to top]

Number of Successful Participants With Unspecified Functional Bowel Disorder

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

[back to top]

Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

[back to top]

Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group15

[back to top]

Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Enrolled Participants With Gastric Outlet Obstruction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

[back to top]

Number of Enrolled Participants With Anxiety and/or Depression

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled125

[back to top]

Number of Enrolled Participants With Achalasia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Aperistalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Belching Disorders

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled130

[back to top]

Number of Enrolled Participants With Candida Esophagitis.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Chronic Idiopathic Nausea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled51

[back to top]

Number of Enrolled Participants With Cyclic Vomiting Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled86

[back to top]

Number of Enrolled Participants With Distal Esophageal Spasm

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Eosinophilic Esophagitis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled16

[back to top]

Number of Enrolled Participants With Esophageal Ulceration.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Functional Bloating

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

[back to top]

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled13

[back to top]

Number of Enrolled Participants With Functional Diarrhea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

[back to top]

Number of Enrolled Participants With Functional Dysphagia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled7

[back to top]

Number of Enrolled Participants With Functional Gallbladder Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

[back to top]

Number of Enrolled Participants With Functional Heartburn

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled221

[back to top]

Number of Enrolled Participants With Functional Vomiting

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled32

[back to top]

Number of Enrolled Participants With Globus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Hypertensive Peristalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Ineffective Esophageal Motility

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

[back to top]

Number of Enrolled Participants With Irritable Bowel Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled152

[back to top]

Number of Enrolled Participants With Jackhammer Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

[back to top]

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Nutcracker Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Enrolled Participants With Rapid Contraction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session

Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL. (NCT01751386)
Timeframe: 2 hours

Interventionmini-drinks (Mean)
Baclofen4.11
Placebo4.5

[back to top]

Cigarettes Smoked Per Day

Cigarettes per day at Scan Day 2; Baclofen group vs. placebo group (NCT01821560)
Timeframe: 3 weeks (Scan Day 1, week1- Scan Day 2, week 4)

,
InterventionCigarettes per day (Mean)
Scan Day 1Scan Day 2
Baclofen14.237.76
Sugar Pill14.197.67

[back to top]

Severity of Alcohol Withdrawal Symptoms as Measured on the CIWA-Ar Scale and Assessed at 24, 48, and 72 Hours After Enrollment

Range: 0 to 67; larger values indicate greater severity (NCT01937364)
Timeframe: 72 hours

,
Interventionunits on a scale (Mean)
24 hours48 hours72 hours
Baclofen2.44181.98781.5339
Placebo3.13251.79130.4501

[back to top]

Peak and Total Benzodiazepine Dose Required

(NCT01937364)
Timeframe: 72 hours

,
InterventionDoses (Median)
Peak Ativan 1mg PO equivalent doseTotal Ativan 1mg PO equivalent dose
Baclofen0.50.5
Placebo1.01.0

[back to top]

Moderate or Severe Alcohol Withdrawal Syndrome

Moderate or severe AWS was defined as a CIWA-AR score of at least 11. (NCT01937364)
Timeframe: 72 hours

InterventionParticipants (Count of Participants)
Placebo2
Baclofen0

[back to top]

Mean Percentage of Abstinent Drinking Days

Percent of abstinent days over the course of the trial. (NCT01980706)
Timeframe: Every 1-2 weeks up to 16 weeks of active trial

Interventionpercentage of days (Least Squares Mean)
Placebo47
30 Mg Baclofen48
90 mg Baclofen59

[back to top]

Mean Percentage of Heavy Drinking Days

The frequency of heavy drinking days (5 or more drinks for a man and 4 or more drinks for a woman) as percentage during the treatment phase. (NCT01980706)
Timeframe: Every 1-2 weeks up to 16 weeks of active trial

Interventionpercentage of heavy drinking days (Least Squares Mean)
Placebo39
30 Mg Baclofen42
90 mg Baclofen28

[back to top]

Mean Spielberger State-Trait Anxiety Inventory Score [State]

The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults.The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety). The scores are averaged over the trial. (NCT01980706)
Timeframe: Every 1-2 weeks up to 16 weeks of active trial

Interventionunits on a scale (Least Squares Mean)
Placebo35.2
30 Mg Baclofen33.8
90 mg Baclofen33.6

[back to top]

Self-reported Sedation on at Least One Occasion by a Participant

Any reporting of feeling sedated/sleepy/drowsy (NCT01980706)
Timeframe: Every 1-2 weeks up to 16 weeks of active trial

InterventionParticipants (Count of Participants)
Placebo14
30 Mg Baclofen25
90 mg Baclofen20

[back to top]

Carbohydrate-deficient Transferrin

Lab test assessing history of heavy drinking with greater specificity than GGT. Higher levels are indicative of greater levels of drinking. (NCT01980706)
Timeframe: End of trial, generally 16 weeks

Intervention% CDT (Least Squares Mean)
Placebo1.81
30 Mg Baclofen2.19
90 mg Baclofen1.96

[back to top]

Mean Penn Alcohol Craving Scale Score

Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol. Scores are averaged over the trial. (NCT01980706)
Timeframe: Every 1-2 weeks up to 16 weeks of active trial

Interventionunits on a scale (Least Squares Mean)
Placebo10.1
30 Mg Baclofen10.8
90 mg Baclofen9.4

[back to top]

Urine Drug Screen

Change from positive to negative over the 12 weeks of a medication regimen (NCT02011516)
Timeframe: study weeks 1-12

InterventionParticipants (Count of Participants)
Sugar Pill, Psychosocial Intervention0
Baclofen, Psychosocial Intervention0

[back to top]

Reduced Severity of Alcohol Withdrawal as Measured by Severity of Ethanol Withdrawal Score. .

Severity of alcholol withdrawal will be assessed by monitoring SEWS scores in both baclofen and placebo group. This score is reported as a cumulative unit on scale ranging from 0 to 23. A value of 1-6 represents mild alcohol withdrawal, 7-12 moderate and >12 severe. Values will be measured 24 hours, 48 hours and 72 hours. A mean of these values was calculated. (NCT02052440)
Timeframe: Over 72 hours

,
InterventionUnit on Scale (Mean)
Highest SEWS score at 24 hoursHighest SEWS score at 48 hoursHighest SEWS score at 72 hours
Baclofen 10mg Three Times Daily642
Sugar Pill Given Three Times Daily643

[back to top]

Difference in Cumulative Dose of Ethanol Withdrawal Symptom Driven Benzodiazepine Administration, as Assessed by SEWS Score, in Treatment Group Compared With Placebo Group.

The null hypotheses of no difference in the cumulative inpatient dosages of symptom-triggered benzodiazepine therapy during the 72 hours following enrollment between those who receive baclofen and those who receive placebo. Total benzodiazepine administration received from 0 to 72 hours was summed for each patient in each arm. A mean of this cumulative dose was then calculated for each arm and is reported below. (NCT02052440)
Timeframe: 72 hours

InterventionMilligram of Diazepam (Mean)
Baclofen 10mg Three Times Daily66
Sugar Pill Given Three Times Daily85

[back to top]

Difference in Maximal Dose of Ethanol Withdrawal Symptom Driven Benzodiazepine Administration, as Assessed by SEWS Score, in Treatment Group When Compared to Placebo Group

The null hypotheses of no difference in the maximum dose of inpatient symptom-triggered benzodiazepine therapy during the 72 hours following enrollment between those who receive baclofen and those who receive placebo. All maximum doses for each treatment arm given anytime between 0 and 72 hours were recorded and a mean calculated for each treatment arm. (NCT02052440)
Timeframe: 72 hours

InterventionMilligram of Diazepam (Mean)
Baclofen 10mg Three Times Daily11
Sugar Pill Given Three Times Daily12

[back to top]

Prevention of Progression to Severe Alcohol Withdrawal as Assessed by Severity of Ethanol Withdrawal Score (SEWS).

Prevention of progression to Severe Alcohol withdrawal as assessed by Severity of Ethanol Withdrawal Score (SEWS). A score of > 7 represents moderate alcohol withdrawal and a score > 12 severe alcohol withdrawal. Reported below as number of patients in each group progressing to moderate or severe alcohol withdrawal as assessed by SEWS score. (NCT02052440)
Timeframe: Within 72 hours

InterventionParticipants (Count of Participants)
Baclofen 10mg Three Times Daily13
Sugar Pill Given Three Times Daily16

[back to top]

Reduction in Daily Genital Pain.

"Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale. A score of 0 was defined as no pain and a score of 10 was defined as worst imaginable pain. These daily values were collected and a mean pain score for the period of treatment was calculated." (NCT02099006)
Timeframe: 13 weeks

,
Interventionunits on a scale (Mean)
LoperamideKetamineGabapentinamtriptyline/baclofenketoprofen
Medications2.43.423.703.875.05
Placebo2.922.773.413.615.05

[back to top]

Reduction in Tampon Test Pain

"Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon. This is a validated surrogate for pain associated with intercourse. Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this. A score of 0 was defined as no pain, and a score of 10 was defined as worst imaginable pain." (NCT02099006)
Timeframe: 13 weeks

,
Interventionunits on a scale (Mean)
loperamideketaminegabapentinketoprofenamitriptyline/baclofen
Medications4.715.925.1256.175.43
Placebo5.295.924.8756.05.36

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Somnolence)

Proportion of patients with somnolence at any time during the 4 weeks of therapy (NCT02298868)
Timeframe: 4 weeks of active therapy

Interventionparticipants (Number)
Treatment1

[back to top]

Change in Frequency of Muscle Cramps After Washout Period

Subjects undertook a muscle cramp questionnaire prior to treatment that measured frequency in the number of days in a week that a subject experienced muscle cramps and repeated this measure at the end of baclofen therapy (end of week 4). Subjects then underwent a 1 week taper of baclofen and a subsequent two week washout period. At the end of the washout period (end of week 7) the subjects underwent a final muscle cramp questionnaire to reassess frequency of muscle cramps. This was then compared to the end of therapy frequency to document the increase in muscle cramps after stopping baclofen. (week 7 result - week 4 result) (NCT02298868)
Timeframe: End of treatment (week 4) to end of washout (week 7)

Interventiondays/week (Mean)
Treatment3.0

[back to top]

Change in Severity of Muscle Cramps After Washout Period

Subjects undertook a muscle cramp questionnaire prior to treatment that measured severity on a 0-10 analog scale (0 is no pain, 10 is most severe pain) and repeated this measure at the end of baclofen therapy (end of week 4). Subjects then underwent a 1 week taper of baclofen and a subsequent two week washout period. At the end of the washout period (end of week 7) the subjects underwent a final muscle cramp questionnaire to reassess severity of muscle cramps. This was then compared to the end of therapy severity to document the increase in muscle cramps after stopping baclofen. (week 7 result - week 4 result) (NCT02298868)
Timeframe: End of treatment (week 4) to end of washout (week 7)

Interventionunits on a scale (Mean)
Treatment4.0

[back to top]

Efficacy of Baclofen to Change Frequency of Muscle Cramps in Patients With Cirrhosis at the End of 4 Weeks of Therapy

Patients undertook a muscle cramp questionnaire prior to treatment that measured frequency in the number of days in a week that a subject experienced muscle cramps. This measures was repeated after 4 weeks of therapy and reported as the mean decrease in frequency of muscle cramps (4 weeks of therapy-Baseline). (NCT02298868)
Timeframe: Baseline to 4 weeks of therapy

Interventiondays/week (Mean)
Treatment-4.4

[back to top]

Efficacy of Baclofen to Change Severity of Muscle Cramps in Patients With Cirrhosis After 4 Weeks of Therapy

Patients undertook a muscle cramp questionnaire prior to treatment that measured severity in a 0-10 analog scale (0 is no pain and 10 is most severe pain). These measures were repeated after 4 weeks of therapy and the difference was assessed (4 weeks of therapy-Baseline). (NCT02298868)
Timeframe: Baseline to end of 4 weeks of therapy

Interventionunits on a scale (Mean)
Treatment-6

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Dizziness)

Proportion of patients with dizziness at any time during the 4 weeks of therapy (NCT02298868)
Timeframe: 4 weeks of active therapy

Interventionparticipants (Number)
Treatment2

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Encephalopathy)

Proportion of patients with endephalopathy at any time during the 4 weeks of therapy (NCT02298868)
Timeframe: 4 weeks of active therapy

Interventionparticipants (Number)
Treatment0

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache)

Proportion of patients with headache at any time during the 4 weeks of therapy (NCT02298868)
Timeframe: 4 weeks of active therapy

Interventionparticipants (Number)
Treatment3

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Nausea)

Proportion of patients with nausea at any time during the 4 weeks of therapy (NCT02298868)
Timeframe: 4 weeks of active therapy

Interventionparticipants (Number)
Treatment4

[back to top]

Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin

"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of spinal origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection

InterventionParticipants (Count of Participants)
Cervical spine level 4 injection siteThoracic level 3 injection siteThoracic level 10 injection siteLumbar level 2 injection site
Subjects With MAS Change - Based on Site of Injection4253

[back to top]

Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin

"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of cerebral origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection

InterventionParticipants (Count of Participants)
Cervical level 4 injection siteThoracic level 3 injection siteThoracic level 10 injection siteLumbar lever 2 injection site
Subjects With Max MAS Change8733

[back to top]

Change From Pre-dose in the Repeatable Battery for the Assessment of Neuropsychological Status at 4 Hours Post Dose

Four 10-item lists of unrelated words were presented orally to the examinee who was then required to immediately recall words presented, at both pre-dose and post-dose timepoints. The impact of drug was assessed by subtracting the number of words remembered post-dose from the number of words remembered pre-dose. Lower numbers indicate more words remembered post-dose; higher numbers indicate more words remembered pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post dose

Interventionnumber of words remembered (Mean)
Placebo-.20
Acamprosate-1.47
Lovastatin-1.25
Minocycline-.69
Baclofen-.88

[back to top]

Change in EEG Relative Gamma Power

EEG relative gamma power at rest was calculated as the percent of power in the gamma frequencies relative to the sum of power in all frequency bands, averaged across electrodes, and calculated separately at pre-dose and post-dose timepoints. To assess the impact of drug, the pre-dose relative gamma power was subtracted from post-dose relative gamma power. Higher numbers indicate more relative gamma power post-dose; lower numbers indicate more relative gamma power pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post-dose

Interventionpercent of power in gamma frequencies (Mean)
Placebo0.0024
Acamprosate-0.0077
Lovastatin-0.0039
Minocycline0.0019
Baclofen-0.0160

[back to top]

Test of Attentional Performance for Children (KiTAP) Test of Alertness

Computerized task where an examinee is required to push a key when a target stimulus is presented on the screen. Scores are presented as change in median reaction time (RT), in milliseconds. (NCT02998151)
Timeframe: Predose, 4-hour post-dose

Interventionchange in median RT in milliseconds (Mean)
Placebo13.76
Acamprosate-28.64
Lovastatin18.59
Minocycline26.85
Baclofen-31.44

[back to top]

Clinical Global Impressions-Improvement

The Clinical Global Impressions - Improvement (CGI-I) requires the clinician to assess how much the patient's illness has changed relative to pre-dose, from 1 (very much improved) to 7 (very much worse). (NCT02998151)
Timeframe: 4-hour post-dose

Interventionscore on a scale (Mean)
Placebo3.70
Acamprosate3.88
Lovastatin3.97
Minocycline3.81
Baclofen3.94

[back to top]

Woodcock Johnson Test of Cognitive Abilities - Auditory Attention Task

Woodcock Johnson Test of Cognitive Abilities III Auditory Attention subscale. Participants must identify orally presented words amid increasingly intense background noise. The scores for this subtask range from 0-50, with higher scores indicating a better outcome. Raw scores for this subscale are reported (rather than standard scores, or age- or grade-equivalents). (NCT02998151)
Timeframe: 4-hour post-dose

Interventionscore on a scale (Mean)
Placebo32.84
Acamprosate33.07
Lovastatin32.93
Minocycline33.24
Baclofen33

[back to top]

Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)

"The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a yes or no. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score." (NCT03068897)
Timeframe: Baseline and 7 days

Interventionunits on a scale (Mean)
Metaxalone10.1
Tizanidine11.2
Baclofen10.6
Placebo11.1

[back to top]

Levels of Disability

Disability will be assessed with the Roland-Morris Disability Questionnaire (RMDQ) where patients are asked to tick a box if they agree with 24 statements regarding their ability to perform certain activities (dressing, housework, walking). If the don't agree with the statement (able to perform those activities) they need to leave the tick-box blank or unchecked. Every agreement (tick) counts as a point and an absolute value is formed (min: 0, max: 24). The higher the value the higher the disability level. (NCT03068897)
Timeframe: 7 days

Interventionunits on a scale (Median)
Metaxalone5
Tizanidine3
Baclofen6
Placebo3

[back to top]

Number of Participants Who Experience Change in Low Back Pain

Change is assessed by verbal numerical scale of which 0 represents no pain and 10 represents the worst pain imaginable between the baseline ED visit and the one week follow-up (baseline - 1 week ). The baseline questions will refer to the time period immediately prior to ED presentation (Before you came to the ER today, were you able to…..) (NCT03068897)
Timeframe: Baseline and 7 days

InterventionParticipants (Count of Participants)
Metaxalone28
Tizanidine25
Baclofen26
Placebo22

[back to top]

Number of Participants With Need for Medication for Low Back Pain

Patients will be asked what medications they have used for low back pain (NCT03068897)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Metaxalone49
Tizanidine48
Baclofen49
Placebo46

[back to top]